>LF855108.1 JP 2015145412-A/21: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
AAAGACACT
>LF855100.1 JP 2015145412-A/13: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGATAGC
>LF855092.1 JP 2015145412-A/5: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
AAGGCGTCT
>LF942786.1 JP 2016532703-A/199: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LF942778.1 JP 2016532703-A/191: ANTI-PRLR ANTIBODIES AND USES THEREOF
GATGCGTCC
>LF942770.1 JP 2016532703-A/183: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LF942762.1 JP 2016532703-A/175: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LF942754.1 JP 2016532703-A/167: ANTI-PRLR ANTIBODIES AND USES THEREOF
GTTGCATCC
>LF942746.1 JP 2016532703-A/159: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTGCGTCC
>LF942738.1 JP 2016532703-A/151: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LF942730.1 JP 2016532703-A/143: ANTI-PRLR ANTIBODIES AND USES THEREOF
TGGTCATCT
>LF942722.1 JP 2016532703-A/135: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LF942714.1 JP 2016532703-A/127: ANTI-PRLR ANTIBODIES AND USES THEREOF
TTTGCATCC
>LF942706.1 JP 2016532703-A/119: ANTI-PRLR ANTIBODIES AND USES THEREOF
ACTGCATCC
>LF942698.1 JP 2016532703-A/111: ANTI-PRLR ANTIBODIES AND USES THEREOF
TGGTCATCT
>LF942690.1 JP 2016532703-A/103: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTACATCC
>LF942682.1 JP 2016532703-A/95: ANTI-PRLR ANTIBODIES AND USES THEREOF
AGGGCGTCT
>LF942674.1 JP 2016532703-A/87: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LF942666.1 JP 2016532703-A/79: ANTI-PRLR ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LF942658.1 JP 2016532703-A/71: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LF942650.1 JP 2016532703-A/63: ANTI-PRLR ANTIBODIES AND USES THEREOF
TGGGCATCT
>LF942642.1 JP 2016532703-A/55: ANTI-PRLR ANTIBODIES AND USES THEREOF
TTTGCATCC
>LF942634.1 JP 2016532703-A/47: ANTI-PRLR ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LF942626.1 JP 2016532703-A/39: ANTI-PRLR ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LF942618.1 JP 2016532703-A/31: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCGTCC
>LF942610.1 JP 2016532703-A/23: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LF942602.1 JP 2016532703-A/15: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTACATCC
>LF942594.1 JP 2016532703-A/7: ANTI-PRLR ANTIBODIES AND USES THEREOF
AGTGCATCC
>LG232401.1 KR 1020160029822-A/280: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232381.1 KR 1020160029822-A/260: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232371.1 KR 1020160029822-A/250: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGCGACATC
>LG232361.1 KR 1020160029822-A/240: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232258.1 KR 1020160019975-A/68: Novel antibodies inhibiting c-Met dimerization, and uses thereof
ACCACATCC
>LG232218.1 KR 1020160019974-A/68: Novel antibodies inhibiting c-Met dimerization, and uses thereof
ACCACATCC
>LG232351.1 KR 1020160029822-A/230: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232331.1 KR 1020160029822-A/210: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232291.1 KR 1020160029822-A/170: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232271.1 KR 1020160029822-A/150: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232311.1 KR 1020160029822-A/190: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232232.1 KR 1020160019975-A/34: Novel antibodies inhibiting c-Met dimerization, and uses thereof
CGTGCATCC
>LG232192.1 KR 1020160019974-A/34: Novel antibodies inhibiting c-Met dimerization, and uses thereof
CGTGCATCC
>LG232341.1 KR 1020160029822-A/220: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232321.1 KR 1020160029822-A/200: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232301.1 KR 1020160029822-A/180: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232281.1 KR 1020160029822-A/160: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LG232237.1 KR 1020160019975-A/39: Novel antibodies inhibiting c-Met dimerization, and uses thereof
GCTGCAACA
>LG232197.1 KR 1020160019974-A/39: Novel antibodies inhibiting c-Met dimerization, and uses thereof
GCTGCAACA
>LG170954.1 KR 1020160013047-A/733: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TTGGGTTTT
>LG170942.1 KR 1020160013047-A/709: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GGTGCATCC
>LG170930.1 KR 1020160013047-A/685: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGTTTCT
>LG170918.1 KR 1020160013047-A/661: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGTTTCT
>LG170906.1 KR 1020160013047-A/637: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGTTTCT
>LG170894.1 KR 1020160013047-A/613: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GGTGCATCC
>LG170882.1 KR 1020160013047-A/589: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GATGCATCC
>LG170870.1 KR 1020160013047-A/565: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GGTGCATCC
>LG170858.1 KR 1020160013047-A/541: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GGTGCATCC
>LG170846.1 KR 1020160013047-A/517: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TTGGGTTTT
>LG170834.1 KR 1020160013047-A/493: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GGTGCATCC
>LG170822.1 KR 1020160013047-A/469: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGCGTCT
>LG170810.1 KR 1020160013047-A/445: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGCGTCT
>LG170798.1 KR 1020160013047-A/421: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGCGTCT
>LG170786.1 KR 1020160013047-A/397: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGCGTCT
>LG170774.1 KR 1020160013047-A/373: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GGTGCATCC
>LG170762.1 KR 1020160013047-A/349: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGCGTCT
>LG170750.1 KR 1020160013047-A/325: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGTTTCT
>LG170738.1 KR 1020160013047-A/301: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TTGGGTTCT
>LG170726.1 KR 1020160013047-A/277: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TTGGGTTTT
>LG170714.1 KR 1020160013047-A/253: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TTGGGTTTT
>LG170702.1 KR 1020160013047-A/229: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TTGGGTTCT
>LG170690.1 KR 1020160013047-A/205: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TTGGGTTCT
>LG170678.1 KR 1020160013047-A/181: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TTGGGTTCT
>LG170666.1 KR 1020160013047-A/157: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGTTTCT
>LG170654.1 KR 1020160013047-A/133: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GCTGCATCC
>LG170642.1 KR 1020160013047-A/109: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GCTGCATCC
>LG170630.1 KR 1020160013047-A/85: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TGGGCATCT
>LG170618.1 KR 1020160013047-A/61: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
TGGGCCTCT
>LG170606.1 KR 1020160013047-A/37: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
AAGGCGTCT
>LG170594.1 KR 1020160013047-A/13: METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
GGTGCATCC
>LG170581.1 KR 1020160013046-A/733: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TTGGGTTTT
>LG170569.1 KR 1020160013046-A/709: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GGTGCATCC
>LG170557.1 KR 1020160013046-A/685: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGTTTCT
>LG170545.1 KR 1020160013046-A/661: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGTTTCT
>LG170533.1 KR 1020160013046-A/637: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGTTTCT
>LG170521.1 KR 1020160013046-A/613: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GGTGCATCC
>LG170509.1 KR 1020160013046-A/589: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GATGCATCC
>LG170497.1 KR 1020160013046-A/565: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GGTGCATCC
>LG170485.1 KR 1020160013046-A/541: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GGTGCATCC
>LG170473.1 KR 1020160013046-A/517: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TTGGGTTTT
>LG170461.1 KR 1020160013046-A/493: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GGTGCATCC
>LG170449.1 KR 1020160013046-A/469: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGCGTCT
>LG170437.1 KR 1020160013046-A/445: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGCGTCT
>LG170425.1 KR 1020160013046-A/421: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGCGTCT
>LG170413.1 KR 1020160013046-A/397: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGCGTCT
>LG170401.1 KR 1020160013046-A/373: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GGTGCATCC
>LG170389.1 KR 1020160013046-A/349: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGCGTCT
>LG170377.1 KR 1020160013046-A/325: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGTTTCT
>LG170365.1 KR 1020160013046-A/301: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TTGGGTTCT
>LG170353.1 KR 1020160013046-A/277: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TTGGGTTTT
>LG170341.1 KR 1020160013046-A/253: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TTGGGTTTT
>LG170329.1 KR 1020160013046-A/229: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TTGGGTTCT
>LG170317.1 KR 1020160013046-A/205: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TTGGGTTCT
>LG170305.1 KR 1020160013046-A/181: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TTGGGTTCT
>LG170293.1 KR 1020160013046-A/157: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGTTTCT
>LG170281.1 KR 1020160013046-A/133: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GCTGCATCC
>LG170269.1 KR 1020160013046-A/109: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GCTGCATCC
>LG170257.1 KR 1020160013046-A/85: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TGGGCATCT
>LG170245.1 KR 1020160013046-A/61: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
TGGGCCTCT
>LG170233.1 KR 1020160013046-A/37: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
AAGGCGTCT
>LG170221.1 KR 1020160013046-A/13: METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
GGTGCATCC
>LG169084.1 KR 1020160007541-A/11: DNA BINDING PROTEIN USING PPR MOTIF, AND USE THEREOF
TCTATCACT
>LG253252.1 KR 1020160049045-A/19: HUMANIZED ANTIBODY AGAINST AMYLOID BETA
GGTGACTAC
>LG165912.1 KR 1020160002819-A/17: METHOD FOR PRODUCING PROTEIN
GAGNNNACV
>LG164812.1 KR 1020150143484-A/69: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
CTCACATCC
>LG164811.1 KR 1020150143484-A/68: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
CGTGCATCC
>LG164810.1 KR 1020150143484-A/67: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
CGGATGTCC
>LG247852.1 KR 1020160047570-A/14: COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA
ACGGGTAGA
>LG242130.1 KR 1020160036630-A/397: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG242122.1 KR 1020160036630-A/381: ANTI-PRLR ANTIBODIES AND USES THEREOF
GATGCGTCC
>LG242114.1 KR 1020160036630-A/365: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LG242106.1 KR 1020160036630-A/349: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LG242098.1 KR 1020160036630-A/333: ANTI-PRLR ANTIBODIES AND USES THEREOF
GTTGCATCC
>LG242090.1 KR 1020160036630-A/317: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTGCGTCC
>LG242082.1 KR 1020160036630-A/301: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG242074.1 KR 1020160036630-A/285: ANTI-PRLR ANTIBODIES AND USES THEREOF
TGGTCATCT
>LG242066.1 KR 1020160036630-A/269: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTGCATCC
>LG242058.1 KR 1020160036630-A/253: ANTI-PRLR ANTIBODIES AND USES THEREOF
TTTGCATCC
>LG242050.1 KR 1020160036630-A/237: ANTI-PRLR ANTIBODIES AND USES THEREOF
ACTGCATCC
>LG242042.1 KR 1020160036630-A/221: ANTI-PRLR ANTIBODIES AND USES THEREOF
TGGTCATCT
>LG242034.1 KR 1020160036630-A/205: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTACATCC
>LG242026.1 KR 1020160036630-A/189: ANTI-PRLR ANTIBODIES AND USES THEREOF
AGGGCGTCT
>LG242018.1 KR 1020160036630-A/173: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG242010.1 KR 1020160036630-A/157: ANTI-PRLR ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG242002.1 KR 1020160036630-A/141: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG241994.1 KR 1020160036630-A/125: ANTI-PRLR ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG241986.1 KR 1020160036630-A/109: ANTI-PRLR ANTIBODIES AND USES THEREOF
TTTGCATCC
>LG241978.1 KR 1020160036630-A/93: ANTI-PRLR ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG241970.1 KR 1020160036630-A/77: ANTI-PRLR ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG241962.1 KR 1020160036630-A/61: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCGTCC
>LG241954.1 KR 1020160036630-A/45: ANTI-PRLR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG241946.1 KR 1020160036630-A/29: ANTI-PRLR ANTIBODIES AND USES THEREOF
GGTACATCC
>LG241938.1 KR 1020160036630-A/13: ANTI-PRLR ANTIBODIES AND USES THEREOF
AGTGCATCC
>LG241767.1 KR 1020160036065-A/582: COMPOSITIONS AND METHODS FOR MODULATING RNA
CCGCCCTCC
>LG241763.1 KR 1020160036065-A/578: COMPOSITIONS AND METHODS FOR MODULATING RNA
GCCCTCCAG
>LG241667.1 KR 1020160036065-A/482: COMPOSITIONS AND METHODS FOR MODULATING RNA
CCGCCCTCC
>LG241663.1 KR 1020160036065-A/478: COMPOSITIONS AND METHODS FOR MODULATING RNA
GCCCTCCAG
>LG238432.1 KR 1020160030581-A/213: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GGTGCATCC
>LG238400.1 KR 1020160030581-A/149: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GGGGCAAGT
>LG238372.1 KR 1020160030581-A/93: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG238364.1 KR 1020160030581-A/77: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GATGCATCC
>LG238356.1 KR 1020160030581-A/61: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GATGCTTCC
>LG238348.1 KR 1020160030581-A/45: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GAGACATCC
>LG238340.1 KR 1020160030581-A/29: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG238332.1 KR 1020160030581-A/13: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG149381.1 KR 1020160057521-A/18: Black pig having enhanced fleshiness and stress tolerance and process for preparing the same
MAGAAACAG
>LG149380.1 KR 1020160057521-A/17: Black pig having enhanced fleshiness and stress tolerance and process for preparing the same
YTGGGACTC
>LG149379.1 KR 1020160057521-A/16: Black pig having enhanced fleshiness and stress tolerance and process for preparing the same
RCGTTTACC
>LG148951.1 KR 1020160054147-A/10: SNP for regulating cortisol secretion level of Pig and use thereof
MAGAAACAG
>LG148949.1 KR 1020160054147-A/8: SNP for regulating cortisol secretion level of Pig and use thereof
YTGGGACTC
>LG148947.1 KR 1020160054147-A/6: SNP for regulating cortisol secretion level of Pig and use thereof
RCGTTTACC
>LF849702.1 JP 2016528897-A/582: COMPOSITIONS AND METHODS FOR MODULATING RNA
CCGCCCTCC
>LF849698.1 JP 2016528897-A/578: COMPOSITIONS AND METHODS FOR MODULATING RNA
GCCCTCCAG
>LF849602.1 JP 2016528897-A/482: COMPOSITIONS AND METHODS FOR MODULATING RNA
CCGCCCTCC
>LF849598.1 JP 2016528897-A/478: COMPOSITIONS AND METHODS FOR MODULATING RNA
GCCCTCCAG
>LF848820.1 JP 2016528256-A/44: ANTIBODIES AGAINST FRIZZLED PROTEINS AND METHODS OF USE THEREOF
CCGGCTATG
>LF848311.1 JP 2016528232-A/107: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GGTGCATCC
>LF848279.1 JP 2016528232-A/75: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GGGGCAAGT
>LF848251.1 JP 2016528232-A/47: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GCTGCATCC
>LF848243.1 JP 2016528232-A/39: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GATGCATCC
>LF848235.1 JP 2016528232-A/31: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GATGCTTCC
>LF848227.1 JP 2016528232-A/23: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GAGACATCC
>LF848219.1 JP 2016528232-A/15: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
GCTGCATCC
>LF848211.1 JP 2016528232-A/7: ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF
TGGGCATCT
>LF838797.1 JP 2016528198-A/140: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838777.1 JP 2016528198-A/120: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838767.1 JP 2016528198-A/110: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGCGACATC
>LF838757.1 JP 2016528198-A/100: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838747.1 JP 2016528198-A/90: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838737.1 JP 2016528198-A/80: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838727.1 JP 2016528198-A/70: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838717.1 JP 2016528198-A/60: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838707.1 JP 2016528198-A/50: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838697.1 JP 2016528198-A/40: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838687.1 JP 2016528198-A/30: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838677.1 JP 2016528198-A/20: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF838667.1 JP 2016528198-A/10: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GGGGACATC
>LF782207.1 JP 2016523564-A/62: COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAS AND METHODS OF USE
CCRCCATGG
>LF716638.1 WO 2016152754-A/14: Method for Determining the Presence of c-Met Positive Tumor
AAACTACCT
>LF716636.1 WO 2016152754-A/12: Method for Determining the Presence of c-Met Positive Tumor
GATTCCGTT
>LF716634.1 WO 2016152754-A/10: Method for Determining the Presence of c-Met Positive Tumor
AGATGTAGC
>LF716632.1 WO 2016152754-A/8: Method for Determining the Presence of c-Met Positive Tumor
CAATGTAGC
>LF716630.1 WO 2016152754-A/6: Method for Determining the Presence of c-Met Positive Tumor
ATGGTGCTA
>LF781011.1 JP 2016523929-A/2: SOLUBLE MIC NEUTRALIZING MONOCLONAL ANTIBODY FOR TREATING CANCER
GATGCAACC
>LF715921.1 WO 2016143700-A/23: Method for stabilizing DNA aptamer
GCGNNACGC
>LF715900.1 WO 2016143700-A/2: Method for stabilizing DNA aptamer
GCCGAAGGC
>LF715899.1 WO 2016143700-A/1: Method for stabilizing DNA aptamer
CGCGAAGCG
>LF715410.1 JP 2016171801-A/21: Compositions of a peptide targeting system for treating cancer
AAAGCGGCG
>LF715398.1 JP 2016171801-A/9: Compositions of a peptide targeting system for treating cancer
CGTGGTGAC
>LF707737.1 JP 2016161390-A/6: A method for diagnosis of rheumatoid arthritis
TACACATCC
>LF647224.1 JP 2016138108-A/12: COMPOSITIONS FOR BACTERIAL MEDIATED GENE SILENCING AND METHODS OF USING SAME
TTCAAGAGA
>LF652942.1 JP 2016521120-A/84: NUCLEIC ACID AMPLIFICATION
GTTTCCCAA
>LF652941.1 JP 2016521120-A/83: NUCLEIC ACID AMPLIFICATION
TTGGGAAAC
>LF650483.1 JP 2016520514-A/10: ANTIGEN BINDING CONSTRUCTS TO CD8 REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING
GGCGGCTGC
>LF650471.1 JP 2016519650-A/295: Human Antibodies to Grem1
GATGCATCC
>LF650463.1 JP 2016519650-A/287: Human Antibodies to Grem1
GCTGCATCC
>LF650455.1 JP 2016519650-A/279: Human Antibodies to Grem1
GATTCATCC
>LF650447.1 JP 2016519650-A/271: Human Antibodies to Grem1
GGTGCATCC
>LF650439.1 JP 2016519650-A/263: Human Antibodies to Grem1
GCTGCATCC
>LF650431.1 JP 2016519650-A/255: Human Antibodies to Grem1
GATGCATCC
>LF650423.1 JP 2016519650-A/247: Human Antibodies to Grem1
GCTGCATCC
>LF650415.1 JP 2016519650-A/239: Human Antibodies to Grem1
GATGCATCC
>LF650407.1 JP 2016519650-A/231: Human Antibodies to Grem1
GCTGCATCC
>LF650399.1 JP 2016519650-A/223: Human Antibodies to Grem1
GATGCATCC
>LF650391.1 JP 2016519650-A/215: Human Antibodies to Grem1
GCTGCATCC
>LF650383.1 JP 2016519650-A/207: Human Antibodies to Grem1
GATTCATCC
>LF650375.1 JP 2016519650-A/199: Human Antibodies to Grem1
GGTGCATCC
>LF650367.1 JP 2016519650-A/191: Human Antibodies to Grem1
GCTGCATCC
>LF650359.1 JP 2016519650-A/183: Human Antibodies to Grem1
GATGCATCC
>LF650351.1 JP 2016519650-A/175: Human Antibodies to Grem1
GCTGCATCC
>LF650343.1 JP 2016519650-A/167: Human Antibodies to Grem1
GGTGCATCC
>LF650335.1 JP 2016519650-A/159: Human Antibodies to Grem1
GTTGCATCC
>LF650327.1 JP 2016519650-A/151: Human Antibodies to Grem1
GATGCATTC
>LF650319.1 JP 2016519650-A/143: Human Antibodies to Grem1
GTTGTATCC
>LF650311.1 JP 2016519650-A/135: Human Antibodies to Grem1
GCTGCATCC
>LF650303.1 JP 2016519650-A/127: Human Antibodies to Grem1
GATGCATCC
>LF650295.1 JP 2016519650-A/119: Human Antibodies to Grem1
GCTGCATCC
>LF650287.1 JP 2016519650-A/111: Human Antibodies to Grem1
TTGGGTTCT
>LF650279.1 JP 2016519650-A/103: Human Antibodies to Grem1
TATGTTTCC
>LF650271.1 JP 2016519650-A/95: Human Antibodies to Grem1
GCTGCATCC
>LF650263.1 JP 2016519650-A/87: Human Antibodies to Grem1
GTTGTATCA
>LF650255.1 JP 2016519650-A/79: Human Antibodies to Grem1
GATGCATCC
>LF650247.1 JP 2016519650-A/71: Human Antibodies to Grem1
GCTGCATCC
>LF650239.1 JP 2016519650-A/63: Human Antibodies to Grem1
GATGCATCC
>LF650231.1 JP 2016519650-A/55: Human Antibodies to Grem1
GATGCATCC
>LF650223.1 JP 2016519650-A/47: Human Antibodies to Grem1
GATGCATCC
>LF650215.1 JP 2016519650-A/39: Human Antibodies to Grem1
GATGCATCC
>LF650207.1 JP 2016519650-A/31: Human Antibodies to Grem1
GATGCATCC
>LF650199.1 JP 2016519650-A/23: Human Antibodies to Grem1
GCTGCATCC
>LF650191.1 JP 2016519650-A/15: Human Antibodies to Grem1
TCTGCATCC
>LF650183.1 JP 2016519650-A/7: Human Antibodies to Grem1
GATGCATCC
>LF645143.1 JP 2016136953-A/58: A Method of Detecting and/or Identifying Adeno-Associated Virus (AAV) Sequences and Isolating Novel Sequences Identified Thereby
CACCACGTC
>LF658998.1 JP 2016521709-A/6: METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES
GCTAGCAGA
>LF658693.1 JP 2016520616-A/367: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LF658681.1 JP 2016520616-A/355: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF658669.1 JP 2016520616-A/343: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF658657.1 JP 2016520616-A/331: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF658645.1 JP 2016520616-A/319: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF658633.1 JP 2016520616-A/307: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF658609.1 JP 2016520616-A/283: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF658597.1 JP 2016520616-A/271: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF658585.1 JP 2016520616-A/259: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LF658573.1 JP 2016520616-A/247: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF658561.1 JP 2016520616-A/235: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF658549.1 JP 2016520616-A/223: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF658537.1 JP 2016520616-A/211: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF658525.1 JP 2016520616-A/199: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF658513.1 JP 2016520616-A/187: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF658501.1 JP 2016520616-A/175: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF658489.1 JP 2016520616-A/163: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF658477.1 JP 2016520616-A/151: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LF658465.1 JP 2016520616-A/139: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LF658453.1 JP 2016520616-A/127: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LF658441.1 JP 2016520616-A/115: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LF658429.1 JP 2016520616-A/103: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LF658417.1 JP 2016520616-A/91: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LF658405.1 JP 2016520616-A/79: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF658393.1 JP 2016520616-A/67: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GCTGCATCC
>LF658381.1 JP 2016520616-A/55: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GCTGCATCC
>LF658369.1 JP 2016520616-A/43: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TGGGCATCT
>LF658357.1 JP 2016520616-A/31: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TGGGCCTCT
>LF658345.1 JP 2016520616-A/19: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF658333.1 JP 2016520616-A/7: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF658621.1 JP 2016520616-A/295: Methods for Reducing Remnant Cholesterol and Other Lipoprotein Fractions by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GATGCATCC
>LQ681933.1 Sequence 326 from Patent EP3074424
TCTGCATCC
>LQ681911.1 Sequence 304 from Patent EP3074424
AGCGCTTCC
>LQ681873.1 Sequence 266 from Patent EP3074424
AGCGCCTCC
>LQ681807.1 Sequence 200 from Patent EP3074424
AGTGCATCA
>LQ681785.1 Sequence 178 from Patent EP3074424
TCTGCATCC
>LQ681763.1 Sequence 156 from Patent EP3074424
TCTGCATCC
>LQ681729.1 Sequence 122 from Patent EP3074424
AGCGCCTCC
>LQ681685.1 Sequence 78 from Patent EP3074424
AGCGCCTCC
>LQ681673.1 Sequence 66 from Patent EP3074424
AGTGCATCA
>LQ681661.1 Sequence 54 from Patent EP3074424
AGTGCATCA
>LQ681649.1 Sequence 42 from Patent EP3074424
AGCGCCTCC
>LQ668961.1 Sequence 77 from Patent EP3077512
ATTGATGGG
>LQ664041.1 Sequence 50 from Patent EP3090064
TTTTTTTTT
>LQ664025.1 Sequence 34 from Patent EP3090064
GGGGGGGGG
>LQ658007.1 Sequence 54 from Patent WO2016161207
GGGGGAAGT
>LQ638946.1 Sequence 364 from Patent WO2016170176
GGGTTTGGG
>LQ638935.1 Sequence 353 from Patent WO2016170176
GGTTTTTGG
>LQ635153.1 Sequence 22 from Patent WO2016172346
CAGTTAGGG
>LQ635152.1 Sequence 21 from Patent WO2016172346
GGGTTAGAC
>LQ628783.1 Sequence 387 from Patent WO2016168613
GCTGCATCC
>LQ628767.1 Sequence 371 from Patent WO2016168613
ACTACATCC
>LQ628721.1 Sequence 325 from Patent WO2016168613
AAGATTTCT
>LQ628713.1 Sequence 317 from Patent WO2016168613
TTGGGTTCT
>LQ628697.1 Sequence 301 from Patent WO2016168613
GCTGCATCC
>LQ628681.1 Sequence 285 from Patent WO2016168613
GGTGCATCC
>LQ628665.1 Sequence 269 from Patent WO2016168613
TTGGGTTCT
>LQ628649.1 Sequence 253 from Patent WO2016168613
GGTGCATCC
>LQ628633.1 Sequence 237 from Patent WO2016168613
GGTGCATCC
>LQ628617.1 Sequence 221 from Patent WO2016168613
GGTGCATCC
>LQ628601.1 Sequence 205 from Patent WO2016168613
GGTGCATCC
>LQ628585.1 Sequence 189 from Patent WO2016168613
GCTACATCC
>LQ628569.1 Sequence 173 from Patent WO2016168613
GGTGCATCC
>LQ628553.1 Sequence 157 from Patent WO2016168613
GCTGCATCC
>LQ628537.1 Sequence 141 from Patent WO2016168613
GTTGCATCC
>LQ628521.1 Sequence 125 from Patent WO2016168613
CGGATGTCC
>LQ628505.1 Sequence 109 from Patent WO2016168613
GCTGCATCC
>LQ628489.1 Sequence 93 from Patent WO2016168613
GCTGCATCC
>LQ628473.1 Sequence 77 from Patent WO2016168613
GCTGCATCC
>LQ628457.1 Sequence 61 from Patent WO2016168613
GCTGCATCC
>LQ628441.1 Sequence 45 from Patent WO2016168613
GCTGCATCC
>LQ628425.1 Sequence 29 from Patent WO2016168613
GCTGCATCC
>LQ628409.1 Sequence 13 from Patent WO2016168613
GGTGTATCC
>LQ624236.1 Sequence 9 from Patent EP3093345
CCTGTTAAG
>LQ620944.1 Sequence 37 from Patent WO2016177682
GTTTTTGTA
>LQ620928.1 Sequence 21 from Patent WO2016177682
TCATTTGAG
>LQ620926.1 Sequence 19 from Patent WO2016177682
CGATTTGAG
>LF560593.1 JP 2015516143-A/154964: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LF643415.1 JP 2016516808-A/25: METHODS OF KILLING SENESCENT CELLS
TTTGTGTAG
>LF401004.1 JP 2014530630-A/5: SELF-COMPETITIVE PRIMER AND METHOD OF USE
CCACCAGCT
>LF580929.1 JP 2015516143-A/175300: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGCTAG
>LF398767.1 JP 2014527967-A/367: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LF398755.1 JP 2014527967-A/355: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF398743.1 JP 2014527967-A/343: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF398731.1 JP 2014527967-A/331: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF398719.1 JP 2014527967-A/319: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF398707.1 JP 2014527967-A/307: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF398695.1 JP 2014527967-A/295: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GATGCATCC
>LF398683.1 JP 2014527967-A/283: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF398671.1 JP 2014527967-A/271: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF398659.1 JP 2014527967-A/259: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LF398647.1 JP 2014527967-A/247: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF398635.1 JP 2014527967-A/235: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF398623.1 JP 2014527967-A/223: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF398611.1 JP 2014527967-A/211: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF398599.1 JP 2014527967-A/199: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF398587.1 JP 2014527967-A/187: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF398575.1 JP 2014527967-A/175: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF398563.1 JP 2014527967-A/163: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF398551.1 JP 2014527967-A/151: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LF398539.1 JP 2014527967-A/139: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LF398527.1 JP 2014527967-A/127: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LF398515.1 JP 2014527967-A/115: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LF398503.1 JP 2014527967-A/103: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LF398491.1 JP 2014527967-A/91: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LF398479.1 JP 2014527967-A/79: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LF398467.1 JP 2014527967-A/67: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GCTGCATCC
>LF398455.1 JP 2014527967-A/55: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GCTGCATCC
>LF398443.1 JP 2014527967-A/43: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TGGGCATCT
>LF398431.1 JP 2014527967-A/31: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TGGGCCTCT
>LF398419.1 JP 2014527967-A/19: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LF398407.1 JP 2014527967-A/7: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LF396983.1 JP 2014515762-A/53: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
CAGGCAGGC
>LF396977.1 JP 2014515762-A/47: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
GCAGCAGCA
>LF396973.1 JP 2014515762-A/43: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
AGCAGCAGC
>LF396969.1 JP 2014515762-A/39: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
CAGCAGCAG
>LF397973.1 JP 2014528713-A/2: METHODS FOR TAGGING DNA-ENCODED LIBRARIES
GCAGCACCC
>LF626779.1 JP 2016128440-A/643: COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM
GCTTCTGGA
>LF626776.1 JP 2016128440-A/640: COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM
GCTTCTGGA
>LF454399.1 JP 2015516143-A/48770: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LF643639.1 JP 2016518382-A/2: AXL ANTIBODY-DRUG CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER
TCTGGATCC
>LF643414.1 JP 2016516808-A/24: METHODS OF KILLING SENESCENT CELLS
TTCAAGAGA
>LF404732.1 JP 2015504858-A/73: Targeting EN2, PAX2, and/or DEFB1 for Treatment of Prostate Conditions
ACCCTTGAC
>LF522396.1 JP 2015516143-A/116767: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGAGGTAG
>LF451600.1 JP 2015516143-A/45971: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGAGATAG
>LF545531.1 JP 2015516143-A/139902: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGCTAG
>LF402870.1 JP 2015505539-A/247: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCAACC
>LF402858.1 JP 2015505539-A/235: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTACATCC
>LF402846.1 JP 2015505539-A/223: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
TCTGCATCC
>LF402834.1 JP 2015505539-A/211: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>LF402822.1 JP 2015505539-A/199: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
TTGGGTTCT
>LF402810.1 JP 2015505539-A/187: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
AAGGCGTCT
>LF402798.1 JP 2015505539-A/175: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
TTGGGTTCT
>LF402786.1 JP 2015505539-A/163: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GGTGCGTCC
>LF402774.1 JP 2015505539-A/151: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
AAGGCGTCT
>LF402762.1 JP 2015505539-A/139: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>LF402750.1 JP 2015505539-A/127: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>LF402738.1 JP 2015505539-A/115: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GGTGCATCC
>LF402726.1 JP 2015505539-A/103: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>LF402714.1 JP 2015505539-A/91: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTACATCC
>LF402702.1 JP 2015505539-A/79: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>LF402690.1 JP 2015505539-A/67: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GGTGCATCC
>LF402678.1 JP 2015505539-A/55: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
AAGGCGTCT
>LF402666.1 JP 2015505539-A/43: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>LF402654.1 JP 2015505539-A/31: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
AGTGCATCC
>LF402642.1 JP 2015505539-A/19: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GATGCATCT
>LF402630.1 JP 2015505539-A/7: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GGTGCATCC
>LF474735.1 JP 2015516143-A/69106: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGCTAG
>LF401839.1 JP 2015502754-A/1: METHOD OF DNA DETECTION AND QUANTIFICATION BY SINGLE-MOLECULE HYBRIDIZATION AND MANIPULATION
ACAGCCAGC
>LF395075.1 JP 2014517845-A/140: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF395055.1 JP 2014517845-A/120: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF395045.1 JP 2014517845-A/110: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGCGACATC
>LF395035.1 JP 2014517845-A/100: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF395025.1 JP 2014517845-A/90: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF395015.1 JP 2014517845-A/80: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF395005.1 JP 2014517845-A/70: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF394995.1 JP 2014517845-A/60: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF394985.1 JP 2014517845-A/50: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF394975.1 JP 2014517845-A/40: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF394965.1 JP 2014517845-A/30: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF394955.1 JP 2014517845-A/20: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF394945.1 JP 2014517845-A/10: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS
GGGGACATC
>LF394935.1 JP 2014517699-A/140: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394915.1 JP 2014517699-A/120: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394905.1 JP 2014517699-A/110: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGCGACATC
>LF394895.1 JP 2014517699-A/100: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394885.1 JP 2014517699-A/90: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394875.1 JP 2014517699-A/80: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394865.1 JP 2014517699-A/70: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394855.1 JP 2014517699-A/60: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394845.1 JP 2014517699-A/50: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394835.1 JP 2014517699-A/40: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394825.1 JP 2014517699-A/30: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394815.1 JP 2014517699-A/20: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF394805.1 JP 2014517699-A/10: ANTI-CGRP COMPOSITIONS AND USE THEREOF
GGGGACATC
>LF489797.1 JP 2015516143-A/84168: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LF393582.1 JP 2014521317-A/37: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
TCTAATGGG
>LF393581.1 JP 2014521317-A/36: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
TCCAATAAA
>LF393580.1 JP 2014521317-A/35: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
AATAATAAC
>LF393579.1 JP 2014521317-A/34: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
TCCCACGAC
>LF393578.1 JP 2014521317-A/33: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
TCTAACATC
>LF616327.1 JP 2015516143-A/210698: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGGTAG
>LF510133.1 JP 2015516143-A/104504: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGTTAG
>LF486998.1 JP 2015516143-A/81369: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCGTTAG
>LF391249.1 JP 2014518062-A/2: Polycistronic expression system for bacteria
TAATCCATG
>LF390562.1 JP 2014515264-A/333: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
TTTCTCCCC
>LF389214.1 JP 2014509852-A/121: MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER
TTCCTTGGT
>LF389141.1 JP 2014509852-A/48: MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER
TCCGTTTGC
>LF389131.1 JP 2014509852-A/38: MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER
CGTTATGGC
>LF389129.1 JP 2014509852-A/36: MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER
TTATGACCT
>LF389126.1 JP 2014509852-A/33: MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER
GCGCGCCGG
>LF389117.1 JP 2014509852-A/24: MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER
CGTTRTGGC
>LF389105.1 JP 2014509852-A/12: MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER
TGTAAATGA
>LF389104.1 JP 2014509852-A/11: MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER
AATGYCTTG
>LF389103.1 JP 2014509852-A/10: MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER
GGGGRCATA
>LF557794.1 JP 2015516143-A/152165: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCGGTAG
>LF625594.1 JP 2016127846-A/43: MONOCLONAL ANTIBODIES AGAINST INFLUENZA VIRUS GENERATED BY CYCLICAL ADMINISTRATION AND USES THEREOF
CTGGCGAGC
>LF625587.1 JP 2016127846-A/36: MONOCLONAL ANTIBODIES AGAINST INFLUENZA VIRUS GENERATED BY CYCLICAL ADMINISTRATION AND USES THEREOF
CGTGCATCC
>LF625571.1 JP 2016127846-A/20: MONOCLONAL ANTIBODIES AGAINST INFLUENZA VIRUS GENERATED BY CYCLICAL ADMINISTRATION AND USES THEREOF
AAAGTTTCC
>LF525195.1 JP 2015516143-A/119566: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LF595991.1 JP 2015516143-A/190362: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LF593192.1 JP 2015516143-A/187563: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCGGTAG
>XM_018792850.1 Schistosoma mansoni ubiquitin-specific peptidase 48 (C19 family) partial mRNA
ATGGAATAG
>LQ281931.1 Sequence 93 from Patent EP2895203
GGCGGCTGC
>LQ276422.1 Sequence 59 from Patent WO2016071758
GCTAGCAGA
>LQ264487.1 Sequence 280 from Patent EP3016684
GGGGACATC
>LQ264467.1 Sequence 260 from Patent EP3016684
GGGGACATC
>LQ264457.1 Sequence 250 from Patent EP3016684
GGCGACATC
>LQ264447.1 Sequence 240 from Patent EP3016684
GGGGACATC
>LQ264437.1 Sequence 230 from Patent EP3016684
GGGGACATC
>LQ264427.1 Sequence 220 from Patent EP3016684
GGGGACATC
>LQ264417.1 Sequence 210 from Patent EP3016684
GGGGACATC
>LQ264407.1 Sequence 200 from Patent EP3016684
GGGGACATC
>LQ264397.1 Sequence 190 from Patent EP3016684
GGGGACATC
>LQ264387.1 Sequence 180 from Patent EP3016684
GGGGACATC
>LQ264377.1 Sequence 170 from Patent EP3016684
GGGGACATC
>LQ264367.1 Sequence 160 from Patent EP3016684
GGGGACATC
>LQ264357.1 Sequence 150 from Patent EP3016684
GGGGACATC
>LQ262215.1 Sequence 2 from Patent EP3016683
GATGCAACC
>LQ260273.1 Sequence 113 from Patent EP2999788
CCCCGCCGA
>LQ254760.1 Sequence 157 from Patent WO2016044337
TGGGCATCT
>LQ254744.1 Sequence 141 from Patent WO2016044337
TGGGCATCT
>LQ254728.1 Sequence 125 from Patent WO2016044337
TGGGCATCT
>LQ254712.1 Sequence 109 from Patent WO2016044337
TGGGCATCT
>LQ254696.1 Sequence 93 from Patent WO2016044337
TGGGCATCT
>LQ254680.1 Sequence 77 from Patent WO2016044337
TGGGCATCT
>LQ254664.1 Sequence 61 from Patent WO2016044337
TGGGCATCT
>LQ254648.1 Sequence 45 from Patent WO2016044337
TGGGCATCT
>LQ254632.1 Sequence 29 from Patent WO2016044337
TGGGCATCT
>LQ254616.1 Sequence 13 from Patent WO2016044337
TGGGCATCT
>LQ337888.1 Sequence 365 from Patent WO2016055950
GGCAACAAC
>LQ337869.1 Sequence 346 from Patent WO2016055950
GATGCATCC
>LQ337849.1 Sequence 326 from Patent WO2016055950
AAGAATAAT
>LQ337811.1 Sequence 288 from Patent WO2016055950
GGTAACAAC
>LQ337795.1 Sequence 272 from Patent WO2016055950
ACTACATCC
>LQ337779.1 Sequence 256 from Patent WO2016055950
GACGTCACT
>LQ337749.1 Sequence 226 from Patent WO2016055950
GCTGCATCC
>LQ337721.1 Sequence 198 from Patent WO2016055950
CAAGATACG
>LQ337678.1 Sequence 155 from Patent WO2016055950
GGTGCATCC
>LQ337662.1 Sequence 139 from Patent WO2016055950
GATGTCGAT
>LQ337646.1 Sequence 123 from Patent WO2016055950
CAAGATTCC
>LQ337630.1 Sequence 107 from Patent WO2016055950
GAGGTTTCT
>LQ337614.1 Sequence 91 from Patent WO2016055950
GATGGCAGT
>LQ337598.1 Sequence 75 from Patent WO2016055950
GATGTCAGT
>LQ337582.1 Sequence 59 from Patent WO2016055950
GACAATGAT
>LQ337566.1 Sequence 43 from Patent WO2016055950
AAAGACACT
>LQ337550.1 Sequence 27 from Patent WO2016055950
GATGATAGC
>LQ337534.1 Sequence 11 from Patent WO2016055950
AAGGCGTCT
>LQ251498.1 Sequence 365 from Patent EP3009449
GGCAACAAC
>LQ251479.1 Sequence 346 from Patent EP3009449
GATGCATCC
>LQ251459.1 Sequence 326 from Patent EP3009449
AAGAATAAT
>LQ251421.1 Sequence 288 from Patent EP3009449
GGTAACAAC
>LQ251405.1 Sequence 272 from Patent EP3009449
ACTACATCC
>LQ251389.1 Sequence 256 from Patent EP3009449
GACGTCACT
>LQ251359.1 Sequence 226 from Patent EP3009449
GCTGCATCC
>LQ251331.1 Sequence 198 from Patent EP3009449
CAAGATACG
>LQ251288.1 Sequence 155 from Patent EP3009449
GGTGCATCC
>LQ251272.1 Sequence 139 from Patent EP3009449
GATGTCGAT
>LQ251256.1 Sequence 123 from Patent EP3009449
CAAGATTCC
>LQ251240.1 Sequence 107 from Patent EP3009449
GAGGTTTCT
>LQ251224.1 Sequence 91 from Patent EP3009449
GATGGCAGT
>LQ251208.1 Sequence 75 from Patent EP3009449
GATGTCAGT
>LQ251192.1 Sequence 59 from Patent EP3009449
GACAATGAT
>LQ251176.1 Sequence 43 from Patent EP3009449
AAAGACACT
>LQ251160.1 Sequence 27 from Patent EP3009449
GATGATAGC
>LQ251144.1 Sequence 11 from Patent EP3009449
AAGGCGTCT
>LQ249537.1 Sequence 2 from Patent EP3000873
TTATCCACA
>LQ439724.1 Sequence 56 from Patent EP3054765
CAATWATTG
>LQ439723.1 Sequence 55 from Patent EP3054765
CAATSATTG
>LQ432145.1 Sequence 3 from Patent EP3063317
AGCGTGTAA
>LQ580554.1 Sequence 17 from Patent WO2016102715
TACACATCA
>LQ429979.1 Sequence 163 from Patent EP3037549
CCGAGTGCG
>LQ429965.1 Sequence 149 from Patent EP3037549
GTTGCCGCT
>LQ429964.1 Sequence 148 from Patent EP3037549
GTTGCCGCC
>LQ429950.1 Sequence 134 from Patent EP3037549
GCGCAGCTA
>LQ429949.1 Sequence 133 from Patent EP3037549
GCGCAGCTC
>LQ429930.1 Sequence 114 from Patent EP3037549
TGGCTGCGG
>LQ429915.1 Sequence 99 from Patent EP3037549
CGACAGGGG
>LQ429889.1 Sequence 73 from Patent EP3037549
GTGGGACGG
>LQ429880.1 Sequence 64 from Patent EP3037549
GGTCCGGGC
>LQ429879.1 Sequence 63 from Patent EP3037549
GGTCCGGGT
>LQ429869.1 Sequence 53 from Patent EP3037549
CCAGGAGCG
>LQ427055.1 Sequence 2 from Patent EP3027754
CCACCATGG
>LQ426321.1 Sequence 9 from Patent EP3037536
CTGTCTCTT
>LQ426332.1 Sequence 20 from Patent EP3037536
BTGTYTCBT
>LQ578098.1 Sequence 250 from Patent EP3068430
AGTGCATCA
>LQ578070.1 Sequence 222 from Patent EP3068430
TCTGCATCC
>LQ578020.1 Sequence 172 from Patent EP3068430
AGCGCCTCC
>LQ578008.1 Sequence 160 from Patent EP3068430
AGCGCCTCC
>LQ577962.1 Sequence 114 from Patent EP3068430
GACCACACA
>LQ577942.1 Sequence 94 from Patent EP3068430
AGCGCCTCC
>LQ576560.1 Sequence 101 from Patent EP3017043
AACCAATCA
>LQ574248.1 Sequence 30 from Patent WO2016094607
AATAAATCA
>LQ573013.1 Sequence 6 from Patent EP3031467
CCCGTGCAT
>LQ573012.1 Sequence 5 from Patent EP3031467
ATGCACGGG
>LQ450303.1 Sequence 3 from Patent EP3066219
TGAAAGTGA
>LQ450302.1 Sequence 2 from Patent EP3066219
CCAGCATTA
>LQ497310.1 Sequence 85 from Patent WO2016075546
GGTACATCA
>LQ497295.1 Sequence 70 from Patent WO2016075546
GCCGCATCC
>LQ497280.1 Sequence 55 from Patent WO2016075546
GGTACATCC
>LQ497264.1 Sequence 39 from Patent WO2016075546
CAAGACAAT
>LQ497248.1 Sequence 23 from Patent WO2016075546
GCCGCTTCT
>LQ497236.1 Sequence 11 from Patent WO2016075546
GCTGCATCC
>LQ585246.1 Sequence 39 from Patent WO2016102687
CGACGACGA
>LQ584778.1 Sequence 38 from Patent WO2016103205
TCGGCATCC
>LQ584772.1 Sequence 32 from Patent WO2016103205
TATGCATCC
>LQ584766.1 Sequence 26 from Patent WO2016103205
GCTGCATCC
>LQ584761.1 Sequence 21 from Patent WO2016103205
CTTGTATCC
>LQ405982.1 Sequence 113 from Patent WO2016142948
CAGGTAAGT
>LQ404593.1 Sequence 25 from Patent WO2016145189
GGAGACACC
>LQ404855.1 Sequence 49 from Patent WO2016147194
GCCACATCC
>LQ404825.1 Sequence 19 from Patent WO2016147194
CGGATGTCC
>LQ404599.1 Sequence 31 from Patent WO2016145189
GGAGACACT
>LQ403266.1 Sequence 61 from Patent EP3036260
GCAAACGGA
>LQ403047.1 Sequence 154 from Patent WO2016142768
AGGGATAGC
>LQ403035.1 Sequence 142 from Patent WO2016142768
GATGTCAAT
>LQ403023.1 Sequence 130 from Patent WO2016142768
TATGATAGC
>LQ403011.1 Sequence 118 from Patent WO2016142768
GATGTCAGT
>LQ402999.1 Sequence 106 from Patent WO2016142768
GAAGATACT
>LQ402987.1 Sequence 94 from Patent WO2016142768
AAGGTTTCT
>LQ402975.1 Sequence 82 from Patent WO2016142768
GATACATCC
>LQ402963.1 Sequence 70 from Patent WO2016142768
AGGAATGAT
>LQ402951.1 Sequence 58 from Patent WO2016142768
AAAGTTTCT
>LQ402939.1 Sequence 46 from Patent WO2016142768
GATAACGCC
>LQ402927.1 Sequence 34 from Patent WO2016142768
GATGCATCC
>LQ402915.1 Sequence 22 from Patent WO2016142768
GGTGCGTCT
>LQ402903.1 Sequence 10 from Patent WO2016142768
GGTAAAAAC
>LQ569539.1 Sequence 31 from Patent EP2968622
GGCGGCTGC
>LQ395974.1 Sequence 85 from Patent EP3071713
GTTTCCCAA
>LQ395973.1 Sequence 84 from Patent EP3071713
TTGGGAAAC
>LQ525477.1 Sequence 28 from Patent WO2016135732
TTTGTGTAG
>LQ525476.1 Sequence 27 from Patent WO2016135732
TTCAAGAGA
>LQ525166.1 Sequence 111 from Patent WO2016139482
GCTGCATCC
>LQ525138.1 Sequence 83 from Patent WO2016139482
GATGCCTCC
>LQ525106.1 Sequence 51 from Patent WO2016139482
GCTGCATCC
>LQ525074.1 Sequence 19 from Patent WO2016139482
GCTGCATCC
>LQ517339.1 Sequence 253 from Patent EP3064511
GATGCATCC
>LQ517315.1 Sequence 229 from Patent EP3064511
GATGCATCC
>LQ517291.1 Sequence 205 from Patent EP3064511
GTTGCATCC
>LQ517267.1 Sequence 181 from Patent EP3064511
GCTGCATCC
>LQ517243.1 Sequence 157 from Patent EP3064511
TTGGGTTCT
>LQ517219.1 Sequence 133 from Patent EP3064511
AGTGCCTCC
>LQ517195.1 Sequence 109 from Patent EP3064511
GCTGCATCC
>LQ517171.1 Sequence 85 from Patent EP3064511
TTGGGTTCT
>LQ517147.1 Sequence 61 from Patent EP3064511
GCTGTATCC
>LQ517123.1 Sequence 37 from Patent EP3064511
GCTGCATCC
>LQ517099.1 Sequence 13 from Patent EP3064511
GCTGCATCC
>LQ514291.1 Sequence 7 from Patent EP3023500
CCTGTTAAG
>LQ512001.1 Sequence 301 from Patent WO2016123019
GCTGCATCC
>LQ511985.1 Sequence 285 from Patent WO2016123019
GCTGCATCC
>LQ511969.1 Sequence 269 from Patent WO2016123019
GCTGCATCC
>LQ511953.1 Sequence 253 from Patent WO2016123019
GCTGCATCC
>LQ511937.1 Sequence 237 from Patent WO2016123019
GCTGCCTCC
>LQ511921.1 Sequence 221 from Patent WO2016123019
GGTGCATCC
>LQ511905.1 Sequence 205 from Patent WO2016123019
GCTGCATCC
>LQ511889.1 Sequence 189 from Patent WO2016123019
GCTGCATCC
>LQ511873.1 Sequence 173 from Patent WO2016123019
GCTGCATCC
>LQ511857.1 Sequence 157 from Patent WO2016123019
GCTGCATCC
>LQ511841.1 Sequence 141 from Patent WO2016123019
GGTGCATCC
>LQ511825.1 Sequence 125 from Patent WO2016123019
GGTGCATCC
>LQ511809.1 Sequence 109 from Patent WO2016123019
GTTGCATCC
>LQ511793.1 Sequence 93 from Patent WO2016123019
GCTGCATCC
>LQ511777.1 Sequence 77 from Patent WO2016123019
GCTGCATCC
>LQ511761.1 Sequence 61 from Patent WO2016123019
GCTGCATCC
>LQ511745.1 Sequence 45 from Patent WO2016123019
GCTGCATCC
>LQ511729.1 Sequence 29 from Patent WO2016123019
TGGGCATCT
>LQ511713.1 Sequence 13 from Patent WO2016123019
GGTGCATCC
>LQ509883.1 Sequence 21 from Patent WO2016081490
GGTGCATCC
>LQ504302.1 Sequence 251 from Patent EP3043819
GACAATTAT
>LQ504296.1 Sequence 245 from Patent EP3043819
GGTGCGTCC
>LQ504290.1 Sequence 239 from Patent EP3043819
GGTGCTTCC
>LQ504278.1 Sequence 227 from Patent EP3043819
GATGCATCC
>LQ504272.1 Sequence 221 from Patent EP3043819
GCTACTTCC
>LQ504266.1 Sequence 215 from Patent EP3043819
GATGTCATT
>LQ504260.1 Sequence 209 from Patent EP3043819
GGTGGTTCC
>LQ504242.1 Sequence 191 from Patent EP3043819
TTGGCTTCT
>LQ314254.1 Sequence 10 from Patent EP3004329
GCTAGCAGA
>LQ314149.1 Sequence 34 from Patent EP3006942
AAAGTTTCC
>LQ245839.1 Sequence 121 from Patent WO2016038095
CCATCAAGA
>LQ245116.1 Sequence 47 from Patent WO2016038609
GGTGCAACC
>LQ245106.1 Sequence 37 from Patent WO2016038609
TACACATCA
>LQ245093.1 Sequence 24 from Patent WO2016038609
AACACAGCA
>LQ308396.1 Sequence 7 from Patent EP2893020
ATCGAATTG
>LQ307017.1 Sequence 269 from Patent WO2016049000
GCTGCGTCC
>LQ307001.1 Sequence 253 from Patent WO2016049000
TGGGCATCT
>LQ306985.1 Sequence 237 from Patent WO2016049000
GATGCATCC
>LQ306969.1 Sequence 221 from Patent WO2016049000
TGGGCTTCC
>LQ306953.1 Sequence 205 from Patent WO2016049000
TGGGCATCT
>LQ306937.1 Sequence 189 from Patent WO2016049000
TGGGCATCT
>LQ306921.1 Sequence 173 from Patent WO2016049000
GCTGCATCC
>LQ306905.1 Sequence 157 from Patent WO2016049000
TGGGCATCT
>LQ306889.1 Sequence 141 from Patent WO2016049000
ACTGCATCC
>LQ306873.1 Sequence 125 from Patent WO2016049000
GCTGCATCC
>LQ306857.1 Sequence 109 from Patent WO2016049000
GCTGCATCC
>LQ306841.1 Sequence 93 from Patent WO2016049000
TCTACATCC
>LQ306825.1 Sequence 77 from Patent WO2016049000
TGGTCATCT
>LQ306809.1 Sequence 61 from Patent WO2016049000
TGGGCGTCT
>LQ306793.1 Sequence 45 from Patent WO2016049000
GCTGCATCC
>LQ306777.1 Sequence 29 from Patent WO2016049000
GCTGCATCC
>LQ306761.1 Sequence 13 from Patent WO2016049000
GCTGCATCC
>LQ293023.1 Sequence 213 from Patent WO2016061142
TGGGCCTCT
>LQ292932.1 Sequence 122 from Patent WO2016061142
TGGGCCTCT
>LQ292921.1 Sequence 111 from Patent WO2016061142
TGGGCATCC
>LF170111.1 JP 2016513664-A/43: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
CTCACATCC
>LF170110.1 JP 2016513664-A/42: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
CGTGCATCC
>LF170109.1 JP 2016513664-A/41: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
CGGATGTCC
>LF169728.1 JP 2016513644-A/39: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169720.1 JP 2016513644-A/31: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169712.1 JP 2016513644-A/23: Anti-IL-33 Antibodies and Uses Thereof
GGTGCATCC
>LF169704.1 JP 2016513644-A/15: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169696.1 JP 2016513644-A/7: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169848.1 JP 2016513644-A/159: Anti-IL-33 Antibodies and Uses Thereof
TGGGCATCT
>LF169840.1 JP 2016513644-A/151: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCA
>LF169832.1 JP 2016513644-A/143: Anti-IL-33 Antibodies and Uses Thereof
GCTGCTTCC
>LF169824.1 JP 2016513644-A/135: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169816.1 JP 2016513644-A/127: Anti-IL-33 Antibodies and Uses Thereof
GTTGCATCC
>LF169808.1 JP 2016513644-A/119: Anti-IL-33 Antibodies and Uses Thereof
GCTGCGTCC
>LF169800.1 JP 2016513644-A/111: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169792.1 JP 2016513644-A/103: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169784.1 JP 2016513644-A/95: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169776.1 JP 2016513644-A/87: Anti-IL-33 Antibodies and Uses Thereof
GCTGCGTCC
>LF169768.1 JP 2016513644-A/79: Anti-IL-33 Antibodies and Uses Thereof
GCTGCAGCC
>LF169760.1 JP 2016513644-A/71: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169752.1 JP 2016513644-A/63: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169744.1 JP 2016513644-A/55: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169736.1 JP 2016513644-A/47: Anti-IL-33 Antibodies and Uses Thereof
GCTGCATCC
>LF169219.1 JP 2016514960-A/6: MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF
GCTAGCAGA
>LF158221.1 JP 2016104027-A/33: Compositions and methods related to mRNA translational enhancer elements
CCCGGCGGA
>LF163225.1 JP 2016514098-A/147: Bispecific T cell activating antigen binding molecules
TTCGACTAC
>LF163196.1 JP 2016514098-A/118: Bispecific T cell activating antigen binding molecules
TTCGACTAC
>LF163115.1 JP 2016514098-A/37: Bispecific T cell activating antigen binding molecules
TTTGACTAC
>LF159163.1 WO 2016093229-A/54: Nucleic acid complex, method for making hybridization of nucleic acid, pharmaceutical composition, probe for detecting nucleic acid and complementary strand nucleic acid complex
AGCNGCAGC
>LF158979.1 WO 2016098595-A/9: Probe and SNP Detection Method
GTCCAGAAC
>LF158978.1 WO 2016098595-A/8: Probe and SNP Detection Method
GACCAGAAC
>LF158220.1 JP 2016104027-A/32: Compositions and methods related to mRNA translational enhancer elements
CGGCTGCTA
>LF158219.1 JP 2016104027-A/31: Compositions and methods related to mRNA translational enhancer elements
CGCGGCTGA
>LF158218.1 JP 2016104027-A/30: Compositions and methods related to mRNA translational enhancer elements
CCCGGCGGA
>LF158217.1 JP 2016104027-A/29: Compositions and methods related to mRNA translational enhancer elements
CCCGCTGAA
>LF158216.1 JP 2016104027-A/28: Compositions and methods related to mRNA translational enhancer elements
CCCGCCGAA
>LF158215.1 JP 2016104027-A/27: Compositions and methods related to mRNA translational enhancer elements
CCCGCGGAA
>LF158211.1 JP 2016104027-A/23: Compositions and methods related to mRNA translational enhancer elements
CCGGCTGAA
>LF158210.1 JP 2016104027-A/22: Compositions and methods related to mRNA translational enhancer elements
GCGGCTGAA
>LF158209.1 JP 2016104027-A/21: Compositions and methods related to mRNA translational enhancer elements
CGCCGCCGC
>LF158208.1 JP 2016104027-A/20: Compositions and methods related to mRNA translational enhancer elements
CGCGGCGGA
>LF158207.1 JP 2016104027-A/19: Compositions and methods related to mRNA translational enhancer elements
GAGAGGAGC
>LF158206.1 JP 2016104027-A/18: Compositions and methods related to mRNA translational enhancer elements
CGAGAGGCA
>LF158205.1 JP 2016104027-A/17: Compositions and methods related to mRNA translational enhancer elements
GCCGAGAGA
>LF158204.1 JP 2016104027-A/16: Compositions and methods related to mRNA translational enhancer elements
AGGAGAGGA
>LF158200.1 JP 2016104027-A/12: Compositions and methods related to mRNA translational enhancer elements
ACGAGCGGA
>LF158199.1 JP 2016104027-A/11: Compositions and methods related to mRNA translational enhancer elements
ACGAGAGGA
>LF158198.1 JP 2016104027-A/10: Compositions and methods related to mRNA translational enhancer elements
CGGAGCGGA
>LF158197.1 JP 2016104027-A/9: Compositions and methods related to mRNA translational enhancer elements
CGGAGCGAA
>LF158196.1 JP 2016104027-A/8: Compositions and methods related to mRNA translational enhancer elements
GCGAGCGGA
>LF158195.1 JP 2016104027-A/7: Compositions and methods related to mRNA translational enhancer elements
GCGAGAGGA
>LF158194.1 JP 2016104027-A/6: Compositions and methods related to mRNA translational enhancer elements
GGGAGCGAA
>LF158193.1 JP 2016104027-A/5: Compositions and methods related to mRNA translational enhancer elements
GCGAGAGAA
>LF153162.1 JP 2016117721-A/6: anti-cMet antibody
AGGGCTTCT
>LQ224806.1 Sequence 13 from Patent WO2016030899
TTTGTGTAG
>LQ224805.1 Sequence 12 from Patent WO2016030899
TTCAAGAGA
>LQ224064.1 Sequence 2 from Patent WO2016026954
TTTAYRTTT
>LQ222945.1 Sequence 10 from Patent WO2016028150
GCCACATCC
>LQ217044.1 Sequence 17 from Patent EP2990476
GAGNNNACV
>LF149923.1 JP 2016512242-A/145: HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES
ATGACGTAC
>LF149909.1 JP 2016512242-A/131: HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES
TTTGCTTAC
>LF147775.1 JP 2016512421-A/147: Bispecific T cell activating antigen binding molecules
TTCGACTAC
>LF147746.1 JP 2016512421-A/118: Bispecific T cell activating antigen binding molecules
TTCGACTAC
>LF147665.1 JP 2016512421-A/37: Bispecific T cell activating antigen binding molecules
TTTGACTAC
>LF138998.1 JP 2016093104-A/21: human antiCD3e antibody
AGGGATGAT
>LF139274.1 JP 2016079153-A/7: A mutant protein G
TAGAAGCTT
>LF139266.1 JP 2016079149-A/8: A mutant protein L
TAGAAGCTT
>HZ795036.1 JP 2016042858-A/3: A method for distinguishing cytosine residue and a kit therefore
NGCATCATT
>LF138742.1 JP 2016508723-A/16: Bispecific T cell activating antigen binding molecules
TTCGACTAC
>LF132435.1 JP 2016506922-A/2: COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
TTCTTCTTC
>S43849.1 antithrombin {Exon 3b frameshift} [human, plasma, Genomic Mutant, 9 nt]
ATCAAATGA
>S76378.1 phenylalanine hydroxylase {aberrant splicing} [human, mRNA Mutant, 9 nt]
GGCCTACAG
>S60983.1 beta-amyloid precursor {exon 17} [human, Genomic Mutant, 9 nt]
ATCGTCATC
>S57224.1 c-erbA (beta)=thyroid hormone receptor [human, Genomic Mutant, 9 nt]
GTGAGGGGC
>LG108797.1 KR 1020150122203-A/344: BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
TTCGACTAC
>LG108768.1 KR 1020150122203-A/238: BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
TTCGACTAC
>LG108687.1 KR 1020150122203-A/74: BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
TTTGACTAC
>LG107031.1 KR 1020150127618-A/834: HUMAN ANTIBODIES TO NAV1.7
TTGGGTTCT
>LG107023.1 KR 1020150127618-A/818: HUMAN ANTIBODIES TO NAV1.7
AAGATTTCT
>LG107015.1 KR 1020150127618-A/802: HUMAN ANTIBODIES TO NAV1.7
GATGCATCC
>LG107007.1 KR 1020150127618-A/786: HUMAN ANTIBODIES TO NAV1.7
GATATATCC
>LG106999.1 KR 1020150127618-A/770: HUMAN ANTIBODIES TO NAV1.7
AAGATTTCT
>LG106991.1 KR 1020150127618-A/754: HUMAN ANTIBODIES TO NAV1.7
AAGATTTCT
>LG106983.1 KR 1020150127618-A/738: HUMAN ANTIBODIES TO NAV1.7
AAGATTTCT
>LG106621.1 KR 1020150129718-A/589: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106613.1 KR 1020150129718-A/573: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106605.1 KR 1020150129718-A/557: HUMAN ANTIBODIES TO GREM1
GATTCATCC
>LG106597.1 KR 1020150129718-A/541: HUMAN ANTIBODIES TO GREM1
GGTGCATCC
>LG106589.1 KR 1020150129718-A/525: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106581.1 KR 1020150129718-A/509: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106573.1 KR 1020150129718-A/493: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106565.1 KR 1020150129718-A/477: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106557.1 KR 1020150129718-A/461: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106549.1 KR 1020150129718-A/445: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106541.1 KR 1020150129718-A/429: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106533.1 KR 1020150129718-A/413: HUMAN ANTIBODIES TO GREM1
GATTCATCC
>LG106525.1 KR 1020150129718-A/397: HUMAN ANTIBODIES TO GREM1
GGTGCATCC
>LG106517.1 KR 1020150129718-A/381: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106509.1 KR 1020150129718-A/365: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106501.1 KR 1020150129718-A/349: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106493.1 KR 1020150129718-A/333: HUMAN ANTIBODIES TO GREM1
GGTGCATCC
>LG106485.1 KR 1020150129718-A/317: HUMAN ANTIBODIES TO GREM1
GTTGCATCC
>LG106477.1 KR 1020150129718-A/301: HUMAN ANTIBODIES TO GREM1
GATGCATTC
>LG106469.1 KR 1020150129718-A/285: HUMAN ANTIBODIES TO GREM1
GTTGTATCC
>LG106461.1 KR 1020150129718-A/269: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106453.1 KR 1020150129718-A/253: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106445.1 KR 1020150129718-A/237: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106437.1 KR 1020150129718-A/221: HUMAN ANTIBODIES TO GREM1
TTGGGTTCT
>LG106429.1 KR 1020150129718-A/205: HUMAN ANTIBODIES TO GREM1
TATGTTTCC
>LG106421.1 KR 1020150129718-A/189: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106413.1 KR 1020150129718-A/173: HUMAN ANTIBODIES TO GREM1
GTTGTATCA
>LG106405.1 KR 1020150129718-A/157: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106397.1 KR 1020150129718-A/141: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106389.1 KR 1020150129718-A/125: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106381.1 KR 1020150129718-A/109: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106373.1 KR 1020150129718-A/93: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106365.1 KR 1020150129718-A/77: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106357.1 KR 1020150129718-A/61: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG106349.1 KR 1020150129718-A/45: HUMAN ANTIBODIES TO GREM1
GCTGCATCC
>LG106341.1 KR 1020150129718-A/29: HUMAN ANTIBODIES TO GREM1
TCTGCATCC
>LG106333.1 KR 1020150129718-A/13: HUMAN ANTIBODIES TO GREM1
GATGCATCC
>LG069245.1 KR 1020150108997-A/12: RNA-SPECIFIC BINDING ANTIBODY
GCAATATAG
>LG135015.1 KR 1020150125735-A/523: High affinity human antibodies to human nerve growth factor
GCTGCATCC
>LG135003.1 KR 1020150125735-A/499: High affinity human antibodies to human nerve growth factor
GGTGCATCC
>LG134991.1 KR 1020150125735-A/475: High affinity human antibodies to human nerve growth factor
GGTACATCC
>LG134979.1 KR 1020150125735-A/451: High affinity human antibodies to human nerve growth factor
GGTGCATCC
>LG134971.1 KR 1020150125735-A/435: High affinity human antibodies to human nerve growth factor
GGTGCATCC
>LG134961.1 KR 1020150125735-A/415: High affinity human antibodies to human nerve growth factor
GCTGCATTC
>LG134951.1 KR 1020150125735-A/395: High affinity human antibodies to human nerve growth factor
GGTGCATCC
>LG134939.1 KR 1020150125735-A/371: High affinity human antibodies to human nerve growth factor
GGTGCATCC
>LG134927.1 KR 1020150125735-A/347: High affinity human antibodies to human nerve growth factor
GGTGCATCC
>LG134915.1 KR 1020150125735-A/323: High affinity human antibodies to human nerve growth factor
GGTTCATCC
>LG134903.1 KR 1020150125735-A/299: High affinity human antibodies to human nerve growth factor
GGTGCATCC
>LG134891.1 KR 1020150125735-A/275: High affinity human antibodies to human nerve growth factor
GCTGCATTC
>LG134879.1 KR 1020150125735-A/251: High affinity human antibodies to human nerve growth factor
GCTGCATCC
>LG134863.1 KR 1020150125735-A/219: High affinity human antibodies to human nerve growth factor
GGTGCATCC
>LG134851.1 KR 1020150125735-A/195: High affinity human antibodies to human nerve growth factor
GCTGCATCC
>LG134839.1 KR 1020150125735-A/171: High affinity human antibodies to human nerve growth factor
GGTGCATTC
>LG134829.1 KR 1020150125735-A/151: High affinity human antibodies to human nerve growth factor
GCTGCATTC
>LG134817.1 KR 1020150125735-A/127: High affinity human antibodies to human nerve growth factor
GCTGCATCC
>LG134801.1 KR 1020150125735-A/95: High affinity human antibodies to human nerve growth factor
GCTGCATTC
>LG134793.1 KR 1020150125735-A/79: High affinity human antibodies to human nerve growth factor
GGTGCGTCC
>LG134785.1 KR 1020150125735-A/63: High affinity human antibodies to human nerve growth factor
GGTGCTTCC
>LG134777.1 KR 1020150125735-A/47: High affinity human antibodies to human nerve growth factor
GGTGCGTCC
>LG134769.1 KR 1020150125735-A/31: High affinity human antibodies to human nerve growth factor
AGTGCATCC
>LG134761.1 KR 1020150125735-A/15: High affinity human antibodies to human nerve growth factor
AGTGCATCC
>LG134309.1 KR 1020150132481-A/85: Nucleic Acid Amplification
GTTTCCCAA
>LG134308.1 KR 1020150132481-A/84: Nucleic Acid Amplification
TTGGGAAAC
>HZ770832.1 JP 2014237714-A/13: NEUTRALIZING ANTI-INFLUENZA VIRUS ANTIBODIES AND USES THEREOF
TGGGCATCT
>HZ770824.1 JP 2014237714-A/5: NEUTRALIZING ANTI-INFLUENZA VIRUS ANTIBODIES AND USES THEREOF
TGGGCATCT
>HZ770670.1 JP 2014240412-A/449: Human Antibodies to Human Delta Like Ligand 4
GGTACATCC
>HZ770662.1 JP 2014240412-A/441: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770654.1 JP 2014240412-A/433: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770646.1 JP 2014240412-A/425: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770638.1 JP 2014240412-A/417: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770630.1 JP 2014240412-A/409: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770622.1 JP 2014240412-A/401: Human Antibodies to Human Delta Like Ligand 4
GGTACATCC
>HZ770614.1 JP 2014240412-A/393: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770606.1 JP 2014240412-A/385: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770598.1 JP 2014240412-A/377: Human Antibodies to Human Delta Like Ligand 4
GGTGCGTCC
>HZ770590.1 JP 2014240412-A/369: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770582.1 JP 2014240412-A/361: Human Antibodies to Human Delta Like Ligand 4
GATGCATCC
>HZ770574.1 JP 2014240412-A/353: Human Antibodies to Human Delta Like Ligand 4
GGTACATCC
>HZ770566.1 JP 2014240412-A/345: Human Antibodies to Human Delta Like Ligand 4
GGTACATCC
>HZ770558.1 JP 2014240412-A/337: Human Antibodies to Human Delta Like Ligand 4
TGGGCATTT
>HZ770550.1 JP 2014240412-A/329: Human Antibodies to Human Delta Like Ligand 4
AAGGCGTCT
>HZ770542.1 JP 2014240412-A/321: Human Antibodies to Human Delta Like Ligand 4
GATGCATCC
>HZ770534.1 JP 2014240412-A/313: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770526.1 JP 2014240412-A/305: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770518.1 JP 2014240412-A/297: Human Antibodies to Human Delta Like Ligand 4
GATACCTCC
>HZ770510.1 JP 2014240412-A/289: Human Antibodies to Human Delta Like Ligand 4
GATGCATCC
>HZ770502.1 JP 2014240412-A/281: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770494.1 JP 2014240412-A/273: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770486.1 JP 2014240412-A/265: Human Antibodies to Human Delta Like Ligand 4
GGTACATCC
>HZ770478.1 JP 2014240412-A/257: Human Antibodies to Human Delta Like Ligand 4
GGTGCGTCC
>HZ770470.1 JP 2014240412-A/249: Human Antibodies to Human Delta Like Ligand 4
GATACATCC
>HZ770462.1 JP 2014240412-A/241: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770454.1 JP 2014240412-A/233: Human Antibodies to Human Delta Like Ligand 4
GGTACATCC
>HZ770446.1 JP 2014240412-A/225: Human Antibodies to Human Delta Like Ligand 4
GATGCATCC
>HZ770438.1 JP 2014240412-A/217: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770430.1 JP 2014240412-A/209: Human Antibodies to Human Delta Like Ligand 4
TTGGTTTCT
>HZ770413.1 JP 2014240412-A/192: Human Antibodies to Human Delta Like Ligand 4
GATGCATCC
>HZ770405.1 JP 2014240412-A/184: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770397.1 JP 2014240412-A/176: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770389.1 JP 2014240412-A/168: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770381.1 JP 2014240412-A/160: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770373.1 JP 2014240412-A/152: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770365.1 JP 2014240412-A/144: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770357.1 JP 2014240412-A/136: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770349.1 JP 2014240412-A/128: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770341.1 JP 2014240412-A/120: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770333.1 JP 2014240412-A/112: Human Antibodies to Human Delta Like Ligand 4
TGGGCATCT
>HZ770325.1 JP 2014240412-A/104: Human Antibodies to Human Delta Like Ligand 4
TGGGCATCT
>HZ770317.1 JP 2014240412-A/96: Human Antibodies to Human Delta Like Ligand 4
AAGGCGTCT
>HZ770309.1 JP 2014240412-A/88: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770301.1 JP 2014240412-A/80: Human Antibodies to Human Delta Like Ligand 4
GGTACATCC
>HZ770293.1 JP 2014240412-A/72: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770285.1 JP 2014240412-A/64: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770277.1 JP 2014240412-A/56: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770269.1 JP 2014240412-A/48: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770261.1 JP 2014240412-A/40: Human Antibodies to Human Delta Like Ligand 4
GGTGCATCC
>HZ770253.1 JP 2014240412-A/32: Human Antibodies to Human Delta Like Ligand 4
TGGGCATCT
>HZ770245.1 JP 2014240412-A/24: Human Antibodies to Human Delta Like Ligand 4
GGAGCATCC
>HZ770237.1 JP 2014240412-A/16: Human Antibodies to Human Delta Like Ligand 4
GCTGCATCC
>HZ770229.1 JP 2014240412-A/8: Human Antibodies to Human Delta Like Ligand 4
TTGCGTTCT
>LG101205.1 KR 1020150109475-A/78: BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
TTCGACTAC
>LG100249.1 KR 1020150107875-A/2: COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
TTCTTCTTC
>LG099339.1 KR 1020150103283-A/28: NEW ANTIBODY FRAGMENTS, COMPOSITIONS AND USES THEREOF
GCTGCATCC
>LG099138.1 KR 1020150126598-A/319: ANTI-IL-33 ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG099130.1 KR 1020150126598-A/301: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCA
>LG099122.1 KR 1020150126598-A/285: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCTTCC
>LG099114.1 KR 1020150126598-A/269: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099106.1 KR 1020150126598-A/253: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GTTGCATCC
>LG099098.1 KR 1020150126598-A/237: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCGTCC
>LG099090.1 KR 1020150126598-A/221: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099082.1 KR 1020150126598-A/205: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099074.1 KR 1020150126598-A/189: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099066.1 KR 1020150126598-A/173: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCGTCC
>LG099058.1 KR 1020150126598-A/157: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCAGCC
>LG099050.1 KR 1020150126598-A/141: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099042.1 KR 1020150126598-A/125: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099034.1 KR 1020150126598-A/109: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099026.1 KR 1020150126598-A/93: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099018.1 KR 1020150126598-A/77: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099010.1 KR 1020150126598-A/61: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG099002.1 KR 1020150126598-A/45: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LG098994.1 KR 1020150126598-A/29: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG098986.1 KR 1020150126598-A/13: ANTI-IL-33 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG098978.1 KR 1020150129668-A/349: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
TCTACATCC
>LG098970.1 KR 1020150129668-A/333: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GGTGCATCC
>LG098962.1 KR 1020150129668-A/317: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
AAGATTTCT
>LG098954.1 KR 1020150129668-A/301: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GGTGCATCC
>LG098946.1 KR 1020150129668-A/285: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GGTGCATCC
>LG098938.1 KR 1020150129668-A/269: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GGTGCATCC
>LG098930.1 KR 1020150129668-A/253: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
TTGGGTTCT
>LG098922.1 KR 1020150129668-A/237: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GCTGCGTCC
>LG098914.1 KR 1020150129668-A/221: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
TGGGCATCT
>LG098906.1 KR 1020150129668-A/205: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GATGCATCC
>LG098898.1 KR 1020150129668-A/189: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GCTGCATCC
>LG098890.1 KR 1020150129668-A/173: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
TTGGGTTCT
>LG098882.1 KR 1020150129668-A/157: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
TTGGGTTCT
>LG098874.1 KR 1020150129668-A/141: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GGTGCATCC
>LG098866.1 KR 1020150129668-A/125: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GGTGCATCC
>LG098858.1 KR 1020150129668-A/109: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GCTGCATCC
>LG098850.1 KR 1020150129668-A/93: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GATGTATCC
>LG098842.1 KR 1020150129668-A/77: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GCTGCATCC
>LG098834.1 KR 1020150129668-A/61: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GCTTCATCC
>LG098826.1 KR 1020150129668-A/45: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GGTGCATCC
>LG098818.1 KR 1020150129668-A/29: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GGTGCATCC
>LG098810.1 KR 1020150129668-A/13: HUMAN ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND METHODS OF USE THEREOF
GCTGCATCC
>LG098572.1 KR 1020150110562-A/46: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
CAATGTAGC
>LG098567.1 KR 1020150110562-A/41: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
TGATAAGCT
>LG098562.1 KR 1020150110562-A/36: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
ACAATGCAC
>LG098561.1 KR 1020150110562-A/35: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
TACAATGCA
>LG098559.1 KR 1020150110562-A/33: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
TCACACTCC
>LG096883.1 KR 1020150087435-A/19: HUMANIZED ANTIBODY AGAINST AMYLOID BETA
GGTGACTAC
>LG094983.1 KR 1020150103682-A/333: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG094975.1 KR 1020150103682-A/317: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG094967.1 KR 1020150103682-A/301: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG094959.1 KR 1020150103682-A/285: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
ATGGCGTCT
>LG094951.1 KR 1020150103682-A/269: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
ATGGCGTCT
>LG094943.1 KR 1020150103682-A/253: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
GCTACATCC
>LG094935.1 KR 1020150103682-A/237: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG094927.1 KR 1020150103682-A/221: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG094919.1 KR 1020150103682-A/205: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
ACTGCATCC
>LG094911.1 KR 1020150103682-A/189: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG094903.1 KR 1020150103682-A/173: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
GAGGCGTCT
>LG094895.1 KR 1020150103682-A/157: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG094887.1 KR 1020150103682-A/141: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
GGTGCATCC
>LG094879.1 KR 1020150103682-A/125: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG094871.1 KR 1020150103682-A/109: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
GATGCATCC
>LG094863.1 KR 1020150103682-A/93: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG094855.1 KR 1020150103682-A/77: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG094847.1 KR 1020150103682-A/61: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG094839.1 KR 1020150103682-A/45: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG094831.1 KR 1020150103682-A/29: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG094823.1 KR 1020150103682-A/13: ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF
TGGACATCC
>LG126537.1 KR 1020150131251-A/2803: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
TGGGAGGTC
>LG126498.1 KR 1020150131251-A/2764: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
CCAAAGCCC
>HZ788125.1 JP 2016504416-A/119: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
TGGGCATCT
>HZ788117.1 JP 2016504416-A/111: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
AAGGCGTCT
>HZ788109.1 JP 2016504416-A/103: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
ACTGCATCC
>HZ788101.1 JP 2016504416-A/95: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
AAGGCGTCT
>HZ788093.1 JP 2016504416-A/87: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
GAGGCGTCT
>HZ788085.1 JP 2016504416-A/79: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
AAGGCGTCT
>HZ788077.1 JP 2016504416-A/71: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
GGTGCATCC
>HZ788069.1 JP 2016504416-A/63: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
GCTGCATCC
>HZ788061.1 JP 2016504416-A/55: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
GATGCATCC
>HZ788053.1 JP 2016504416-A/47: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
TGGGCATCT
>HZ788173.1 JP 2016504416-A/167: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
TGGGCATCT
>HZ788165.1 JP 2016504416-A/159: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
AAGGCGTCT
>HZ788157.1 JP 2016504416-A/151: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
AAGGCGTCT
>HZ788149.1 JP 2016504416-A/143: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
ATGGCGTCT
>HZ788141.1 JP 2016504416-A/135: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
ATGGCGTCT
>HZ788133.1 JP 2016504416-A/127: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
GCTACATCC
>HZ788045.1 JP 2016504416-A/39: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
TGGGCATCT
>HZ788037.1 JP 2016504416-A/31: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
GCTGCATCC
>HZ788029.1 JP 2016504416-A/23: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
TGGGCATCT
>HZ788021.1 JP 2016504416-A/15: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
TGGGCATCT
>HZ788013.1 JP 2016504416-A/7: ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
TGGACATCC
>HZ783242.1 JP 2016041069-A/127: High Affinity Human Antibodies to Human IL-4R Receptor
GATGCATCC
>HZ783230.1 JP 2016041069-A/115: High Affinity Human Antibodies to Human IL-4R Receptor
GATGCATCC
>HZ783218.1 JP 2016041069-A/103: High Affinity Human Antibodies to Human IL-4R Receptor
GTTGCATCC
>HZ783206.1 JP 2016041069-A/91: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGCATCC
>HZ783194.1 JP 2016041069-A/79: High Affinity Human Antibodies to Human IL-4R Receptor
TTGGGTTCT
>HZ783182.1 JP 2016041069-A/67: High Affinity Human Antibodies to Human IL-4R Receptor
AGTGCCTCC
>HZ783170.1 JP 2016041069-A/55: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGCATCC
>HZ783158.1 JP 2016041069-A/43: High Affinity Human Antibodies to Human IL-4R Receptor
TTGGGTTCT
>HZ783146.1 JP 2016041069-A/31: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGTATCC
>HZ783134.1 JP 2016041069-A/19: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGCATCC
>HZ783122.1 JP 2016041069-A/7: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGCATCC
>HZ782946.1 JP 2016039810-A/5: DNA binding proteins using PPR motifs and use thereof
TCTATCACT
>LG087008.1 KR 1020150091130-A/20: USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
CAGTTAGGG
>LG087007.1 KR 1020150091130-A/19: USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
GGGTTAGAC
>HZ778619.1 JP 2015061875-A/21: CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES
GCCGCCACC
>LG082556.1 KR 1020150070451-A/68: Novel antibodies inhibiting c-Met dimerization, and uses thereof
ACCACATCC
>LG082535.1 KR 1020150070451-A/39: Novel antibodies inhibiting c-Met dimerization, and uses thereof
GCTGCAACA
>LG082530.1 KR 1020150070451-A/34: Novel antibodies inhibiting c-Met dimerization, and uses thereof
CGTGCATCC
>LG082394.1 KR 1020150082628-A/45: MATERIALS AND METHODS FOR RESPIRATORY DISEASE CONTROL IN CANINES
GATGTACCC
>LG082392.1 KR 1020150082628-A/43: MATERIALS AND METHODS FOR RESPIRATORY DISEASE CONTROL IN CANINES
ACAATGAGT
>LG082387.1 KR 1020150082628-A/38: MATERIALS AND METHODS FOR RESPIRATORY DISEASE CONTROL IN CANINES
AGAACTGGG
>LG082386.1 KR 1020150082628-A/37: MATERIALS AND METHODS FOR RESPIRATORY DISEASE CONTROL IN CANINES
CAAACCAGA
>LG082385.1 KR 1020150082628-A/36: MATERIALS AND METHODS FOR RESPIRATORY DISEASE CONTROL IN CANINES
CCGTTGGTC
>LG082384.1 KR 1020150082628-A/35: MATERIALS AND METHODS FOR RESPIRATORY DISEASE CONTROL IN CANINES
GAGAGTTGG
>LG114783.1 KR 1020150131208-A/31: ANTIGEN BINDING CONSTRUCTS TO CD8
GGCGGCTGC
>HZ774874.1 JP 2015057394-A/36: Cancer Therapy Sensitizer
CTGACCAAG
>LG077904.1 KR 1020150082327-A/111: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTGCATCC
>LG077896.1 KR 1020150082327-A/95: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTGCATCC
>LG077888.1 KR 1020150082327-A/79: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTACATCC
>LG077880.1 KR 1020150082327-A/63: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTGCGTCC
>LG077872.1 KR 1020150082327-A/47: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTGCATCC
>LG077864.1 KR 1020150082327-A/31: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GATGCATCC
>LG077856.1 KR 1020150082327-A/15: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
TTGGTTTCT
>LG110636.1 KR 1020150133753-A/20: Microvesicle and method for producing the same
TTCAAGAGA
>LG077646.1 KR 1020150082316-A/79: Novel antigen binding proteins and its use as addressing product for the treatment of cancer
TGGGCTTCC
>LG077632.1 KR 1020150082316-A/51: Novel antigen binding proteins and its use as addressing product for the treatment of cancer
TGGGCATCC
>LG077618.1 KR 1020150082316-A/16: Novel antigen binding proteins and its use as addressing product for the treatment of cancer
TGGGCATCC
>LG076945.1 KR 1020150084007-A/173: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076937.1 KR 1020150084007-A/157: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076929.1 KR 1020150084007-A/141: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076921.1 KR 1020150084007-A/125: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076913.1 KR 1020150084007-A/109: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076905.1 KR 1020150084007-A/93: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076897.1 KR 1020150084007-A/77: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076889.1 KR 1020150084007-A/61: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076881.1 KR 1020150084007-A/45: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076873.1 KR 1020150084007-A/29: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG076865.1 KR 1020150084007-A/13: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>LG075538.1 KR 1020150064068-A/109: FC-FREE ANTIBODIES COMPRISING TWO Fab-FRAGMENTS AND METHODS OF USE
TTTGACTAC
>LG109204.1 KR 1020150122761-A/356: BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
TTCGACTAC
>LG109175.1 KR 1020150122761-A/238: BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
TTCGACTAC
>LG109094.1 KR 1020150122761-A/74: BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
TTTGACTAC
>HZ530756.1 JP 2016502520-A/87: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530748.1 JP 2016502520-A/79: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530740.1 JP 2016502520-A/71: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530732.1 JP 2016502520-A/63: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530724.1 JP 2016502520-A/55: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530716.1 JP 2016502520-A/47: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530708.1 JP 2016502520-A/39: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530700.1 JP 2016502520-A/31: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530692.1 JP 2016502520-A/23: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530684.1 JP 2016502520-A/15: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ530676.1 JP 2016502520-A/7: ANTI-PROKINETICIN RECEPTOR (PROKR) ANTIBODIES AND USES THEREOF
AAGATTTCT
>HZ492997.1 JP 2016019523-A/58: NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF
TTCGGAGTT
>HZ492990.1 JP 2016019523-A/51: NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF
TTCGGAGTT
>HZ492980.1 JP 2016019523-A/41: NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF
GGATCTTAT
>HZ492971.1 JP 2016019523-A/32: NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF
CTACACAAA
>HZ492968.1 JP 2016019523-A/29: NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF
GCGATTTTT
>HZ492959.1 JP 2016019523-A/20: NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF
GGATCTTAT
>HZ530525.1 JP 2016502515-A/30: NOVEL ANTIGEN BINDING PROTEINS AND THEIR USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER
TGGGCTTCC
>HZ530511.1 JP 2016502515-A/16: NOVEL ANTIGEN BINDING PROTEINS AND THEIR USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER
TGGGCATCC
>HZ530497.1 JP 2016502515-A/2: NOVEL ANTIGEN BINDING PROTEINS AND THEIR USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER
TGGGCATCC
>HZ492918.1 JP 2016027800-A/50: TELOMERASE INHIBITORS AND METHODS OF USE THEREOF
NGGTTAAGN
>HZ492892.1 JP 2016027800-A/24: TELOMERASE INHIBITORS AND METHODS OF USE THEREOF
GGTGGAAGG
>HZ489707.1 JP 2016020334-A/89: Dengue Virus Neutralizing Antibodies and Use Thereof
GATGATAGC
>HZ489699.1 JP 2016020334-A/81: Dengue Virus Neutralizing Antibodies and Use Thereof
GAAGTTTCC
>HZ489682.1 JP 2016020334-A/64: Dengue Virus Neutralizing Antibodies and Use Thereof
GGTAATAGC
>HZ489675.1 JP 2016020334-A/57: Dengue Virus Neutralizing Antibodies and Use Thereof
CAAGATACC
>HZ489664.1 JP 2016020334-A/46: Dengue Virus Neutralizing Antibodies and Use Thereof
ACTACATCC
>HZ489656.1 JP 2016020334-A/38: Dengue Virus Neutralizing Antibodies and Use Thereof
GGTAACAAC
>HZ489647.1 JP 2016020334-A/29: Dengue Virus Neutralizing Antibodies and Use Thereof
GCTGCATCC
>HZ489639.1 JP 2016020334-A/21: Dengue Virus Neutralizing Antibodies and Use Thereof
TATGATAGC
>HZ489631.1 JP 2016020334-A/13: Dengue Virus Neutralizing Antibodies and Use Thereof
GGTGCATCC
>HZ489623.1 JP 2016020334-A/5: Dengue Virus Neutralizing Antibodies and Use Thereof
AGGGATACC
>HZ531924.1 JP 2016501877-A/475: Antibodies Against Clostridium Difficle
GAAACTTCA
>HZ531908.1 JP 2016501877-A/459: Antibodies Against Clostridium Difficle
GAAACCAGT
>HZ531844.1 JP 2016501877-A/395: Antibodies Against Clostridium Difficle
GAGACTAGT
>HZ531860.1 JP 2016501877-A/411: Antibodies Against Clostridium Difficle
GAGACTTCC
>HZ531892.1 JP 2016501877-A/443: Antibodies Against Clostridium Difficle
GAGACTAGT
>HZ531876.1 JP 2016501877-A/427: Antibodies Against Clostridium Difficle
GAGACAAGC
>HZ531828.1 JP 2016501877-A/379: Antibodies Against Clostridium Difficle
GAGACTTCT
>HZ531812.1 JP 2016501877-A/363: Antibodies Against Clostridium Difficle
GAGACTTCT
>HZ531796.1 JP 2016501877-A/347: Antibodies Against Clostridium Difficle
GAGACTAGT
>HZ531780.1 JP 2016501877-A/331: Antibodies Against Clostridium Difficle
AGGACATCT
>HZ531764.1 JP 2016501877-A/315: Antibodies Against Clostridium Difficle
AGGACATCT
>HZ531748.1 JP 2016501877-A/299: Antibodies Against Clostridium Difficle
CGGACCTCC
>HZ531732.1 JP 2016501877-A/283: Antibodies Against Clostridium Difficle
GAGACCTCC
>HZ531716.1 JP 2016501877-A/267: Antibodies Against Clostridium Difficle
GAGACCTCC
>HZ531700.1 JP 2016501877-A/251: Antibodies Against Clostridium Difficle
GAGACCTCC
>HZ531684.1 JP 2016501877-A/235: Antibodies Against Clostridium Difficle
GAGACCTCC
>HZ531668.1 JP 2016501877-A/219: Antibodies Against Clostridium Difficle
GAGACCTCC
>HZ531652.1 JP 2016501877-A/203: Antibodies Against Clostridium Difficle
GAGACCTCC
>HZ531636.1 JP 2016501877-A/187: Antibodies Against Clostridium Difficle
CGCACCTCC
>HZ531620.1 JP 2016501877-A/171: Antibodies Against Clostridium Difficle
CGCACCTCC
>HZ531604.1 JP 2016501877-A/155: Antibodies Against Clostridium Difficle
CGCACCTCC
>HZ531588.1 JP 2016501877-A/139: Antibodies Against Clostridium Difficle
GAAACATCC
>HZ531572.1 JP 2016501877-A/123: Antibodies Against Clostridium Difficle
GAAACATCC
>HZ531556.1 JP 2016501877-A/107: Antibodies Against Clostridium Difficle
AGGACATCC
>HZ531500.1 JP 2016501877-A/51: Antibodies Against Clostridium Difficle
GAAACATCC
>HZ531516.1 JP 2016501877-A/67: Antibodies Against Clostridium Difficle
GAAACATCC
>HZ531548.1 JP 2016501877-A/99: Antibodies Against Clostridium Difficle
GAAACATCC
>HZ531532.1 JP 2016501877-A/83: Antibodies Against Clostridium Difficle
GGTGCAACC
>HZ531484.1 JP 2016501877-A/35: Antibodies Against Clostridium Difficle
AGGACATCC
>HZ493743.1 JP 2016026171-A/79: High Affinity Antibodies to Human IL-6 Receptor
GCTGCATCC
>HZ493735.1 JP 2016026171-A/71: High Affinity Antibodies to Human IL-6 Receptor
GATGCATCC
>HZ493727.1 JP 2016026171-A/63: High Affinity Antibodies to Human IL-6 Receptor
GTTGCATCC
>HZ493719.1 JP 2016026171-A/55: High Affinity Antibodies to Human IL-6 Receptor
GATGCATCC
>HZ493711.1 JP 2016026171-A/47: High Affinity Antibodies to Human IL-6 Receptor
GATGCATCC
>HZ493703.1 JP 2016026171-A/39: High Affinity Antibodies to Human IL-6 Receptor
GATGCATCC
>HZ493695.1 JP 2016026171-A/31: High Affinity Antibodies to Human IL-6 Receptor
GATGCATCC
>HZ493687.1 JP 2016026171-A/23: High Affinity Antibodies to Human IL-6 Receptor
GATGCATCC
>HZ493679.1 JP 2016026171-A/15: High Affinity Antibodies to Human IL-6 Receptor
GGTGCATCC
>HZ493671.1 JP 2016026171-A/7: High Affinity Antibodies to Human IL-6 Receptor
GGTGCATCC
>HZ531468.1 JP 2016501877-A/19: Antibodies Against Clostridium Difficle
GAAACATCC
>HZ531452.1 JP 2016501877-A/3: Antibodies Against Clostridium Difficle
GAAACATCC
>HZ493815.1 JP 2016020371-A/31: Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
GTTGCATCC
>HZ493807.1 JP 2016020371-A/23: Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
GCTGCATCC
>HZ493799.1 JP 2016020371-A/15: Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
GGTGCATCC
>HZ493791.1 JP 2016020371-A/7: Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
GGTGCATCC
>HZ493775.1 JP 2016026171-A/111: High Affinity Antibodies to Human IL-6 Receptor
GCTGCATCC
>HZ493767.1 JP 2016026171-A/103: High Affinity Antibodies to Human IL-6 Receptor
GATGCATCC
>HZ493759.1 JP 2016026171-A/95: High Affinity Antibodies to Human IL-6 Receptor
GTTGCATCC
>HZ493751.1 JP 2016026171-A/87: High Affinity Antibodies to Human IL-6 Receptor
GCTGCATCC
>HZ531226.1 JP 2016501201-A/8: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
TTGGTTTCT
>HZ531274.1 JP 2016501201-A/56: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTGCATCC
>HZ531266.1 JP 2016501201-A/48: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTGCATCC
>HZ531258.1 JP 2016501201-A/40: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTACATCC
>HZ531250.1 JP 2016501201-A/32: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTGCGTCC
>HZ531242.1 JP 2016501201-A/24: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GGTGCATCC
>HZ531234.1 JP 2016501201-A/16: METHODS OF TREATING OVARIAN CANCER WITH DLL4 ANTAGONISTS
GATGCATCC
>HZ478591.1 JP 2015534821-A/3: HCV GENOTYPE 6 REPLICONS
GGCCGGCCA
>HZ478592.1 JP 2015534821-A/4: HCV GENOTYPE 6 REPLICONS
ACGCGTATG
>HZ475538.1 JP 2015535828-A/679: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GAAGCATCT
>HZ475530.1 JP 2015535828-A/671: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTACATCC
>HZ475522.1 JP 2015535828-A/663: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475514.1 JP 2015535828-A/655: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475506.1 JP 2015535828-A/647: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475498.1 JP 2015535828-A/639: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474584.1 JP 2015534548-A/19: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGCATCC
>HZ474572.1 JP 2015534548-A/7: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGCATCC
>HZ475186.1 JP 2015535828-A/327: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475178.1 JP 2015535828-A/319: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475170.1 JP 2015535828-A/311: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475162.1 JP 2015535828-A/303: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475154.1 JP 2015535828-A/295: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GATGCATCC
>HZ475146.1 JP 2015535828-A/287: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGTATCC
>HZ475138.1 JP 2015535828-A/279: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GAAGCTTCT
>HZ475130.1 JP 2015535828-A/271: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCTTCC
>HZ475122.1 JP 2015535828-A/263: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475114.1 JP 2015535828-A/255: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475106.1 JP 2015535828-A/247: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475098.1 JP 2015535828-A/239: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475090.1 JP 2015535828-A/231: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475082.1 JP 2015535828-A/223: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475074.1 JP 2015535828-A/215: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCAACC
>HZ475066.1 JP 2015535828-A/207: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCAACC
>HZ475058.1 JP 2015535828-A/199: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475050.1 JP 2015535828-A/191: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475042.1 JP 2015535828-A/183: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
TGGGCATCT
>HZ475034.1 JP 2015535828-A/175: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475026.1 JP 2015535828-A/167: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475018.1 JP 2015535828-A/159: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCAACC
>HZ475010.1 JP 2015535828-A/151: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCAACC
>HZ475002.1 JP 2015535828-A/143: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474994.1 JP 2015535828-A/135: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475667.1 JP 2015536908-A/29: FC-FREE ANTIBODIES COMPRISING TWO FAB-FRAGMENTS AND METHODS OF USE
TTTGACTAC
>HZ475490.1 JP 2015535828-A/631: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475478.1 JP 2015535828-A/619: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475378.1 JP 2015535828-A/519: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GTTGCATCC
>HZ475370.1 JP 2015535828-A/511: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
ACTGCATCC
>HZ475362.1 JP 2015535828-A/503: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
ACTGCATCC
>HZ475354.1 JP 2015535828-A/495: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GTTGCATCC
>HZ475346.1 JP 2015535828-A/487: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475338.1 JP 2015535828-A/479: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
ACTGCATCC
>HZ475330.1 JP 2015535828-A/471: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GTTGCATCC
>HZ475322.1 JP 2015535828-A/463: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
ACTGCATCC
>HZ475314.1 JP 2015535828-A/455: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
ACTGCATCC
>HZ475306.1 JP 2015535828-A/447: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
ACTGCATCC
>HZ475298.1 JP 2015535828-A/439: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475290.1 JP 2015535828-A/431: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
ACTGCATCC
>HZ475282.1 JP 2015535828-A/423: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
TGGGCATCT
>HZ475274.1 JP 2015535828-A/415: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
AAGGCGTCT
>HZ475266.1 JP 2015535828-A/407: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCGTCC
>HZ475258.1 JP 2015535828-A/399: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCGTCC
>HZ475250.1 JP 2015535828-A/391: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ475242.1 JP 2015535828-A/383: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCGTCC
>HZ475234.1 JP 2015535828-A/375: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCGTCC
>HZ475226.1 JP 2015535828-A/367: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCGTCC
>HZ475218.1 JP 2015535828-A/359: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCGTCC
>HZ475210.1 JP 2015535828-A/351: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ475202.1 JP 2015535828-A/343: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCGTCC
>HZ475194.1 JP 2015535828-A/335: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ474986.1 JP 2015535828-A/127: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474978.1 JP 2015535828-A/119: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474970.1 JP 2015535828-A/111: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474962.1 JP 2015535828-A/103: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474954.1 JP 2015535828-A/95: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474946.1 JP 2015535828-A/87: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474938.1 JP 2015535828-A/79: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474930.1 JP 2015535828-A/71: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474922.1 JP 2015535828-A/63: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474914.1 JP 2015535828-A/55: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GATGCATCC
>HZ474906.1 JP 2015535828-A/47: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ474898.1 JP 2015535828-A/39: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ474890.1 JP 2015535828-A/31: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474882.1 JP 2015535828-A/23: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GCTGCATCC
>HZ474874.1 JP 2015535828-A/15: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474866.1 JP 2015535828-A/7: Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules That Bind CD3 and CD20, and Uses Thereof
GGTGCATCC
>HZ474692.1 JP 2015534548-A/127: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GATGCATCC
>HZ474680.1 JP 2015534548-A/115: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GATGCATCC
>HZ474668.1 JP 2015534548-A/103: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GTTGCATCC
>HZ474656.1 JP 2015534548-A/91: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGCATCC
>HZ474644.1 JP 2015534548-A/79: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
TTGGGTTCT
>HZ474632.1 JP 2015534548-A/67: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
AGTGCCTCC
>HZ474620.1 JP 2015534548-A/55: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGCATCC
>HZ474608.1 JP 2015534548-A/43: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
TTGGGTTCT
>HZ474596.1 JP 2015534548-A/31: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GCTGTATCC
>HZ471208.1 JP 2016006101-A/32: Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
GGTGCGTCC
>HZ471200.1 JP 2016006101-A/24: Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
GGTGCATCC
>HZ474108.1 WO 2016006628-A/18: RNA-protein complex and delivery system for RNA and protein thereby
GCTCTGCCC
>HZ474096.1 WO 2016006628-A/6: RNA-protein complex and delivery system for RNA and protein thereby
GCTCTGACC
>HZ473821.1 WO 2016002189-A/5: Anti-proglucagon antibody
TGGGCCTCC
>HZ473819.1 WO 2016002189-A/3: Anti-proglucagon antibody
ACAAGAGAT
>HZ471192.1 JP 2016006101-A/16: Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
GATGCATCC
>HZ471184.1 JP 2016006101-A/8: Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
TTGGTTTCT
>HZ471232.1 JP 2016006101-A/56: Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
GGTGCATCC
>HZ471224.1 JP 2016006101-A/48: Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
GGTGCATCC
>HZ471216.1 JP 2016006101-A/40: Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
GGTACATCC
>HZ469453.1 JP 2016002018-A/1: Forward primer
CCATTGACG
>HZ466797.1 JP 2015532647-A/200: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466789.1 JP 2015532647-A/192: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466780.1 JP 2015532647-A/183: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466772.1 JP 2015532647-A/175: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
ACTACATCC
>HZ466764.1 JP 2015532647-A/167: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
AAGGCGTCT
>HZ466756.1 JP 2015532647-A/159: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466748.1 JP 2015532647-A/151: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GGTGCATCC
>HZ466740.1 JP 2015532647-A/143: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466732.1 JP 2015532647-A/135: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466724.1 JP 2015532647-A/127: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
TCTGCATCC
>HZ466716.1 JP 2015532647-A/119: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466708.1 JP 2015532647-A/111: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466700.1 JP 2015532647-A/103: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466692.1 JP 2015532647-A/95: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466684.1 JP 2015532647-A/87: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
ACTGCATCC
>HZ466676.1 JP 2015532647-A/79: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466668.1 JP 2015532647-A/71: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466660.1 JP 2015532647-A/63: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466652.1 JP 2015532647-A/55: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466644.1 JP 2015532647-A/47: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
TGGGCATCT
>HZ466636.1 JP 2015532647-A/39: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
AGTGCATCC
>HZ466628.1 JP 2015532647-A/31: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466620.1 JP 2015532647-A/23: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
GCTGCATCC
>HZ466612.1 JP 2015532647-A/15: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
TGGGCATCT
>HZ466604.1 JP 2015532647-A/7: Human Antibodies to GFR-alpha-3 and Methods of Use Thereof
AAGGCGTCT
>HZ458324.1 JP 2015231380-A/5: Methods for selecting protease resistant polypeptides
CCAAGCTCG
>HZ456897.1 JP 2015231993-A/22: Urate excretion transporter and medicine for its disease or inflammation
GTAAATGCT
>HZ456896.1 JP 2015231993-A/21: Urate excretion transporter and medicine for its disease or inflammation
GTAATGTGG
>HZ456895.1 JP 2015231993-A/20: Urate excretion transporter and medicine for its disease or inflammation
GTAAGTATT
>HZ456894.1 JP 2015231993-A/19: Urate excretion transporter and medicine for its disease or inflammation
GTGAGTATA
>HZ456893.1 JP 2015231993-A/18: Urate excretion transporter and medicine for its disease or inflammation
GTATGTACA
>HZ456892.1 JP 2015231993-A/17: Urate excretion transporter and medicine for its disease or inflammation
GTGAGTAAA
>HZ456891.1 JP 2015231993-A/16: Urate excretion transporter and medicine for its disease or inflammation
TATATCCTA
>HZ456890.1 JP 2015231993-A/15: Urate excretion transporter and medicine for its disease or inflammation
CTATGCAAC
>HZ456889.1 JP 2015231993-A/14: Urate excretion transporter and medicine for its disease or inflammation
GGATTTACG
>HZ456888.1 JP 2015231993-A/13: Urate excretion transporter and medicine for its disease or inflammation
TTTATGATG
>HZ456887.1 JP 2015231993-A/12: Urate excretion transporter and medicine for its disease or inflammation
TCATGTTAG
>HZ456886.1 JP 2015231993-A/11: Urate excretion transporter and medicine for its disease or inflammation
GCTCTTCAT
>HZ456885.1 JP 2015231993-A/10: Urate excretion transporter and medicine for its disease or inflammation
CCAGAACAG
>HZ456884.1 JP 2015231993-A/9: Urate excretion transporter and medicine for its disease or inflammation
ATAGCTCAG
>HZ456883.1 JP 2015231993-A/8: Urate excretion transporter and medicine for its disease or inflammation
ACTTTAAAG
>HZ456882.1 JP 2015231993-A/7: Urate excretion transporter and medicine for its disease or inflammation
AATCAGCTG
>HZ456881.1 JP 2015231993-A/6: Urate excretion transporter and medicine for its disease or inflammation
CCTGAAAAG
>HZ456880.1 JP 2015231993-A/5: Urate excretion transporter and medicine for its disease or inflammation
GACTCCAAG
>HZ456879.1 JP 2015231993-A/4: Urate excretion transporter and medicine for its disease or inflammation
GTGGTACAA
>HZ456878.1 JP 2015231993-A/3: Urate excretion transporter and medicine for its disease or inflammation
CAAATCAAC
>HZ456877.1 JP 2015231993-A/2: Urate excretion transporter and medicine for its disease or inflammation
GAATATCAA
>HZ456876.1 JP 2015231993-A/1: Urate excretion transporter and medicine for its disease or inflammation
TTAAGCTGA
>HZ456786.1 JP 2015221036-A/275: RNAse H-Based Assays Utilizing Modified RNA Monomers
TAGCTGAAG
>HZ456785.1 JP 2015221036-A/274: RNAse H-Based Assays Utilizing Modified RNA Monomers
AAGCTGAAG
>HZ456784.1 JP 2015221036-A/273: RNAse H-Based Assays Utilizing Modified RNA Monomers
GAGCTGAAG
>HZ456783.1 JP 2015221036-A/272: RNAse H-Based Assays Utilizing Modified RNA Monomers
CAGCTGAAG
>HZ456499.1 JP 2015221035-A/34: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACAGCCTG
>HZ456498.1 JP 2015221035-A/33: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CAGGCTGTC
>HZ456495.1 JP 2015221035-A/30: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACACCGCA
>HZ456494.1 JP 2015221035-A/29: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TGCGGTGTC
>HZ456489.1 JP 2015221035-A/24: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CCTCCTCAG
>HZ456488.1 JP 2015221035-A/23: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CTGAGGAGG
>HZ456481.1 JP 2015221035-A/16: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GTCCCATTA
>HZ456480.1 JP 2015221035-A/15: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TAATGGGAC
>HZ456477.1 JP 2015221035-A/12: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GGTAGCGAA
>HZ456476.1 JP 2015221035-A/11: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TTCGCTACC
>HZ456475.1 JP 2015221035-A/10: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACCGTTAT
>HZ456474.1 JP 2015221035-A/9: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
ATAACGGTC
>HZ456473.1 JP 2015221035-A/8: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACAGTTCC
>HZ456472.1 JP 2015221035-A/7: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GGAACTGTC
>HZ456471.1 JP 2015221035-A/6: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACGTTCTG
>HZ456470.1 JP 2015221035-A/5: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CAGAACGTC
>HZ456469.1 JP 2015221035-A/4: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACGTTTTG
>HZ456468.1 JP 2015221035-A/3: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CAAAACGTC
>HZ456467.1 JP 2015221035-A/2: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACAGTTTC
>HZ456466.1 JP 2015221035-A/1: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GAAACTGTC
>HZ456936.1 JP 2015231993-A/61: Urate excretion transporter and medicine for its disease or inflammation
ATGTACTGG
>HZ456935.1 JP 2015231993-A/60: Urate excretion transporter and medicine for its disease or inflammation
GCTTTGCAG
>HZ456934.1 JP 2015231993-A/59: Urate excretion transporter and medicine for its disease or inflammation
ATTTTTTCA
>HZ456933.1 JP 2015231993-A/58: Urate excretion transporter and medicine for its disease or inflammation
GATTGAAGC
>HZ456932.1 JP 2015231993-A/57: Urate excretion transporter and medicine for its disease or inflammation
ACATGAATA
>HZ456931.1 JP 2015231993-A/56: Urate excretion transporter and medicine for its disease or inflammation
AGCAGGGGT
>HZ456930.1 JP 2015231993-A/55: Urate excretion transporter and medicine for its disease or inflammation
ATCATTGTC
>HZ456929.1 JP 2015231993-A/54: Urate excretion transporter and medicine for its disease or inflammation
CCACAGAGA
>HZ456928.1 JP 2015231993-A/53: Urate excretion transporter and medicine for its disease or inflammation
GTTATCACT
>HZ456927.1 JP 2015231993-A/52: Urate excretion transporter and medicine for its disease or inflammation
GATGTCTAA
>HZ456926.1 JP 2015231993-A/51: Urate excretion transporter and medicine for its disease or inflammation
GTTGGAACT
>HZ456925.1 JP 2015231993-A/50: Urate excretion transporter and medicine for its disease or inflammation
GATGATGTT
>HZ456924.1 JP 2015231993-A/49: Urate excretion transporter and medicine for its disease or inflammation
GTTATTAGA
>HZ456923.1 JP 2015231993-A/48: Urate excretion transporter and medicine for its disease or inflammation
TGGGATCAT
>HZ456922.1 JP 2015231993-A/47: Urate excretion transporter and medicine for its disease or inflammation
AAAGATAAA
>HZ456921.1 JP 2015231993-A/46: Urate excretion transporter and medicine for its disease or inflammation
TAATTTCAG
>HZ456920.1 JP 2015231993-A/45: Urate excretion transporter and medicine for its disease or inflammation
GTGTTATAG
>HZ456919.1 JP 2015231993-A/44: Urate excretion transporter and medicine for its disease or inflammation
TTTTTGTAG
>HZ456918.1 JP 2015231993-A/43: Urate excretion transporter and medicine for its disease or inflammation
CTGACTAAG
>HZ456917.1 JP 2015231993-A/42: Urate excretion transporter and medicine for its disease or inflammation
GTTCTATAG
>HZ456916.1 JP 2015231993-A/41: Urate excretion transporter and medicine for its disease or inflammation
TCATGGCAG
>HZ456915.1 JP 2015231993-A/40: Urate excretion transporter and medicine for its disease or inflammation
TTTGAAAAG
>HZ456914.1 JP 2015231993-A/39: Urate excretion transporter and medicine for its disease or inflammation
ATTGCAAAG
>HZ456913.1 JP 2015231993-A/38: Urate excretion transporter and medicine for its disease or inflammation
CTTTCATAG
>HZ456912.1 JP 2015231993-A/37: Urate excretion transporter and medicine for its disease or inflammation
TTAACTTAG
>HZ456911.1 JP 2015231993-A/36: Urate excretion transporter and medicine for its disease or inflammation
GTGATTTAG
>HZ456910.1 JP 2015231993-A/35: Urate excretion transporter and medicine for its disease or inflammation
TGCCTTAAG
>HZ456909.1 JP 2015231993-A/34: Urate excretion transporter and medicine for its disease or inflammation
CTCTTATAG
>HZ456908.1 JP 2015231993-A/33: Urate excretion transporter and medicine for its disease or inflammation
TGTTTACAG
>HZ456907.1 JP 2015231993-A/32: Urate excretion transporter and medicine for its disease or inflammation
TGTCTGCAG
>HZ456906.1 JP 2015231993-A/31: Urate excretion transporter and medicine for its disease or inflammation
GTAAGTTTT
>HZ456905.1 JP 2015231993-A/30: Urate excretion transporter and medicine for its disease or inflammation
GTATGTCTT
>HZ456904.1 JP 2015231993-A/29: Urate excretion transporter and medicine for its disease or inflammation
GTGAGTCTG
>HZ456903.1 JP 2015231993-A/28: Urate excretion transporter and medicine for its disease or inflammation
GTAAGTATG
>HZ456902.1 JP 2015231993-A/27: Urate excretion transporter and medicine for its disease or inflammation
GTGAGTAGG
>HZ456901.1 JP 2015231993-A/26: Urate excretion transporter and medicine for its disease or inflammation
GTAAGTAAA
>HZ456900.1 JP 2015231993-A/25: Urate excretion transporter and medicine for its disease or inflammation
GTAACCAGC
>HZ456899.1 JP 2015231993-A/24: Urate excretion transporter and medicine for its disease or inflammation
GTATATGAA
>HZ456898.1 JP 2015231993-A/23: Urate excretion transporter and medicine for its disease or inflammation
GTATGGTTG
>HZ455745.1 JP 2015221793-A/23: anti-hTROP-2 antibody
TCCAKAGTT
>LP645555.1 Sequence 24 from Patent WO2016022753
CAATGCTGC
>LP031045.1 Sequence 16362 from Patent EP2834358
ATGCAGTAG
>LP720196.1 Sequence 2 from Patent EP2872680
GCAGCACCC
>LP061500.1 Sequence 5 from Patent WO2015032800
CCTCTCGGG
>LP061499.1 Sequence 4 from Patent WO2015032800
GGAGAGCCC
>LP639140.1 Sequence 77 from Patent EP2834356
GCGGCGTAT
>LP027343.1 Sequence 12660 from Patent EP2834358
ATGCAATAG
>LP714565.1 Sequence 11 from Patent WO2015088346
GGTGCATCC
>LP058325.1 Sequence 8 from Patent WO2015071552
CACCTCGGC
>LP057465.1 Sequence 5 from Patent EP2839023
CCACCAGCT
>LP056885.1 Sequence 25 from Patent EP2837695
AACCACACA
>LQ060414.1 Sequence 10 from Patent EP2967081
GCTAGCAGA
>LP055320.1 Sequence 617 from Patent EP2839005
CAAGCTCGT
>LP055319.1 Sequence 616 from Patent EP2839005
AATCATGTG
>LP055318.1 Sequence 615 from Patent EP2839005
ACTGCTGAG
>LP055317.1 Sequence 614 from Patent EP2839005
TCCTCTTCT
>LP055316.1 Sequence 613 from Patent EP2839005
GGCGGAGGG
>LP055314.1 Sequence 611 from Patent EP2839005
GGGATCGCG
>LP055312.1 Sequence 609 from Patent EP2839005
AACTACTGA
>LP055311.1 Sequence 608 from Patent EP2839005
CTTCTTGTG
>LP055310.1 Sequence 607 from Patent EP2839005
TGAGTTGGC
>LP055309.1 Sequence 606 from Patent EP2839005
GTCTTACTC
>LP055306.1 Sequence 603 from Patent EP2839005
GAAAGCGCT
>LP055305.1 Sequence 602 from Patent EP2839005
TTCTCCAAA
>LP055304.1 Sequence 601 from Patent EP2839005
TTGACACTT
>LP055301.1 Sequence 598 from Patent EP2839005
GATTGTAGC
>LP055300.1 Sequence 597 from Patent EP2839005
GTCAACACT
>LP055299.1 Sequence 596 from Patent EP2839005
ATCCTTTGT
>LP055298.1 Sequence 595 from Patent EP2839005
AGCAGCACA
>LP055297.1 Sequence 594 from Patent EP2839005
AATGACACG
>LP055294.1 Sequence 591 from Patent EP2839005
CCGTCTCAG
>LP055292.1 Sequence 589 from Patent EP2839005
GCCCCTGGG
>LP055288.1 Sequence 585 from Patent EP2839005
CCTATTCTT
>LP055287.1 Sequence 584 from Patent EP2839005
AGAGTTGAG
>LP055286.1 Sequence 583 from Patent EP2839005
TGGTTCCGT
>LP055284.1 Sequence 581 from Patent EP2839005
TGAAATGTT
>LP055282.1 Sequence 579 from Patent EP2839005
TCACCACCT
>LP055281.1 Sequence 578 from Patent EP2839005
TGTAACAGC
>LP055280.1 Sequence 577 from Patent EP2839005
CTGACCTAT
>LP055279.1 Sequence 576 from Patent EP2839005
CAACGGAAT
>LP055278.1 Sequence 575 from Patent EP2839005
TGATATGTT
>LP055275.1 Sequence 572 from Patent EP2839005
TTAATGCTA
>LP055274.1 Sequence 571 from Patent EP2839005
CTCCATTTG
>LP055273.1 Sequence 570 from Patent EP2839005
TTAGAGACG
>LP055272.1 Sequence 569 from Patent EP2839005
TGGGACATA
>LP055270.1 Sequence 567 from Patent EP2839005
TCTCACCAC
>LP055269.1 Sequence 566 from Patent EP2839005
TGGGCGGGG
>LP055268.1 Sequence 565 from Patent EP2839005
CTGCGCAAG
>LP055267.1 Sequence 564 from Patent EP2839005
TAGAGTTAC
>LP055266.1 Sequence 563 from Patent EP2839005
TTTAGGGCC
>LP055264.1 Sequence 561 from Patent EP2839005
CACCAGGCA
>LP055263.1 Sequence 560 from Patent EP2839005
TGAGGCAGT
>LP055251.1 Sequence 548 from Patent EP2839005
CAGGAGATA
>LP055250.1 Sequence 547 from Patent EP2839005
CTGGAGAAA
>LP055249.1 Sequence 546 from Patent EP2839005
CTGGAGATG
>LP055248.1 Sequence 545 from Patent EP2839005
CTGGAAATA
>LP055247.1 Sequence 544 from Patent EP2839005
CGGGCGTGG
>LP055244.1 Sequence 541 from Patent EP2839005
AGTCTAGCT
>LP055243.1 Sequence 540 from Patent EP2839005
ACTCCAGCT
>LP055242.1 Sequence 539 from Patent EP2839005
ACTCTATCT
>LP055241.1 Sequence 538 from Patent EP2839005
ACTCTAGGT
>LP055239.1 Sequence 536 from Patent EP2839005
AAGTGATCT
>LP055238.1 Sequence 535 from Patent EP2839005
AAGTGATCT
>LP055237.1 Sequence 534 from Patent EP2839005
GTGTCCGGG
>LP055236.1 Sequence 533 from Patent EP2839005
GTGTCTGGC
>LP055235.1 Sequence 532 from Patent EP2839005
TCACGCCTG
>LP055234.1 Sequence 531 from Patent EP2839005
TCCCACCTG
>LP055223.1 Sequence 520 from Patent EP2839005
CACCCAGCC
>LP055222.1 Sequence 519 from Patent EP2839005
CTCCCGGGT
>LP055221.1 Sequence 518 from Patent EP2839005
CACCAGGCA
>LP055220.1 Sequence 517 from Patent EP2839005
CTCCCTGCT
>LP055219.1 Sequence 516 from Patent EP2839005
CACGCCGCT
>LP055218.1 Sequence 515 from Patent EP2839005
CACCTGACT
>LP055217.1 Sequence 514 from Patent EP2839005
CAGCCCGCT
>LP055216.1 Sequence 513 from Patent EP2839005
CTCACGGCT
>LP055215.1 Sequence 512 from Patent EP2839005
CTCCCAGCT
>LP055214.1 Sequence 511 from Patent EP2839005
CACTCGACT
>LP055213.1 Sequence 510 from Patent EP2839005
CATCTGGCT
>LP055212.1 Sequence 509 from Patent EP2839005
CACCTGGCC
>LP055211.1 Sequence 508 from Patent EP2839005
CACCCACCT
>LP055210.1 Sequence 507 from Patent EP2839005
CAGCCTGCT
>LP055209.1 Sequence 506 from Patent EP2839005
CTCCCGGGT
>LP055208.1 Sequence 505 from Patent EP2839005
CACTCAGCT
>LP055207.1 Sequence 504 from Patent EP2839005
CACCCCTCT
>LP055206.1 Sequence 503 from Patent EP2839005
CACCCTGCC
>LP055205.1 Sequence 502 from Patent EP2839005
CACCCAGGT
>LP055204.1 Sequence 501 from Patent EP2839005
AAGGCAGTG
>LP055200.1 Sequence 497 from Patent EP2839005
TGGATTTCT
>LP055199.1 Sequence 496 from Patent EP2839005
TGGATTTCT
>LP055196.1 Sequence 493 from Patent EP2839005
TCTTCTCAT
>LP055195.1 Sequence 492 from Patent EP2839005
CCTGCTCAT
>LP055191.1 Sequence 488 from Patent EP2839005
TATTCATTT
>LP055190.1 Sequence 487 from Patent EP2839005
AATATTATA
>LP055189.1 Sequence 486 from Patent EP2839005
ACAATACAT
>LP055188.1 Sequence 485 from Patent EP2839005
ATAATACAG
>LP055187.1 Sequence 484 from Patent EP2839005
ATAAGACAT
>LP055186.1 Sequence 483 from Patent EP2839005
ATAGTACAT
>LP055185.1 Sequence 482 from Patent EP2839005
GTAATACAT
>LP055161.1 Sequence 458 from Patent EP2839005
ATGAGGCAG
>LP055160.1 Sequence 457 from Patent EP2839005
AGGAGCCAG
>LP055159.1 Sequence 456 from Patent EP2839005
AGAAGGCAG
>LP055158.1 Sequence 455 from Patent EP2839005
AGGAGGCAC
>LP055145.1 Sequence 442 from Patent EP2839005
GTCCCTCCC
>LP055144.1 Sequence 441 from Patent EP2839005
ATCCCTCTC
>LP055140.1 Sequence 437 from Patent EP2839005
AACCAGCAC
>LP055139.1 Sequence 436 from Patent EP2839005
GACATGGCC
>LP055138.1 Sequence 435 from Patent EP2839005
CACCTGGCC
>LP055122.1 Sequence 419 from Patent EP2839005
ACTCTAAAC
>LP055117.1 Sequence 414 from Patent EP2839005
AGGCACCAG
>LP055116.1 Sequence 413 from Patent EP2839005
AGGCACCAG
>LP055115.1 Sequence 412 from Patent EP2839005
TGCCTCTGC
>LP055114.1 Sequence 411 from Patent EP2839005
TGGCTCTGC
>LP055113.1 Sequence 410 from Patent EP2839005
TGTCTCTGT
>LP055112.1 Sequence 409 from Patent EP2839005
CAAAGAAGA
>LP055111.1 Sequence 408 from Patent EP2839005
CAACGAGGA
>LP055110.1 Sequence 407 from Patent EP2839005
CAAATAGGA
>LP055109.1 Sequence 406 from Patent EP2839005
AAAAGAGGA
>LP055108.1 Sequence 405 from Patent EP2839005
AACAGGTAA
>LP055107.1 Sequence 404 from Patent EP2839005
AACAGGTTA
>LP055106.1 Sequence 403 from Patent EP2839005
AACATGTGA
>LP055105.1 Sequence 402 from Patent EP2839005
AACAGGTCA
>LP055104.1 Sequence 401 from Patent EP2839005
CACAGGTGA
>LP055103.1 Sequence 400 from Patent EP2839005
GCTACCCAT
>LP055097.1 Sequence 394 from Patent EP2839005
AAGTGCCTC
>LP055096.1 Sequence 393 from Patent EP2839005
AAAGTGCAT
>LP055092.1 Sequence 389 from Patent EP2839005
GAGTGACTT
>LP055091.1 Sequence 388 from Patent EP2839005
GACTGCCTT
>LP055090.1 Sequence 387 from Patent EP2839005
GTGTGCCTT
>LP055089.1 Sequence 386 from Patent EP2839005
ATGACACTT
>LP055088.1 Sequence 385 from Patent EP2839005
TTAACACTT
>LP055087.1 Sequence 384 from Patent EP2839005
TTGACAGTT
>LP055086.1 Sequence 383 from Patent EP2839005
TTGACTCTT
>LP055075.1 Sequence 372 from Patent EP2839005
AGACCCGGG
>LP055074.1 Sequence 371 from Patent EP2839005
AGTCCCTGG
>LP055073.1 Sequence 370 from Patent EP2839005
AGCCCCTGG
>LP055072.1 Sequence 369 from Patent EP2839005
AGACCCTGT
>LP055068.1 Sequence 365 from Patent EP2839005
TCAGTATTA
>LP055067.1 Sequence 364 from Patent EP2839005
TGAGTATAA
>LP055066.1 Sequence 363 from Patent EP2839005
TTAGTATTA
>LP055056.1 Sequence 353 from Patent EP2839005
TCCTGTCCT
>LP055055.1 Sequence 352 from Patent EP2839005
TCATGTACT
>LP055033.1 Sequence 330 from Patent EP2839005
TCTTGGAGC
>LP055032.1 Sequence 329 from Patent EP2839005
TCTTAGAGT
>LP055031.1 Sequence 328 from Patent EP2839005
TCTTAGAGT
>LP055030.1 Sequence 327 from Patent EP2839005
TATTGGAGT
>LP055029.1 Sequence 326 from Patent EP2839005
TCCTGGAGT
>LP055028.1 Sequence 325 from Patent EP2839005
TGTCTAGCA
>LP055027.1 Sequence 324 from Patent EP2839005
TGTCTGGCA
>LP055025.1 Sequence 322 from Patent EP2839005
ACTGGACGT
>LP055024.1 Sequence 321 from Patent EP2839005
ACTGGTCTT
>LP055023.1 Sequence 320 from Patent EP2839005
ACTGGCCTT
>LP055016.1 Sequence 313 from Patent EP2839005
ACTTCACCT
>LP055015.1 Sequence 312 from Patent EP2839005
AGAACAGAA
>LP055014.1 Sequence 311 from Patent EP2839005
AGATTAGAA
>LP055013.1 Sequence 310 from Patent EP2839005
AGATTAGAA
>LP055003.1 Sequence 300 from Patent EP2839005
AAAGTGCTG
>LP055002.1 Sequence 299 from Patent EP2839005
AAAGTGCTG
>LP054995.1 Sequence 292 from Patent EP2839005
AATAATACA
>LP054973.1 Sequence 270 from Patent EP2839005
TTTAACATG
>LP054972.1 Sequence 269 from Patent EP2839005
TGTGCTTGA
>LP054971.1 Sequence 268 from Patent EP2839005
CACCAGGCA
>LP054970.1 Sequence 267 from Patent EP2839005
CCGCAGGCA
>LP054969.1 Sequence 266 from Patent EP2839005
CAGAAGGCA
>LP054968.1 Sequence 265 from Patent EP2839005
CAGCAAGCA
>LP054963.1 Sequence 260 from Patent EP2839005
ATAAGAAGA
>LP054962.1 Sequence 259 from Patent EP2839005
ATAAGAAGA
>LP054961.1 Sequence 258 from Patent EP2839005
TCCTTCATT
>LP054958.1 Sequence 255 from Patent EP2839005
TGAAAGGTT
>LP054957.1 Sequence 254 from Patent EP2839005
TGAAATTTT
>LP054956.1 Sequence 253 from Patent EP2839005
TTAAATGTT
>LP054955.1 Sequence 252 from Patent EP2839005
TAATACAGC
>LP054954.1 Sequence 251 from Patent EP2839005
GAATACTGC
>LP054953.1 Sequence 250 from Patent EP2839005
TAATAATGC
>LP054952.1 Sequence 249 from Patent EP2839005
TAATACTGT
>LP054947.1 Sequence 244 from Patent EP2839005
AGGTAGTTT
>LP054944.1 Sequence 241 from Patent EP2839005
TGGAGAGAA
>LP054943.1 Sequence 240 from Patent EP2839005
AACCATCAC
>LP054942.1 Sequence 239 from Patent EP2839005
AACCATAGG
>LP054941.1 Sequence 238 from Patent EP2839005
AGCCAGCGA
>LP054940.1 Sequence 237 from Patent EP2839005
AACCCTCTA
>LP054939.1 Sequence 236 from Patent EP2839005
AACCCCCGA
>LP054938.1 Sequence 235 from Patent EP2839005
AAAAATCGA
>LP054937.1 Sequence 234 from Patent EP2839005
AAACATCTA
>LP054936.1 Sequence 233 from Patent EP2839005
ATCCAGCGA
>LP054935.1 Sequence 232 from Patent EP2839005
AACCATCAC
>LP054934.1 Sequence 231 from Patent EP2839005
AACCAAAGA
>LP054933.1 Sequence 230 from Patent EP2839005
AACCATAGT
>LP054932.1 Sequence 229 from Patent EP2839005
AATCATACA
>LP054931.1 Sequence 228 from Patent EP2839005
AATCATACA
>LP054918.1 Sequence 215 from Patent EP2839005
CCTCTGAAA
>LP054917.1 Sequence 214 from Patent EP2839005
GACAGTATA
>LP054916.1 Sequence 213 from Patent EP2839005
TACAATATA
>LP054915.1 Sequence 212 from Patent EP2839005
TACAGTATT
>LP054911.1 Sequence 208 from Patent EP2839005
GGTGCAGTG
>LP054898.1 Sequence 195 from Patent EP2839005
TCATACAGT
>LP054897.1 Sequence 194 from Patent EP2839005
TGGTCCCGT
>LP054896.1 Sequence 193 from Patent EP2839005
TTGTACTGT
>LP054895.1 Sequence 192 from Patent EP2839005
TCATACAGT
>LP054871.1 Sequence 168 from Patent EP2839005
GGCTATGCC
>LP054838.1 Sequence 135 from Patent EP2839005
CAAAGTGCT
>LP054837.1 Sequence 134 from Patent EP2839005
CAAAGTGCT
>LP054836.1 Sequence 133 from Patent EP2839005
CAAAGTGCT
>LP054826.1 Sequence 123 from Patent EP2839005
TGTGCAAAT
>LP054825.1 Sequence 122 from Patent EP2839005
TGTGCAAAT
>LP054824.1 Sequence 121 from Patent EP2839005
CAAAGTGCT
>LP054823.1 Sequence 120 from Patent EP2839005
CAAAGTGCT
>LP054822.1 Sequence 119 from Patent EP2839005
CAAAGTGCT
>LP054821.1 Sequence 118 from Patent EP2839005
CTGTGCAAG
>LP054820.1 Sequence 117 from Patent EP2839005
AGAGGTAGG
>LP054819.1 Sequence 116 from Patent EP2839005
TGAAGTAGG
>LP054818.1 Sequence 115 from Patent EP2839005
GGAGGTAGG
>LP054817.1 Sequence 114 from Patent EP2839005
TAGAGTTTC
>LP054815.1 Sequence 112 from Patent EP2839005
CACCCAGGT
>LP054812.1 Sequence 109 from Patent EP2839005
CCTGCTCAT
>LP054811.1 Sequence 108 from Patent EP2839005
GTAATACAT
>LP054800.1 Sequence 97 from Patent EP2839005
ACTCTAAAC
>LP054799.1 Sequence 96 from Patent EP2839005
CACAGGTGA
>LP054795.1 Sequence 92 from Patent EP2839005
GTGTGCCTT
>LP054794.1 Sequence 91 from Patent EP2839005
GACTGCCTT
>LP054793.1 Sequence 90 from Patent EP2839005
TTGACTCTT
>LP054790.1 Sequence 87 from Patent EP2839005
AGACCCTGT
>LP054782.1 Sequence 79 from Patent EP2839005
TGTCTGGCA
>LP054781.1 Sequence 78 from Patent EP2839005
ACTGGCCTT
>LP054778.1 Sequence 75 from Patent EP2839005
AGATTAGAA
>LP054761.1 Sequence 58 from Patent EP2839005
CAGCAAGCA
>LP054756.1 Sequence 53 from Patent EP2839005
TTAAATGTT
>LP054754.1 Sequence 51 from Patent EP2839005
AACCATAGT
>LP054747.1 Sequence 44 from Patent EP2839005
GAGTGCAAT
>LP054364.1 Sequence 109 from Patent WO2015071385
GGTTATACT
>LP054310.1 Sequence 55 from Patent WO2015071385
AGACCGGCA
>LP054294.1 Sequence 39 from Patent WO2015071385
GAGGCGGAA
>LP054261.1 Sequence 6 from Patent WO2015071385
ACGCGTCCT
>LP054260.1 Sequence 5 from Patent WO2015071385
TCCCCTGCA
>LP054258.1 Sequence 3 from Patent WO2015071385
ACGCTGAGT
>LQ112019.1 Sequence 21 from Patent WO2015143079
GGTGCATCC
>LQ111846.1 Sequence 182 from Patent WO2015138920
TACACTAGC
>LQ111835.1 Sequence 171 from Patent WO2015138920
TACACCTCC
>LQ055201.1 Sequence 289 from Patent EP2971046
ATGACGTAC
>LQ055173.1 Sequence 261 from Patent EP2971046
TTTGCTTAC
>LQ111824.1 Sequence 160 from Patent WO2015138920
TATACATCC
>LQ111813.1 Sequence 149 from Patent WO2015138920
TACACATCA
>LQ111126.1 Sequence 141 from Patent WO2015138460
GCTACATCC
>LQ111110.1 Sequence 125 from Patent WO2015138460
GCTGCATCC
>LQ111094.1 Sequence 109 from Patent WO2015138460
GCTACATCC
>LQ111078.1 Sequence 93 from Patent WO2015138460
AAGGTTTCT
>LQ111062.1 Sequence 77 from Patent WO2015138460
GGTGCATCC
>LQ111046.1 Sequence 61 from Patent WO2015138460
AAGGCGTCT
>LQ111030.1 Sequence 45 from Patent WO2015138460
GCTGCATCC
>LQ111014.1 Sequence 29 from Patent WO2015138460
GCTGCATCC
>LQ110998.1 Sequence 13 from Patent WO2015138460
TGGGCATCT
>LQ050560.1 Sequence 85 from Patent EP2971123
GTTTCCCAA
>LQ050559.1 Sequence 84 from Patent EP2971123
TTGGGAAAC
>LP023641.1 Sequence 8958 from Patent EP2834358
ATGCAGTAG
>LQ047104.1 Sequence 111 from Patent WO2015132580
GCTGCATCC
>LQ047076.1 Sequence 83 from Patent WO2015132580
GATGCCTCC
>LQ047044.1 Sequence 51 from Patent WO2015132580
GCTGCATCC
>LQ047012.1 Sequence 19 from Patent WO2015132580
GCTGCATCC
>LP631875.1 Sequence 7 from Patent EP2846623
GCTTCTTCT
>LP631754.1 Sequence 36 from Patent EP2828395
CAGGCAGGC
>LP631748.1 Sequence 30 from Patent EP2828395
GCAGCAGCA
>LP631744.1 Sequence 26 from Patent EP2828395
AGCAGCAGC
>LP631740.1 Sequence 22 from Patent EP2828395
CAGCAGCAG
>LQ103855.1 Sequence 17 from Patent WO2015097287
TACACATCA
>LQ103784.1 Sequence 765 from Patent EP2925362
GAAACTTCA
>LQ103768.1 Sequence 749 from Patent EP2925362
GAAACCAGT
>LQ023007.1 Sequence 429 from Patent WO2015148708
ACGCTTTCC
>LQ022991.1 Sequence 413 from Patent WO2015148708
TGGGCATCG
>LQ022975.1 Sequence 397 from Patent WO2015148708
GGTGCATCC
>LQ022959.1 Sequence 381 from Patent WO2015148708
GATGCATCC
>LQ022943.1 Sequence 365 from Patent WO2015148708
ACTGCATCC
>LQ022927.1 Sequence 349 from Patent WO2015148708
GTTACATCC
>LQ022911.1 Sequence 333 from Patent WO2015148708
GATGCATCC
>LQ022895.1 Sequence 317 from Patent WO2015148708
AAGGTTTCT
>LQ103752.1 Sequence 733 from Patent EP2925362
GAGACTAGT
>LQ103736.1 Sequence 717 from Patent EP2925362
GAGACAAGC
>LQ103720.1 Sequence 701 from Patent EP2925362
GAGACTTCC
>LQ103704.1 Sequence 685 from Patent EP2925362
GAGACTAGT
>LQ103688.1 Sequence 669 from Patent EP2925362
GAGACTTCT
>LQ103672.1 Sequence 653 from Patent EP2925362
GAGACTTCT
>LQ103656.1 Sequence 637 from Patent EP2925362
GAGACTAGT
>LQ103640.1 Sequence 621 from Patent EP2925362
AGGACATCT
>LQ103624.1 Sequence 605 from Patent EP2925362
AGGACATCT
>LQ103608.1 Sequence 589 from Patent EP2925362
CGGACCTCC
>LQ103592.1 Sequence 573 from Patent EP2925362
GAGACCTCC
>LQ103576.1 Sequence 557 from Patent EP2925362
GAGACCTCC
>LQ103560.1 Sequence 541 from Patent EP2925362
GAGACCTCC
>LQ103544.1 Sequence 525 from Patent EP2925362
GAGACCTCC
>LQ103528.1 Sequence 509 from Patent EP2925362
GAGACCTCC
>LQ103512.1 Sequence 493 from Patent EP2925362
GAGACCTCC
>LQ103496.1 Sequence 477 from Patent EP2925362
CGCACCTCC
>LQ103480.1 Sequence 461 from Patent EP2925362
CGCACCTCC
>LQ103464.1 Sequence 445 from Patent EP2925362
CGCACCTCC
>LQ103448.1 Sequence 429 from Patent EP2925362
GAAACATCC
>LQ103432.1 Sequence 413 from Patent EP2925362
GAAACATCC
>LQ103416.1 Sequence 397 from Patent EP2925362
AGGACATCC
>LQ103408.1 Sequence 389 from Patent EP2925362
GAAACATCC
>LQ103392.1 Sequence 373 from Patent EP2925362
GGTGCAACC
>LQ103376.1 Sequence 357 from Patent EP2925362
GAAACATCC
>LQ022879.1 Sequence 301 from Patent WO2015148708
AAGGTTTCT
>LQ022863.1 Sequence 285 from Patent WO2015148708
GATGTATCC
>LQ022847.1 Sequence 269 from Patent WO2015148708
GATGCATCC
>LQ022831.1 Sequence 253 from Patent WO2015148708
AAGACGTCT
>LQ022815.1 Sequence 237 from Patent WO2015148708
GCTGCATCC
>LQ022799.1 Sequence 221 from Patent WO2015148708
GCTGCATCC
>LQ022783.1 Sequence 205 from Patent WO2015148708
GCTGCATCC
>LQ022767.1 Sequence 189 from Patent WO2015148708
GGTGCTTCC
>LQ022751.1 Sequence 173 from Patent WO2015148708
GGTGCATCC
>LQ022735.1 Sequence 157 from Patent WO2015148708
CTTGCAACC
>LQ022719.1 Sequence 141 from Patent WO2015148708
GCTGCATCC
>LQ022703.1 Sequence 125 from Patent WO2015148708
AAGGCGTCT
>LQ022687.1 Sequence 109 from Patent WO2015148708
AAGGCGTCT
>LQ022671.1 Sequence 93 from Patent WO2015148708
GGTGCATCC
>LQ022655.1 Sequence 77 from Patent WO2015148708
GCTGCATAC
>LQ022639.1 Sequence 61 from Patent WO2015148708
TGGGCATCT
>LQ022623.1 Sequence 45 from Patent WO2015148708
GCTGCATCC
>LQ022607.1 Sequence 29 from Patent WO2015148708
TTGGGTTCT
>LQ022591.1 Sequence 13 from Patent WO2015148708
AATCTTTCT
>LQ103360.1 Sequence 341 from Patent EP2925362
GAAACATCC
>LQ103344.1 Sequence 325 from Patent EP2925362
AGGACATCC
>LQ103328.1 Sequence 309 from Patent EP2925362
GAAACATCC
>LQ103312.1 Sequence 293 from Patent EP2925362
GAAACATCC
>LQ095687.1 Sequence 35 from Patent WO2015112830
CTGGTGTCT
>LQ015185.1 Sequence 20 from Patent EP2975125
TTCAAGAGA
>LP133425.1 Sequence 5 from Patent EP2866822
CACCCCTAC
>LP133424.1 Sequence 4 from Patent EP2866822
CTACAGATG
>LP133423.1 Sequence 3 from Patent EP2866822
TGAATGGAC
>LP133422.1 Sequence 2 from Patent EP2866822
CTGCTGTTG
>LP133421.1 Sequence 1 from Patent EP2866822
ACTTACCTG
>LP034747.1 Sequence 20064 from Patent EP2834358
ATGCAGTAG
>LQ100311.1 Sequence 8 from Patent EP2980222
AAGCGGGGC
>LP009240.1 Sequence 21 from Patent EP2976427
CCTACATTC
>LP038449.1 Sequence 23766 from Patent EP2834358
ATGCAGTAG
>HZ437563.1 JP 2015530870-A/72: METHODS OF PRODUCTION OF PRODUCTS OF METABOLIC PATHWAYS
AAGGAAAAT
>HZ437562.1 JP 2015530870-A/71: METHODS OF PRODUCTION OF PRODUCTS OF METABOLIC PATHWAYS
AAGGAAAAG
>HZ437561.1 JP 2015530870-A/70: METHODS OF PRODUCTION OF PRODUCTS OF METABOLIC PATHWAYS
AAGGAAAAA
>HZ437214.1 JP 2015528704-A/6: light-switchable gene expression system and the methods for controlling gene expression in prokaryotic bacterium
CTGTNACAG
>HZ432408.1 JP 2014221067-A/12: COMPOSITIONS FOR BACTERIAL MEDIATED GENE SILENCING AND METHODS OF USING SAME
TTCAAGAGA
>HZ422755.1 JP 2014139244-A/63: IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
GCCGCCACC
>HZ417954.1 JP 2014113163-A/23: Compositions and methods related to mRNA translational enhancer elements
CCGGCTGAA
>HZ417953.1 JP 2014113163-A/22: Compositions and methods related to mRNA translational enhancer elements
GCGGCTGAA
>HZ417952.1 JP 2014113163-A/21: Compositions and methods related to mRNA translational enhancer elements
CGCCGCCGC
>HZ417951.1 JP 2014113163-A/20: Compositions and methods related to mRNA translational enhancer elements
CGCGGCGGA
>HZ417950.1 JP 2014113163-A/19: Compositions and methods related to mRNA translational enhancer elements
GAGAGGAGC
>HZ417949.1 JP 2014113163-A/18: Compositions and methods related to mRNA translational enhancer elements
CGAGAGGCA
>HZ417948.1 JP 2014113163-A/17: Compositions and methods related to mRNA translational enhancer elements
GCCGAGAGA
>HZ417947.1 JP 2014113163-A/16: Compositions and methods related to mRNA translational enhancer elements
AGGAGAGGA
>HZ417943.1 JP 2014113163-A/12: Compositions and methods related to mRNA translational enhancer elements
ACGAGCGGA
>HZ417942.1 JP 2014113163-A/11: Compositions and methods related to mRNA translational enhancer elements
ACGAGAGGA
>HZ417941.1 JP 2014113163-A/10: Compositions and methods related to mRNA translational enhancer elements
CGGAGCGGA
>HZ417940.1 JP 2014113163-A/9: Compositions and methods related to mRNA translational enhancer elements
CGGAGCGAA
>HZ417939.1 JP 2014113163-A/8: Compositions and methods related to mRNA translational enhancer elements
GCGAGCGGA
>HZ417938.1 JP 2014113163-A/7: Compositions and methods related to mRNA translational enhancer elements
GCGAGAGGA
>HZ417937.1 JP 2014113163-A/6: Compositions and methods related to mRNA translational enhancer elements
GGGAGCGAA
>HZ417936.1 JP 2014113163-A/5: Compositions and methods related to mRNA translational enhancer elements
GCGAGAGAA
>HZ417964.1 JP 2014113163-A/33: Compositions and methods related to mRNA translational enhancer elements
CCCGGCGGA
>HZ417963.1 JP 2014113163-A/32: Compositions and methods related to mRNA translational enhancer elements
CGGCTGCTA
>HZ417962.1 JP 2014113163-A/31: Compositions and methods related to mRNA translational enhancer elements
CGCGGCTGA
>HZ417961.1 JP 2014113163-A/30: Compositions and methods related to mRNA translational enhancer elements
CCCGGCGGA
>HZ417960.1 JP 2014113163-A/29: Compositions and methods related to mRNA translational enhancer elements
CCCGCTGAA
>HZ417959.1 JP 2014113163-A/28: Compositions and methods related to mRNA translational enhancer elements
CCCGCCGAA
>HZ417958.1 JP 2014113163-A/27: Compositions and methods related to mRNA translational enhancer elements
CCCGCGGAA
>HZ392287.1 JP 2015186478-A/27: INFLUENZA VIRUSES ABLE TO INFECT CANIDS, USES THEREOF
GATGTACCC
>HZ392285.1 JP 2015186478-A/25: INFLUENZA VIRUSES ABLE TO INFECT CANIDS, USES THEREOF
ACAATGAGT
>HZ392280.1 JP 2015186478-A/20: INFLUENZA VIRUSES ABLE TO INFECT CANIDS, USES THEREOF
AGAACTGGG
>HZ392279.1 JP 2015186478-A/19: INFLUENZA VIRUSES ABLE TO INFECT CANIDS, USES THEREOF
CAAACCAGA
>HZ392278.1 JP 2015186478-A/18: INFLUENZA VIRUSES ABLE TO INFECT CANIDS, USES THEREOF
CCGTTGGTC
>HZ392277.1 JP 2015186478-A/17: INFLUENZA VIRUSES ABLE TO INFECT CANIDS, USES THEREOF
GAGAGTTGG
>HZ412447.1 JP 2015527074-A/4: COMPOSITIONS AND METHODS FOR INCREASING THE EXPRESSION AND SIGNALLING OF PROTEINS ON CELL SURFACES
ATCGAATTG
>HZ410922.1 JP 2015527364-A/127: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GATGCATCC
>HZ410910.1 JP 2015527364-A/115: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GATGCATCC
>HZ410898.1 JP 2015527364-A/103: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GTTGCATCC
>HZ410886.1 JP 2015527364-A/91: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGCATCC
>HZ410874.1 JP 2015527364-A/79: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
TTGGGTTCT
>HZ410862.1 JP 2015527364-A/67: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
AGTGCCTCC
>HZ410850.1 JP 2015527364-A/55: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGCATCC
>HZ410838.1 JP 2015527364-A/43: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
TTGGGTTCT
>HZ410826.1 JP 2015527364-A/31: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGTATCC
>HZ410814.1 JP 2015527364-A/19: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGCATCC
>HZ410802.1 JP 2015527364-A/7: Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
GCTGCATCC
>HZ410753.1 JP 2015526440-A/367: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTTT
>HZ410741.1 JP 2015526440-A/355: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>HZ410729.1 JP 2015526440-A/343: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>HZ410717.1 JP 2015526440-A/331: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>HZ410705.1 JP 2015526440-A/319: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>HZ410693.1 JP 2015526440-A/307: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>HZ410681.1 JP 2015526440-A/295: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GATGCATCC
>HZ410669.1 JP 2015526440-A/283: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>HZ410657.1 JP 2015526440-A/271: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>HZ410645.1 JP 2015526440-A/259: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTTT
>HZ410633.1 JP 2015526440-A/247: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>HZ410621.1 JP 2015526440-A/235: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>HZ410609.1 JP 2015526440-A/223: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>HZ410597.1 JP 2015526440-A/211: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>HZ410585.1 JP 2015526440-A/199: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>HZ410573.1 JP 2015526440-A/187: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>HZ410561.1 JP 2015526440-A/175: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>HZ410549.1 JP 2015526440-A/163: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>HZ410537.1 JP 2015526440-A/151: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTCT
>HZ410525.1 JP 2015526440-A/139: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTTT
>HZ410513.1 JP 2015526440-A/127: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTTT
>HZ410501.1 JP 2015526440-A/115: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTCT
>HZ410489.1 JP 2015526440-A/103: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTCT
>HZ410477.1 JP 2015526440-A/91: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTCT
>HZ410465.1 JP 2015526440-A/79: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>HZ410453.1 JP 2015526440-A/67: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GCTGCATCC
>HZ410441.1 JP 2015526440-A/55: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GCTGCATCC
>HZ410429.1 JP 2015526440-A/43: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TGGGCATCT
>HZ410417.1 JP 2015526440-A/31: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TGGGCCTCT
>HZ410405.1 JP 2015526440-A/19: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>HZ410393.1 JP 2015526440-A/7: ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>HZ409702.1 JP 2015528002-A/2299: CHIRAL CONTROL
CAGGTAAGT
>HZ409995.1 JP 2015525567-A/84: HIGH-THROUGHPUT DNA FRAGMENT ASSEMBLY
CCACCATGG
>HZ409993.1 JP 2015525567-A/82: HIGH-THROUGHPUT DNA FRAGMENT ASSEMBLY
CCACCATGG
>HZ407436.1 JP 2015528002-A/33: CHIRAL CONTROL
CAACGTTCT
>LG053854.1 KR 1020150044901-A/48: ENGINEERING T-CELL RECEPTORS
TCTGCTAGC
>LG053036.1 KR 1020150036642-A/2302: CHIRAL CONTROL
CAGGTAAGT
>LG050770.1 KR 1020150036642-A/33: CHIRAL CONTROL
CAACGTTCT
>LG049270.1 KR 1020150030260-A/2: DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES
GCAGCACCC
>LG027511.1 KR 1020150023387-A/381: ANTI-EGFR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG027503.1 KR 1020150023387-A/365: ANTI-EGFR ANTIBODIES AND USES THEREOF
TTTGCTTCC
>LG027495.1 KR 1020150023387-A/349: ANTI-EGFR ANTIBODIES AND USES THEREOF
GCGGCATCC
>LG027487.1 KR 1020150023387-A/333: ANTI-EGFR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG027479.1 KR 1020150023387-A/317: ANTI-EGFR ANTIBODIES AND USES THEREOF
TTTGCTTCC
>LG027471.1 KR 1020150023387-A/301: ANTI-EGFR ANTIBODIES AND USES THEREOF
GCTGCTTCC
>LG027463.1 KR 1020150023387-A/285: ANTI-EGFR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG027455.1 KR 1020150023387-A/269: ANTI-EGFR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG027447.1 KR 1020150023387-A/253: ANTI-EGFR ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG027439.1 KR 1020150023387-A/237: ANTI-EGFR ANTIBODIES AND USES THEREOF
GATGCGTCT
>LG027431.1 KR 1020150023387-A/221: ANTI-EGFR ANTIBODIES AND USES THEREOF
GATGCATCC
>LG027423.1 KR 1020150023387-A/205: ANTI-EGFR ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG027415.1 KR 1020150023387-A/189: ANTI-EGFR ANTIBODIES AND USES THEREOF
GATGCATCC
>LG027407.1 KR 1020150023387-A/173: ANTI-EGFR ANTIBODIES AND USES THEREOF
GATGCATCC
>LG027399.1 KR 1020150023387-A/157: ANTI-EGFR ANTIBODIES AND USES THEREOF
GATGCATCC
>LG027391.1 KR 1020150023387-A/141: ANTI-EGFR ANTIBODIES AND USES THEREOF
GATGCATCC
>LG027383.1 KR 1020150023387-A/125: ANTI-EGFR ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG027375.1 KR 1020150023387-A/109: ANTI-EGFR ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG027367.1 KR 1020150023387-A/93: ANTI-EGFR ANTIBODIES AND USES THEREOF
GATGCATCT
>LG027359.1 KR 1020150023387-A/77: ANTI-EGFR ANTIBODIES AND USES THEREOF
TTGGTCTCT
>LG027351.1 KR 1020150023387-A/61: ANTI-EGFR ANTIBODIES AND USES THEREOF
GATGCATCC
>LG027343.1 KR 1020150023387-A/45: ANTI-EGFR ANTIBODIES AND USES THEREOF
TTGGTTTCT
>LG027335.1 KR 1020150023387-A/29: ANTI-EGFR ANTIBODIES AND USES THEREOF
TTGGTTTCT
>LG027327.1 KR 1020150023387-A/13: ANTI-EGFR ANTIBODIES AND USES THEREOF
TTGGTTTCT
>LG047894.1 KR 1020150032306-A/84: HIGH-THROUGHPUT DNA FRAGMENT ASSEMBLY
CCACCATGG
>LG047892.1 KR 1020150032306-A/82: HIGH-THROUGHPUT DNA FRAGMENT ASSEMBLY
CCACCATGG
>LG026599.1 KR 1020150014481-A/11: NUCLEIC ACID CONSTRUCT AND USE OF THE SAME
CAGGTACGG
>LG047476.1 KR 1020150013359-A/733: High affinity human antibodies to PCSK9
TTGGGTTTT
>LG047464.1 KR 1020150013359-A/709: High affinity human antibodies to PCSK9
GGTGCATCC
>LG047452.1 KR 1020150013359-A/685: High affinity human antibodies to PCSK9
AAGGTTTCT
>LG047440.1 KR 1020150013359-A/661: High affinity human antibodies to PCSK9
AAGGTTTCT
>LG047428.1 KR 1020150013359-A/637: High affinity human antibodies to PCSK9
AAGGTTTCT
>LG047416.1 KR 1020150013359-A/613: High affinity human antibodies to PCSK9
GGTGCATCC
>LG047404.1 KR 1020150013359-A/589: High affinity human antibodies to PCSK9
GATGCATCC
>LG047392.1 KR 1020150013359-A/565: High affinity human antibodies to PCSK9
GGTGCATCC
>LG047380.1 KR 1020150013359-A/541: High affinity human antibodies to PCSK9
GGTGCATCC
>LG047368.1 KR 1020150013359-A/517: High affinity human antibodies to PCSK9
TTGGGTTTT
>LG047356.1 KR 1020150013359-A/493: High affinity human antibodies to PCSK9
GGTGCATCC
>LG047344.1 KR 1020150013359-A/469: High affinity human antibodies to PCSK9
AAGGCGTCT
>LG047332.1 KR 1020150013359-A/445: High affinity human antibodies to PCSK9
AAGGCGTCT
>LG047320.1 KR 1020150013359-A/421: High affinity human antibodies to PCSK9
AAGGCGTCT
>LG047308.1 KR 1020150013359-A/397: High affinity human antibodies to PCSK9
AAGGCGTCT
>LG047296.1 KR 1020150013359-A/373: High affinity human antibodies to PCSK9
GGTGCATCC
>LG047284.1 KR 1020150013359-A/349: High affinity human antibodies to PCSK9
AAGGCGTCT
>LG047272.1 KR 1020150013359-A/325: High affinity human antibodies to PCSK9
AAGGTTTCT
>LG047260.1 KR 1020150013359-A/301: High affinity human antibodies to PCSK9
TTGGGTTCT
>LG047248.1 KR 1020150013359-A/277: High affinity human antibodies to PCSK9
TTGGGTTTT
>LG047236.1 KR 1020150013359-A/253: High affinity human antibodies to PCSK9
TTGGGTTTT
>LG047224.1 KR 1020150013359-A/229: High affinity human antibodies to PCSK9
TTGGGTTCT
>LG047212.1 KR 1020150013359-A/205: High affinity human antibodies to PCSK9
TTGGGTTCT
>LG047200.1 KR 1020150013359-A/181: High affinity human antibodies to PCSK9
TTGGGTTCT
>LG047188.1 KR 1020150013359-A/157: High affinity human antibodies to PCSK9
AAGGTTTCT
>LG047176.1 KR 1020150013359-A/133: High affinity human antibodies to PCSK9
GCTGCATCC
>LG047164.1 KR 1020150013359-A/109: High affinity human antibodies to PCSK9
GCTGCATCC
>LG047152.1 KR 1020150013359-A/85: High affinity human antibodies to PCSK9
TGGGCATCT
>LG047140.1 KR 1020150013359-A/61: High affinity human antibodies to PCSK9
TGGGCCTCT
>LG047128.1 KR 1020150013359-A/37: High affinity human antibodies to PCSK9
AAGGCGTCT
>LG047116.1 KR 1020150013359-A/13: High affinity human antibodies to PCSK9
GGTGCATCC
>LG025413.1 KR 1020150002895-A/15: HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF
AAGGTTTCT
>LG001625.1 KR 1020140138995-A/36: Boronic acid conjugates of oligonucleotide analogues
CAGGCAGGC
>LG001619.1 KR 1020140138995-A/30: Boronic acid conjugates of oligonucleotide analogues
GCAGCAGCA
>LG001615.1 KR 1020140138995-A/26: Boronic acid conjugates of oligonucleotide analogues
AGCAGCAGC
>LG001611.1 KR 1020140138995-A/22: Boronic acid conjugates of oligonucleotide analogues
CAGCAGCAG
>LG001500.1 KR 1020140146105-A/93: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
AAGAAAAAG
>LG001499.1 KR 1020140146105-A/92: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
AAGAAGAAA
>LG001489.1 KR 1020140146105-A/82: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
GAGGAAGAG
>LG001488.1 KR 1020140146105-A/81: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
GAGGAGGAA
>LG001463.1 KR 1020140146105-A/53: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
TACTATTAC
>LG001462.1 KR 1020140146105-A/52: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
TACTACTAT
>LG001440.1 KR 1020140146105-A/30: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
ATCATTATC
>LG001439.1 KR 1020140146105-A/29: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
ATCATCATT
>LG001438.1 KR 1020140146105-A/28: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
CACCATCAC
>LG001437.1 KR 1020140146105-A/27: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
CACCACCAT
>LG001417.1 KR 1020140146105-A/7: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
CGTCGCCGT
>LG001416.1 KR 1020140146105-A/6: METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
CGTCGTCGC
>LG064851.1 KR 1020150055103-A/19: HUMANIZED ANTIBODIES TO AMYLOID BETA
GGTGACTAC
>LG064709.1 KR 1020150046789-A/1365: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GAAGCATCT
>LG064701.1 KR 1020150046789-A/1349: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTACATCC
>LG064693.1 KR 1020150046789-A/1325: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064685.1 KR 1020150046789-A/1309: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064677.1 KR 1020150046789-A/1293: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064669.1 KR 1020150046789-A/1277: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064661.1 KR 1020150046789-A/1261: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064649.1 KR 1020150046789-A/1237: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064549.1 KR 1020150046789-A/1037: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GTTGCATCC
>LG064541.1 KR 1020150046789-A/1021: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>LG064533.1 KR 1020150046789-A/1005: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>LG064517.1 KR 1020150046789-A/973: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064509.1 KR 1020150046789-A/957: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>LG064501.1 KR 1020150046789-A/941: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GTTGCATCC
>LG064493.1 KR 1020150046789-A/925: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>LG064485.1 KR 1020150046789-A/909: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>LG064477.1 KR 1020150046789-A/893: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>LG064469.1 KR 1020150046789-A/877: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064461.1 KR 1020150046789-A/861: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>LG064453.1 KR 1020150046789-A/845: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
TGGGCATCT
>LG064445.1 KR 1020150046789-A/829: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
AAGGCGTCT
>LG064437.1 KR 1020150046789-A/813: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>LG064429.1 KR 1020150046789-A/797: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>LG064421.1 KR 1020150046789-A/781: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064413.1 KR 1020150046789-A/765: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>LG064405.1 KR 1020150046789-A/749: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>LG064397.1 KR 1020150046789-A/733: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>LG064389.1 KR 1020150046789-A/717: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>LG064381.1 KR 1020150046789-A/701: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064373.1 KR 1020150046789-A/685: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCGTCC
>LG064365.1 KR 1020150046789-A/669: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064357.1 KR 1020150046789-A/653: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064349.1 KR 1020150046789-A/637: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064341.1 KR 1020150046789-A/621: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064333.1 KR 1020150046789-A/605: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064525.1 KR 1020150046789-A/989: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GTTGCATCC
>LG064325.1 KR 1020150046789-A/589: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GATGCATCC
>LG064317.1 KR 1020150046789-A/573: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGTATCC
>LG064309.1 KR 1020150046789-A/557: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GAAGCTTCT
>LG064301.1 KR 1020150046789-A/541: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCTTCC
>LG064293.1 KR 1020150046789-A/525: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064285.1 KR 1020150046789-A/509: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064277.1 KR 1020150046789-A/493: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064269.1 KR 1020150046789-A/477: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064261.1 KR 1020150046789-A/461: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064253.1 KR 1020150046789-A/445: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064245.1 KR 1020150046789-A/429: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCAACC
>LG064237.1 KR 1020150046789-A/413: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCAACC
>LG064229.1 KR 1020150046789-A/397: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064221.1 KR 1020150046789-A/381: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064213.1 KR 1020150046789-A/365: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
TGGGCATCT
>LG064205.1 KR 1020150046789-A/349: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064197.1 KR 1020150046789-A/333: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064189.1 KR 1020150046789-A/317: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCAACC
>LG064181.1 KR 1020150046789-A/301: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCAACC
>LG064173.1 KR 1020150046789-A/285: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064165.1 KR 1020150046789-A/269: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064157.1 KR 1020150046789-A/253: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064149.1 KR 1020150046789-A/237: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064141.1 KR 1020150046789-A/221: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064133.1 KR 1020150046789-A/205: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>DI499593.1 KR 1020150009953-A/5: METHOD FOR REDUCTION OF 1-_3 READING FRAME SHIFTS
CAGAAAAAA
>DI499592.1 KR 1020150009953-A/4: METHOD FOR REDUCTION OF 1-_3 READING FRAME SHIFTS
CAAAAGAAA
>DI499591.1 KR 1020150009953-A/3: METHOD FOR REDUCTION OF 1-_3 READING FRAME SHIFTS
CAGAAGAAG
>DI499590.1 KR 1020150009953-A/2: METHOD FOR REDUCTION OF 1-_3 READING FRAME SHIFTS
CAAAAGAAG
>DI499589.1 KR 1020150009953-A/1: METHOD FOR REDUCTION OF 1-_3 READING FRAME SHIFTS
CAAAAAAAG
>DI499555.1 KR 1020150000873-A/493: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCAACC
>DI499543.1 KR 1020150000873-A/469: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTACATCC
>DI499531.1 KR 1020150000873-A/445: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
TCTGCATCC
>DI499519.1 KR 1020150000873-A/421: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>DI499507.1 KR 1020150000873-A/397: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
TTGGGTTCT
>DI499495.1 KR 1020150000873-A/373: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
AAGGCGTCT
>DI499483.1 KR 1020150000873-A/349: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
TTGGGTTCT
>DI499471.1 KR 1020150000873-A/325: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GGTGCGTCC
>DI499459.1 KR 1020150000873-A/301: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
AAGGCGTCT
>DI499447.1 KR 1020150000873-A/277: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>DI499435.1 KR 1020150000873-A/253: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>DI499423.1 KR 1020150000873-A/229: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GGTGCATCC
>DI499411.1 KR 1020150000873-A/205: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>DI499399.1 KR 1020150000873-A/181: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTACATCC
>DI499387.1 KR 1020150000873-A/157: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>DI499375.1 KR 1020150000873-A/133: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GGTGCATCC
>DI499363.1 KR 1020150000873-A/109: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
AAGGCGTCT
>DI499351.1 KR 1020150000873-A/85: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GCTGCATCC
>DI499339.1 KR 1020150000873-A/61: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
AGTGCATCC
>LG064125.1 KR 1020150046789-A/189: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064117.1 KR 1020150046789-A/173: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064109.1 KR 1020150046789-A/157: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064101.1 KR 1020150046789-A/141: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064093.1 KR 1020150046789-A/125: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064085.1 KR 1020150046789-A/109: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GATGCATCC
>LG064077.1 KR 1020150046789-A/93: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064069.1 KR 1020150046789-A/77: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064061.1 KR 1020150046789-A/61: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064053.1 KR 1020150046789-A/45: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>LG064045.1 KR 1020150046789-A/29: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>LG064037.1 KR 1020150046789-A/13: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>DI499327.1 KR 1020150000873-A/37: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GATGCATCT
>DI499315.1 KR 1020150000873-A/13: STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
GGTGCATCC
>LG042695.1 KR 1020150033620-A/54: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>LG042692.1 KR 1020150033620-A/51: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>LG042691.1 KR 1020150033620-A/50: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>LG042689.1 KR 1020150033620-A/48: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
TGATCCTGT
>LG042688.1 KR 1020150033620-A/47: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>LG042685.1 KR 1020150033620-A/44: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
TGATCCTGT
>LG042681.1 KR 1020150033620-A/40: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>LG042678.1 KR 1020150033620-A/37: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>LG042675.1 KR 1020150033620-A/34: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>LG042672.1 KR 1020150033620-A/31: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>LG042644.1 KR 1020150033620-A/3: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
TGATCCTGT
>LG042642.1 KR 1020150033620-A/1: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>LG021358.1 KR 1020150005666-A/487: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GGTGCATCC
>LG021350.1 KR 1020150005666-A/471: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGGCGTCT
>LG021342.1 KR 1020150005666-A/455: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>LG021334.1 KR 1020150005666-A/439: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TGGGCATCT
>LG021326.1 KR 1020150005666-A/381: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TCTGCATCC
>LG021318.1 KR 1020150005666-A/365: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>LG021310.1 KR 1020150005666-A/349: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
ACTTCATCC
>LG021302.1 KR 1020150005666-A/333: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GGTGCATCC
>LG021294.1 KR 1020150005666-A/317: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGGCGTCT
>LG021286.1 KR 1020150005666-A/301: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>LG021278.1 KR 1020150005666-A/285: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>LG021270.1 KR 1020150005666-A/269: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>LG021262.1 KR 1020150005666-A/253: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>LG021254.1 KR 1020150005666-A/237: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>LG021246.1 KR 1020150005666-A/221: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>LG021238.1 KR 1020150005666-A/205: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>LG021230.1 KR 1020150005666-A/189: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GGTTCTTCC
>LG021222.1 KR 1020150005666-A/173: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>LG021214.1 KR 1020150005666-A/157: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AGGGCGTCT
>LG021206.1 KR 1020150005666-A/141: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GATGCATCC
>LG021198.1 KR 1020150005666-A/125: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGACGTCT
>LG021190.1 KR 1020150005666-A/109: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GATGCATCC
>LG021182.1 KR 1020150005666-A/93: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGGCGTCT
>LG021174.1 KR 1020150005666-A/77: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TGGACATCT
>LG021166.1 KR 1020150005666-A/61: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>LG021158.1 KR 1020150005666-A/45: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TGGGCATCT
>LG021150.1 KR 1020150005666-A/29: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>LG021142.1 KR 1020150005666-A/13: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>LG020891.1 KR 1020150002879-A/19: HUMANIZED ANTIBODY AGAINST AMYLOID BETA
GGTGACTAC
>LG041007.1 KR 1020150016336-A/27: RIBOSOMAL POLYNUCLEOTIDES AND RELATED EXPRESSION SYSTEMS
ATCGACCTT
>LG018532.1 KR 1020150008120-A/7: SYNTHETIC BRASSICA-DERIVED CHLOROPLAST TRANSIT PEPTIDES
GCTTCTTCT
>LG059342.1 KR 1020150048887-A/253: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>LG059330.1 KR 1020150048887-A/229: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>LG059318.1 KR 1020150048887-A/205: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GTTGCATCC
>LG059306.1 KR 1020150048887-A/181: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>LG059294.1 KR 1020150048887-A/157: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>LG059282.1 KR 1020150048887-A/133: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
AGTGCCTCC
>LG059270.1 KR 1020150048887-A/109: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>LG059258.1 KR 1020150048887-A/85: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>LG059246.1 KR 1020150048887-A/61: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGTATCC
>LG059234.1 KR 1020150048887-A/37: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>LG059222.1 KR 1020150048887-A/13: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>LG057136.1 KR 1020150041664-A/408: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057128.1 KR 1020150041664-A/392: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057119.1 KR 1020150041664-A/365: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057111.1 KR 1020150041664-A/349: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
ACTACATCC
>LG057103.1 KR 1020150041664-A/333: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
AAGGCGTCT
>LG057095.1 KR 1020150041664-A/317: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057087.1 KR 1020150041664-A/301: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GGTGCATCC
>LG057079.1 KR 1020150041664-A/285: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057071.1 KR 1020150041664-A/269: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057063.1 KR 1020150041664-A/253: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
TCTGCATCC
>LG057055.1 KR 1020150041664-A/237: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057047.1 KR 1020150041664-A/221: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057039.1 KR 1020150041664-A/205: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057031.1 KR 1020150041664-A/189: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057023.1 KR 1020150041664-A/173: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
ACTGCATCC
>LG057015.1 KR 1020150041664-A/157: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG057007.1 KR 1020150041664-A/141: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG056999.1 KR 1020150041664-A/125: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG056991.1 KR 1020150041664-A/109: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG056983.1 KR 1020150041664-A/93: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
TGGGCATCT
>LG056975.1 KR 1020150041664-A/77: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
AGTGCATCC
>LG056967.1 KR 1020150041664-A/61: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG056959.1 KR 1020150041664-A/45: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
GCTGCATCC
>LG056951.1 KR 1020150041664-A/29: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
TGGGCATCT
>LG056943.1 KR 1020150041664-A/13: HUMAN ANTIBODIES TO GFR(alpha3) AND METHODS OF USE THEREOF
AAGGCGTCT
>LG056519.1 KR 1020150041662-A/733: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTTT
>LG056507.1 KR 1020150041662-A/709: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>LG056495.1 KR 1020150041662-A/685: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>LG056483.1 KR 1020150041662-A/661: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>LG056471.1 KR 1020150041662-A/637: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>LG056459.1 KR 1020150041662-A/613: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>LG056447.1 KR 1020150041662-A/589: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GATGCATCC
>LG056435.1 KR 1020150041662-A/565: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>LG056423.1 KR 1020150041662-A/541: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>LG056411.1 KR 1020150041662-A/517: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTTT
>LG056399.1 KR 1020150041662-A/493: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>LG056387.1 KR 1020150041662-A/469: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>LG056375.1 KR 1020150041662-A/445: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>LG056363.1 KR 1020150041662-A/421: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>LG056351.1 KR 1020150041662-A/397: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>LG056339.1 KR 1020150041662-A/373: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>LG056327.1 KR 1020150041662-A/349: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>LG056315.1 KR 1020150041662-A/325: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>LG056303.1 KR 1020150041662-A/301: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTCT
>LG056291.1 KR 1020150041662-A/277: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTTT
>LG056279.1 KR 1020150041662-A/253: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTTT
>LG056267.1 KR 1020150041662-A/229: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTCT
>LG056255.1 KR 1020150041662-A/205: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTCT
>LG056243.1 KR 1020150041662-A/181: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TTGGGTTCT
>LG056231.1 KR 1020150041662-A/157: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGTTTCT
>LG056219.1 KR 1020150041662-A/133: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GCTGCATCC
>LG056207.1 KR 1020150041662-A/109: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GCTGCATCC
>LG056195.1 KR 1020150041662-A/85: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TGGGCATCT
>LG056183.1 KR 1020150041662-A/61: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
TGGGCCTCT
>LG056171.1 KR 1020150041662-A/37: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
AAGGCGTCT
>LG056159.1 KR 1020150041662-A/13: ANTI-PCSK9 ANTIBODIES WITH PH-DEPENDENT BINDING CHARACTERISTICS
GGTGCATCC
>LG055588.1 KR 1020150028856-A/35: NUCLEIC ACID NANOPARTICLES AND USES THEREFOR
GGGTTAGGG
>LG055587.1 KR 1020150028856-A/34: NUCLEIC ACID NANOPARTICLES AND USES THEREFOR
GAGTATGAG
>LG055580.1 KR 1020150028856-A/27: NUCLEIC ACID NANOPARTICLES AND USES THEREFOR
TTAGGGTTA
>LG055579.1 KR 1020150028856-A/26: NUCLEIC ACID NANOPARTICLES AND USES THEREFOR
GTTAGGGTT
>DI487424.1 KR 1020100051697-A/40: Novel polygalacturonase and their uses
CACGTATCG
>LG013010.1 KR 1020150003256-A/381: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG013002.1 KR 1020150003256-A/365: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LG012994.1 KR 1020150003256-A/349: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG012986.1 KR 1020150003256-A/333: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG012978.1 KR 1020150003256-A/317: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG012970.1 KR 1020150003256-A/301: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GGTACATCC
>LG012962.1 KR 1020150003256-A/285: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG012954.1 KR 1020150003256-A/269: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GATGCATCC
>LG012946.1 KR 1020150003256-A/253: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG012938.1 KR 1020150003256-A/237: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LG012930.1 KR 1020150003256-A/221: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012922.1 KR 1020150003256-A/205: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012914.1 KR 1020150003256-A/189: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LG012906.1 KR 1020150003256-A/173: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012898.1 KR 1020150003256-A/157: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GATGCATCC
>LG012890.1 KR 1020150003256-A/141: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012882.1 KR 1020150003256-A/125: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
TGGGCATCT
>LG012874.1 KR 1020150003256-A/109: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012866.1 KR 1020150003256-A/93: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012858.1 KR 1020150003256-A/77: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012850.1 KR 1020150003256-A/61: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012842.1 KR 1020150003256-A/45: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012834.1 KR 1020150003256-A/29: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LG012826.1 KR 1020150003256-A/13: ANTI-HLA-B*27 ANTIBODIES AND USES THEREOF
GCTGCATCC
>DI487426.1 KR 1020100051697-A/42: Novel polygalacturonase and their uses
CAAGTTTGA
>DI487425.1 KR 1020100051697-A/41: Novel polygalacturonase and their uses
CAGGTTTGA
>DI487423.1 KR 1020100051697-A/39: Novel polygalacturonase and their uses
CAGGTATCG
>HZ377951.1 JP 2015523962-A/135: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>HZ378039.1 JP 2015523962-A/223: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GGTGCATCC
>HZ378031.1 JP 2015523962-A/215: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGGCGTCT
>HZ378023.1 JP 2015523962-A/207: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>HZ378015.1 JP 2015523962-A/199: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TGGGCATCT
>HZ378007.1 JP 2015523962-A/191: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TCTGCATCC
>HZ377999.1 JP 2015523962-A/183: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>HZ377991.1 JP 2015523962-A/175: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
ACTTCATCC
>HZ377983.1 JP 2015523962-A/167: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GGTGCATCC
>HZ377975.1 JP 2015523962-A/159: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGGCGTCT
>HZ377967.1 JP 2015523962-A/151: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>HZ377959.1 JP 2015523962-A/143: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>HZ377943.1 JP 2015523962-A/127: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>HZ377935.1 JP 2015523962-A/119: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>HZ377927.1 JP 2015523962-A/111: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>HZ377919.1 JP 2015523962-A/103: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TATGCTTCC
>HZ377911.1 JP 2015523962-A/95: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GGTTCTTCC
>HZ377903.1 JP 2015523962-A/87: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>HZ377895.1 JP 2015523962-A/79: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AGGGCGTCT
>HZ377887.1 JP 2015523962-A/71: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GATGCATCC
>HZ377879.1 JP 2015523962-A/63: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGACGTCT
>HZ377871.1 JP 2015523962-A/55: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GATGCATCC
>HZ377863.1 JP 2015523962-A/47: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
AAGGCGTCT
>HZ377855.1 JP 2015523962-A/39: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TGGACATCT
>HZ377847.1 JP 2015523962-A/31: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>HZ377839.1 JP 2015523962-A/23: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
TGGGCATCT
>HZ377831.1 JP 2015523962-A/15: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>HZ377823.1 JP 2015523962-A/7: HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF
GCTGCATCC
>HZ376286.1 WO 2015129774-A/9: Novel anti-presepsin antibody
GGTGGTTTG
>HZ376283.1 WO 2015129774-A/6: Novel anti-presepsin antibody
GGGGACTTT
>HZ376280.1 WO 2015129774-A/3: Novel anti-presepsin antibody
GGGGACTTT
>HZ375629.1 JP 2015165804-A/64: TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES
GAAGCAGCA
>HZ375592.1 JP 2015165804-A/27: TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES
GGAGAAAGG
>HZ375340.1 JP 2015163075-A/35: Genotyping Method
AGCTGGTGC
>HZ375339.1 JP 2015163075-A/34: Genotyping Method
GAGCTGGTT
>HZ375338.1 JP 2015163075-A/33: Genotyping Method
TGGAGCTGT
>HZ390597.1 JP 2015522292-A/66: COOPERATIVE PRIMERS, PROBES, AND APPLICATIONS THEREOF
ACTGTATGG
>HZ390596.1 JP 2015522292-A/65: COOPERATIVE PRIMERS, PROBES, AND APPLICATIONS THEREOF
ACTGTATGG
>HZ390580.1 JP 2015522292-A/49: COOPERATIVE PRIMERS, PROBES, AND APPLICATIONS THEREOF
ACTGTATGG
>HZ390577.1 JP 2015522292-A/46: COOPERATIVE PRIMERS, PROBES, AND APPLICATIONS THEREOF
ACTGTATGG
>HZ233585.1 JP 2015519881-A/16300: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>HZ254394.1 JP 2015518816-A/14698: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCCTAG
>HZ313605.1 JP 2015518704-A/39507: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATCTAG
>HZ294932.1 JP 2015518704-A/20834: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTTTAG
>HZ294931.1 JP 2015518704-A/20833: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>HZ312485.1 JP 2015518704-A/38387: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGCTAG
>HZ273947.1 JP 2015518485-A/617: MIRNA MODULATORS OF THERMOGENESIS
CAAGCTCGT
>HZ273946.1 JP 2015518485-A/616: MIRNA MODULATORS OF THERMOGENESIS
AATCATGTG
>HZ273945.1 JP 2015518485-A/615: MIRNA MODULATORS OF THERMOGENESIS
ACTGCTGAG
>HZ273944.1 JP 2015518485-A/614: MIRNA MODULATORS OF THERMOGENESIS
TCCTCTTCT
>HZ273943.1 JP 2015518485-A/613: MIRNA MODULATORS OF THERMOGENESIS
GGCGGAGGG
>HZ273941.1 JP 2015518485-A/611: MIRNA MODULATORS OF THERMOGENESIS
GGGATCGCG
>HZ273939.1 JP 2015518485-A/609: MIRNA MODULATORS OF THERMOGENESIS
AACTACTGA
>HZ273938.1 JP 2015518485-A/608: MIRNA MODULATORS OF THERMOGENESIS
CTTCTTGTG
>HZ273937.1 JP 2015518485-A/607: MIRNA MODULATORS OF THERMOGENESIS
TGAGTTGGC
>HZ273936.1 JP 2015518485-A/606: MIRNA MODULATORS OF THERMOGENESIS
GTCTTACTC
>HZ273933.1 JP 2015518485-A/603: MIRNA MODULATORS OF THERMOGENESIS
GAAAGCGCT
>HZ273932.1 JP 2015518485-A/602: MIRNA MODULATORS OF THERMOGENESIS
TTCTCCAAA
>HZ273931.1 JP 2015518485-A/601: MIRNA MODULATORS OF THERMOGENESIS
TTGACACTT
>HZ273928.1 JP 2015518485-A/598: MIRNA MODULATORS OF THERMOGENESIS
GATTGTAGC
>HZ273927.1 JP 2015518485-A/597: MIRNA MODULATORS OF THERMOGENESIS
GTCAACACT
>HZ273926.1 JP 2015518485-A/596: MIRNA MODULATORS OF THERMOGENESIS
ATCCTTTGT
>HZ273925.1 JP 2015518485-A/595: MIRNA MODULATORS OF THERMOGENESIS
AGCAGCACA
>HZ273924.1 JP 2015518485-A/594: MIRNA MODULATORS OF THERMOGENESIS
AATGACACG
>HZ273921.1 JP 2015518485-A/591: MIRNA MODULATORS OF THERMOGENESIS
CCGTCTCAG
>HZ273919.1 JP 2015518485-A/589: MIRNA MODULATORS OF THERMOGENESIS
GCCCCTGGG
>HZ273915.1 JP 2015518485-A/585: MIRNA MODULATORS OF THERMOGENESIS
CCTATTCTT
>HZ273914.1 JP 2015518485-A/584: MIRNA MODULATORS OF THERMOGENESIS
AGAGTTGAG
>HZ273913.1 JP 2015518485-A/583: MIRNA MODULATORS OF THERMOGENESIS
TGGTTCCGT
>HZ273911.1 JP 2015518485-A/581: MIRNA MODULATORS OF THERMOGENESIS
TGAAATGTT
>HZ273909.1 JP 2015518485-A/579: MIRNA MODULATORS OF THERMOGENESIS
TCACCACCT
>HZ273908.1 JP 2015518485-A/578: MIRNA MODULATORS OF THERMOGENESIS
TGTAACAGC
>HZ273907.1 JP 2015518485-A/577: MIRNA MODULATORS OF THERMOGENESIS
CTGACCTAT
>HZ273906.1 JP 2015518485-A/576: MIRNA MODULATORS OF THERMOGENESIS
CAACGGAAT
>HZ273905.1 JP 2015518485-A/575: MIRNA MODULATORS OF THERMOGENESIS
TGATATGTT
>HZ273902.1 JP 2015518485-A/572: MIRNA MODULATORS OF THERMOGENESIS
TTAATGCTA
>HZ273901.1 JP 2015518485-A/571: MIRNA MODULATORS OF THERMOGENESIS
CTCCATTTG
>HZ273900.1 JP 2015518485-A/570: MIRNA MODULATORS OF THERMOGENESIS
TTAGAGACG
>HZ273899.1 JP 2015518485-A/569: MIRNA MODULATORS OF THERMOGENESIS
TGGGACATA
>HZ273897.1 JP 2015518485-A/567: MIRNA MODULATORS OF THERMOGENESIS
TCTCACCAC
>HZ273896.1 JP 2015518485-A/566: MIRNA MODULATORS OF THERMOGENESIS
TGGGCGGGG
>HZ273895.1 JP 2015518485-A/565: MIRNA MODULATORS OF THERMOGENESIS
CTGCGCAAG
>HZ273894.1 JP 2015518485-A/564: MIRNA MODULATORS OF THERMOGENESIS
TAGAGTTAC
>HZ273893.1 JP 2015518485-A/563: MIRNA MODULATORS OF THERMOGENESIS
TTTAGGGCC
>HZ273891.1 JP 2015518485-A/561: MIRNA MODULATORS OF THERMOGENESIS
CACCAGGCA
>HZ273890.1 JP 2015518485-A/560: MIRNA MODULATORS OF THERMOGENESIS
TGAGGCAGT
>HZ273878.1 JP 2015518485-A/548: MIRNA MODULATORS OF THERMOGENESIS
CAGGAGATA
>HZ273877.1 JP 2015518485-A/547: MIRNA MODULATORS OF THERMOGENESIS
CTGGAGAAA
>HZ273876.1 JP 2015518485-A/546: MIRNA MODULATORS OF THERMOGENESIS
CTGGAGATG
>HZ273875.1 JP 2015518485-A/545: MIRNA MODULATORS OF THERMOGENESIS
CTGGAAATA
>HZ273874.1 JP 2015518485-A/544: MIRNA MODULATORS OF THERMOGENESIS
CGGGCGTGG
>HZ273871.1 JP 2015518485-A/541: MIRNA MODULATORS OF THERMOGENESIS
AGTCTAGCT
>HZ273870.1 JP 2015518485-A/540: MIRNA MODULATORS OF THERMOGENESIS
ACTCCAGCT
>HZ273869.1 JP 2015518485-A/539: MIRNA MODULATORS OF THERMOGENESIS
ACTCTATCT
>HZ273868.1 JP 2015518485-A/538: MIRNA MODULATORS OF THERMOGENESIS
ACTCTAGGT
>HZ273866.1 JP 2015518485-A/536: MIRNA MODULATORS OF THERMOGENESIS
AAGTGATCT
>HZ273865.1 JP 2015518485-A/535: MIRNA MODULATORS OF THERMOGENESIS
AAGTGATCT
>HZ273864.1 JP 2015518485-A/534: MIRNA MODULATORS OF THERMOGENESIS
GTGTCCGGG
>HZ273863.1 JP 2015518485-A/533: MIRNA MODULATORS OF THERMOGENESIS
GTGTCTGGC
>HZ273862.1 JP 2015518485-A/532: MIRNA MODULATORS OF THERMOGENESIS
TCACGCCTG
>HZ273861.1 JP 2015518485-A/531: MIRNA MODULATORS OF THERMOGENESIS
TCCCACCTG
>HZ273850.1 JP 2015518485-A/520: MIRNA MODULATORS OF THERMOGENESIS
CACCCAGCC
>HZ273849.1 JP 2015518485-A/519: MIRNA MODULATORS OF THERMOGENESIS
CTCCCGGGT
>HZ273848.1 JP 2015518485-A/518: MIRNA MODULATORS OF THERMOGENESIS
CACCAGGCA
>HZ273847.1 JP 2015518485-A/517: MIRNA MODULATORS OF THERMOGENESIS
CTCCCTGCT
>HZ273846.1 JP 2015518485-A/516: MIRNA MODULATORS OF THERMOGENESIS
CACGCCGCT
>HZ273845.1 JP 2015518485-A/515: MIRNA MODULATORS OF THERMOGENESIS
CACCTGACT
>HZ273844.1 JP 2015518485-A/514: MIRNA MODULATORS OF THERMOGENESIS
CAGCCCGCT
>HZ273843.1 JP 2015518485-A/513: MIRNA MODULATORS OF THERMOGENESIS
CTCACGGCT
>HZ273842.1 JP 2015518485-A/512: MIRNA MODULATORS OF THERMOGENESIS
CTCCCAGCT
>HZ273841.1 JP 2015518485-A/511: MIRNA MODULATORS OF THERMOGENESIS
CACTCGACT
>HZ273840.1 JP 2015518485-A/510: MIRNA MODULATORS OF THERMOGENESIS
CATCTGGCT
>HZ273839.1 JP 2015518485-A/509: MIRNA MODULATORS OF THERMOGENESIS
CACCTGGCC
>HZ273838.1 JP 2015518485-A/508: MIRNA MODULATORS OF THERMOGENESIS
CACCCACCT
>HZ273837.1 JP 2015518485-A/507: MIRNA MODULATORS OF THERMOGENESIS
CAGCCTGCT
>HZ273836.1 JP 2015518485-A/506: MIRNA MODULATORS OF THERMOGENESIS
CTCCCGGGT
>HZ273835.1 JP 2015518485-A/505: MIRNA MODULATORS OF THERMOGENESIS
CACTCAGCT
>HZ273834.1 JP 2015518485-A/504: MIRNA MODULATORS OF THERMOGENESIS
CACCCCTCT
>HZ273833.1 JP 2015518485-A/503: MIRNA MODULATORS OF THERMOGENESIS
CACCCTGCC
>HZ273832.1 JP 2015518485-A/502: MIRNA MODULATORS OF THERMOGENESIS
CACCCAGGT
>HZ273831.1 JP 2015518485-A/501: MIRNA MODULATORS OF THERMOGENESIS
AAGGCAGTG
>HZ273827.1 JP 2015518485-A/497: MIRNA MODULATORS OF THERMOGENESIS
TGGATTTCT
>HZ273826.1 JP 2015518485-A/496: MIRNA MODULATORS OF THERMOGENESIS
TGGATTTCT
>HZ312383.1 JP 2015518704-A/38285: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCCTAG
>HZ273823.1 JP 2015518485-A/493: MIRNA MODULATORS OF THERMOGENESIS
TCTTCTCAT
>HZ273822.1 JP 2015518485-A/492: MIRNA MODULATORS OF THERMOGENESIS
CCTGCTCAT
>HZ273818.1 JP 2015518485-A/488: MIRNA MODULATORS OF THERMOGENESIS
TATTCATTT
>HZ273817.1 JP 2015518485-A/487: MIRNA MODULATORS OF THERMOGENESIS
AATATTATA
>HZ273816.1 JP 2015518485-A/486: MIRNA MODULATORS OF THERMOGENESIS
ACAATACAT
>HZ273815.1 JP 2015518485-A/485: MIRNA MODULATORS OF THERMOGENESIS
ATAATACAG
>HZ273814.1 JP 2015518485-A/484: MIRNA MODULATORS OF THERMOGENESIS
ATAAGACAT
>HZ273813.1 JP 2015518485-A/483: MIRNA MODULATORS OF THERMOGENESIS
ATAGTACAT
>HZ273812.1 JP 2015518485-A/482: MIRNA MODULATORS OF THERMOGENESIS
GTAATACAT
>HZ273788.1 JP 2015518485-A/458: MIRNA MODULATORS OF THERMOGENESIS
ATGAGGCAG
>HZ273787.1 JP 2015518485-A/457: MIRNA MODULATORS OF THERMOGENESIS
AGGAGCCAG
>HZ273786.1 JP 2015518485-A/456: MIRNA MODULATORS OF THERMOGENESIS
AGAAGGCAG
>HZ273785.1 JP 2015518485-A/455: MIRNA MODULATORS OF THERMOGENESIS
AGGAGGCAC
>HZ273772.1 JP 2015518485-A/442: MIRNA MODULATORS OF THERMOGENESIS
GTCCCTCCC
>HZ273771.1 JP 2015518485-A/441: MIRNA MODULATORS OF THERMOGENESIS
ATCCCTCTC
>HZ273767.1 JP 2015518485-A/437: MIRNA MODULATORS OF THERMOGENESIS
AACCAGCAC
>HZ273766.1 JP 2015518485-A/436: MIRNA MODULATORS OF THERMOGENESIS
GACATGGCC
>HZ273765.1 JP 2015518485-A/435: MIRNA MODULATORS OF THERMOGENESIS
CACCTGGCC
>HZ273749.1 JP 2015518485-A/419: MIRNA MODULATORS OF THERMOGENESIS
ACTCTAAAC
>HZ273744.1 JP 2015518485-A/414: MIRNA MODULATORS OF THERMOGENESIS
AGGCACCAG
>HZ273743.1 JP 2015518485-A/413: MIRNA MODULATORS OF THERMOGENESIS
AGGCACCAG
>HZ273742.1 JP 2015518485-A/412: MIRNA MODULATORS OF THERMOGENESIS
TGCCTCTGC
>HZ273741.1 JP 2015518485-A/411: MIRNA MODULATORS OF THERMOGENESIS
TGGCTCTGC
>HZ273740.1 JP 2015518485-A/410: MIRNA MODULATORS OF THERMOGENESIS
TGTCTCTGT
>HZ273739.1 JP 2015518485-A/409: MIRNA MODULATORS OF THERMOGENESIS
CAAAGAAGA
>HZ273738.1 JP 2015518485-A/408: MIRNA MODULATORS OF THERMOGENESIS
CAACGAGGA
>HZ273737.1 JP 2015518485-A/407: MIRNA MODULATORS OF THERMOGENESIS
CAAATAGGA
>HZ273736.1 JP 2015518485-A/406: MIRNA MODULATORS OF THERMOGENESIS
AAAAGAGGA
>HZ273735.1 JP 2015518485-A/405: MIRNA MODULATORS OF THERMOGENESIS
AACAGGTAA
>HZ273734.1 JP 2015518485-A/404: MIRNA MODULATORS OF THERMOGENESIS
AACAGGTTA
>HZ273733.1 JP 2015518485-A/403: MIRNA MODULATORS OF THERMOGENESIS
AACATGTGA
>HZ273732.1 JP 2015518485-A/402: MIRNA MODULATORS OF THERMOGENESIS
AACAGGTCA
>HZ273731.1 JP 2015518485-A/401: MIRNA MODULATORS OF THERMOGENESIS
CACAGGTGA
>HZ273730.1 JP 2015518485-A/400: MIRNA MODULATORS OF THERMOGENESIS
GCTACCCAT
>HZ273724.1 JP 2015518485-A/394: MIRNA MODULATORS OF THERMOGENESIS
AAGTGCCTC
>HZ273723.1 JP 2015518485-A/393: MIRNA MODULATORS OF THERMOGENESIS
AAAGTGCAT
>HZ273719.1 JP 2015518485-A/389: MIRNA MODULATORS OF THERMOGENESIS
GAGTGACTT
>HZ273718.1 JP 2015518485-A/388: MIRNA MODULATORS OF THERMOGENESIS
GACTGCCTT
>HZ273717.1 JP 2015518485-A/387: MIRNA MODULATORS OF THERMOGENESIS
GTGTGCCTT
>HZ273716.1 JP 2015518485-A/386: MIRNA MODULATORS OF THERMOGENESIS
ATGACACTT
>HZ273715.1 JP 2015518485-A/385: MIRNA MODULATORS OF THERMOGENESIS
TTAACACTT
>HZ273714.1 JP 2015518485-A/384: MIRNA MODULATORS OF THERMOGENESIS
TTGACAGTT
>HZ273713.1 JP 2015518485-A/383: MIRNA MODULATORS OF THERMOGENESIS
TTGACTCTT
>HZ273702.1 JP 2015518485-A/372: MIRNA MODULATORS OF THERMOGENESIS
AGACCCGGG
>HZ273701.1 JP 2015518485-A/371: MIRNA MODULATORS OF THERMOGENESIS
AGTCCCTGG
>HZ273700.1 JP 2015518485-A/370: MIRNA MODULATORS OF THERMOGENESIS
AGCCCCTGG
>HZ273699.1 JP 2015518485-A/369: MIRNA MODULATORS OF THERMOGENESIS
AGACCCTGT
>HZ273695.1 JP 2015518485-A/365: MIRNA MODULATORS OF THERMOGENESIS
TCAGTATTA
>HZ273694.1 JP 2015518485-A/364: MIRNA MODULATORS OF THERMOGENESIS
TGAGTATAA
>HZ273693.1 JP 2015518485-A/363: MIRNA MODULATORS OF THERMOGENESIS
TTAGTATTA
>HZ273683.1 JP 2015518485-A/353: MIRNA MODULATORS OF THERMOGENESIS
TCCTGTCCT
>HZ273682.1 JP 2015518485-A/352: MIRNA MODULATORS OF THERMOGENESIS
TCATGTACT
>HZ273660.1 JP 2015518485-A/330: MIRNA MODULATORS OF THERMOGENESIS
TCTTGGAGC
>HZ273659.1 JP 2015518485-A/329: MIRNA MODULATORS OF THERMOGENESIS
TCTTAGAGT
>HZ273658.1 JP 2015518485-A/328: MIRNA MODULATORS OF THERMOGENESIS
TCTTAGAGT
>HZ273657.1 JP 2015518485-A/327: MIRNA MODULATORS OF THERMOGENESIS
TATTGGAGT
>HZ273656.1 JP 2015518485-A/326: MIRNA MODULATORS OF THERMOGENESIS
TCCTGGAGT
>HZ273655.1 JP 2015518485-A/325: MIRNA MODULATORS OF THERMOGENESIS
TGTCTAGCA
>HZ273654.1 JP 2015518485-A/324: MIRNA MODULATORS OF THERMOGENESIS
TGTCTGGCA
>HZ273652.1 JP 2015518485-A/322: MIRNA MODULATORS OF THERMOGENESIS
ACTGGACGT
>HZ273651.1 JP 2015518485-A/321: MIRNA MODULATORS OF THERMOGENESIS
ACTGGTCTT
>HZ273650.1 JP 2015518485-A/320: MIRNA MODULATORS OF THERMOGENESIS
ACTGGCCTT
>HZ273643.1 JP 2015518485-A/313: MIRNA MODULATORS OF THERMOGENESIS
ACTTCACCT
>HZ273642.1 JP 2015518485-A/312: MIRNA MODULATORS OF THERMOGENESIS
AGAACAGAA
>HZ273641.1 JP 2015518485-A/311: MIRNA MODULATORS OF THERMOGENESIS
AGATTAGAA
>HZ273640.1 JP 2015518485-A/310: MIRNA MODULATORS OF THERMOGENESIS
AGATTAGAA
>HZ273630.1 JP 2015518485-A/300: MIRNA MODULATORS OF THERMOGENESIS
AAAGTGCTG
>HZ273629.1 JP 2015518485-A/299: MIRNA MODULATORS OF THERMOGENESIS
AAAGTGCTG
>HZ273622.1 JP 2015518485-A/292: MIRNA MODULATORS OF THERMOGENESIS
AATAATACA
>HZ273600.1 JP 2015518485-A/270: MIRNA MODULATORS OF THERMOGENESIS
TTTAACATG
>HZ273599.1 JP 2015518485-A/269: MIRNA MODULATORS OF THERMOGENESIS
TGTGCTTGA
>HZ273598.1 JP 2015518485-A/268: MIRNA MODULATORS OF THERMOGENESIS
CACCAGGCA
>HZ273597.1 JP 2015518485-A/267: MIRNA MODULATORS OF THERMOGENESIS
CCGCAGGCA
>HZ273596.1 JP 2015518485-A/266: MIRNA MODULATORS OF THERMOGENESIS
CAGAAGGCA
>HZ273595.1 JP 2015518485-A/265: MIRNA MODULATORS OF THERMOGENESIS
CAGCAAGCA
>HZ273590.1 JP 2015518485-A/260: MIRNA MODULATORS OF THERMOGENESIS
ATAAGAAGA
>HZ273589.1 JP 2015518485-A/259: MIRNA MODULATORS OF THERMOGENESIS
ATAAGAAGA
>HZ273588.1 JP 2015518485-A/258: MIRNA MODULATORS OF THERMOGENESIS
TCCTTCATT
>HZ273585.1 JP 2015518485-A/255: MIRNA MODULATORS OF THERMOGENESIS
TGAAAGGTT
>HZ273584.1 JP 2015518485-A/254: MIRNA MODULATORS OF THERMOGENESIS
TGAAATTTT
>HZ273583.1 JP 2015518485-A/253: MIRNA MODULATORS OF THERMOGENESIS
TTAAATGTT
>HZ273582.1 JP 2015518485-A/252: MIRNA MODULATORS OF THERMOGENESIS
TAATACAGC
>HZ273581.1 JP 2015518485-A/251: MIRNA MODULATORS OF THERMOGENESIS
GAATACTGC
>HZ273580.1 JP 2015518485-A/250: MIRNA MODULATORS OF THERMOGENESIS
TAATAATGC
>HZ273579.1 JP 2015518485-A/249: MIRNA MODULATORS OF THERMOGENESIS
TAATACTGT
>HZ273574.1 JP 2015518485-A/244: MIRNA MODULATORS OF THERMOGENESIS
AGGTAGTTT
>HZ273571.1 JP 2015518485-A/241: MIRNA MODULATORS OF THERMOGENESIS
TGGAGAGAA
>HZ273570.1 JP 2015518485-A/240: MIRNA MODULATORS OF THERMOGENESIS
AACCATCAC
>HZ273569.1 JP 2015518485-A/239: MIRNA MODULATORS OF THERMOGENESIS
AACCATAGG
>HZ273568.1 JP 2015518485-A/238: MIRNA MODULATORS OF THERMOGENESIS
AGCCAGCGA
>HZ273567.1 JP 2015518485-A/237: MIRNA MODULATORS OF THERMOGENESIS
AACCCTCTA
>HZ273566.1 JP 2015518485-A/236: MIRNA MODULATORS OF THERMOGENESIS
AACCCCCGA
>HZ273565.1 JP 2015518485-A/235: MIRNA MODULATORS OF THERMOGENESIS
AAAAATCGA
>HZ273564.1 JP 2015518485-A/234: MIRNA MODULATORS OF THERMOGENESIS
AAACATCTA
>HZ273563.1 JP 2015518485-A/233: MIRNA MODULATORS OF THERMOGENESIS
ATCCAGCGA
>HZ273562.1 JP 2015518485-A/232: MIRNA MODULATORS OF THERMOGENESIS
AACCATCAC
>HZ273561.1 JP 2015518485-A/231: MIRNA MODULATORS OF THERMOGENESIS
AACCAAAGA
>HZ273560.1 JP 2015518485-A/230: MIRNA MODULATORS OF THERMOGENESIS
AACCATAGT
>HZ273559.1 JP 2015518485-A/229: MIRNA MODULATORS OF THERMOGENESIS
AATCATACA
>HZ273558.1 JP 2015518485-A/228: MIRNA MODULATORS OF THERMOGENESIS
AATCATACA
>HZ273545.1 JP 2015518485-A/215: MIRNA MODULATORS OF THERMOGENESIS
CCTCTGAAA
>HZ273544.1 JP 2015518485-A/214: MIRNA MODULATORS OF THERMOGENESIS
GACAGTATA
>HZ273543.1 JP 2015518485-A/213: MIRNA MODULATORS OF THERMOGENESIS
TACAATATA
>HZ273542.1 JP 2015518485-A/212: MIRNA MODULATORS OF THERMOGENESIS
TACAGTATT
>HZ273538.1 JP 2015518485-A/208: MIRNA MODULATORS OF THERMOGENESIS
GGTGCAGTG
>HZ273525.1 JP 2015518485-A/195: MIRNA MODULATORS OF THERMOGENESIS
TCATACAGT
>HZ273524.1 JP 2015518485-A/194: MIRNA MODULATORS OF THERMOGENESIS
TGGTCCCGT
>HZ273523.1 JP 2015518485-A/193: MIRNA MODULATORS OF THERMOGENESIS
TTGTACTGT
>HZ273522.1 JP 2015518485-A/192: MIRNA MODULATORS OF THERMOGENESIS
TCATACAGT
>HZ273498.1 JP 2015518485-A/168: MIRNA MODULATORS OF THERMOGENESIS
GGCTATGCC
>HZ273465.1 JP 2015518485-A/135: MIRNA MODULATORS OF THERMOGENESIS
CAAAGTGCT
>HZ273464.1 JP 2015518485-A/134: MIRNA MODULATORS OF THERMOGENESIS
CAAAGTGCT
>HZ273463.1 JP 2015518485-A/133: MIRNA MODULATORS OF THERMOGENESIS
CAAAGTGCT
>HZ273453.1 JP 2015518485-A/123: MIRNA MODULATORS OF THERMOGENESIS
TGTGCAAAT
>HZ273452.1 JP 2015518485-A/122: MIRNA MODULATORS OF THERMOGENESIS
TGTGCAAAT
>HZ273451.1 JP 2015518485-A/121: MIRNA MODULATORS OF THERMOGENESIS
CAAAGTGCT
>HZ273450.1 JP 2015518485-A/120: MIRNA MODULATORS OF THERMOGENESIS
CAAAGTGCT
>HZ273449.1 JP 2015518485-A/119: MIRNA MODULATORS OF THERMOGENESIS
CAAAGTGCT
>HZ273448.1 JP 2015518485-A/118: MIRNA MODULATORS OF THERMOGENESIS
CTGTGCAAG
>HZ273447.1 JP 2015518485-A/117: MIRNA MODULATORS OF THERMOGENESIS
AGAGGTAGG
>HZ273446.1 JP 2015518485-A/116: MIRNA MODULATORS OF THERMOGENESIS
TGAAGTAGG
>HZ273445.1 JP 2015518485-A/115: MIRNA MODULATORS OF THERMOGENESIS
GGAGGTAGG
>HZ273444.1 JP 2015518485-A/114: MIRNA MODULATORS OF THERMOGENESIS
TAGAGTTTC
>HZ273442.1 JP 2015518485-A/112: MIRNA MODULATORS OF THERMOGENESIS
CACCCAGGT
>HZ273439.1 JP 2015518485-A/109: MIRNA MODULATORS OF THERMOGENESIS
CCTGCTCAT
>HZ273438.1 JP 2015518485-A/108: MIRNA MODULATORS OF THERMOGENESIS
GTAATACAT
>HZ273427.1 JP 2015518485-A/97: MIRNA MODULATORS OF THERMOGENESIS
ACTCTAAAC
>HZ273426.1 JP 2015518485-A/96: MIRNA MODULATORS OF THERMOGENESIS
CACAGGTGA
>HZ273422.1 JP 2015518485-A/92: MIRNA MODULATORS OF THERMOGENESIS
GTGTGCCTT
>HZ273421.1 JP 2015518485-A/91: MIRNA MODULATORS OF THERMOGENESIS
GACTGCCTT
>HZ273420.1 JP 2015518485-A/90: MIRNA MODULATORS OF THERMOGENESIS
TTGACTCTT
>HZ273417.1 JP 2015518485-A/87: MIRNA MODULATORS OF THERMOGENESIS
AGACCCTGT
>HZ273409.1 JP 2015518485-A/79: MIRNA MODULATORS OF THERMOGENESIS
TGTCTGGCA
>HZ273408.1 JP 2015518485-A/78: MIRNA MODULATORS OF THERMOGENESIS
ACTGGCCTT
>HZ273405.1 JP 2015518485-A/75: MIRNA MODULATORS OF THERMOGENESIS
AGATTAGAA
>HZ273388.1 JP 2015518485-A/58: MIRNA MODULATORS OF THERMOGENESIS
CAGCAAGCA
>HZ273383.1 JP 2015518485-A/53: MIRNA MODULATORS OF THERMOGENESIS
TTAAATGTT
>HZ273381.1 JP 2015518485-A/51: MIRNA MODULATORS OF THERMOGENESIS
AACCATAGT
>HZ273374.1 JP 2015518485-A/44: MIRNA MODULATORS OF THERMOGENESIS
GAGTGCAAT
>HZ311731.1 JP 2015518704-A/37633: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAGTAG
>HZ310908.1 JP 2015518704-A/36810: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>HZ310907.1 JP 2015518704-A/36809: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>HZ207285.1 JP 2015519040-A/17336: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
ATGGCCTAG
>HZ229883.1 JP 2015519881-A/12598: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>HZ249906.1 JP 2015518816-A/10210: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCTTAG
>HZ305617.1 JP 2015518704-A/31519: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATCTAG
>HZ304497.1 JP 2015518704-A/30399: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGCTAG
>HZ304395.1 JP 2015518704-A/30297: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCCTAG
>HZ263370.1 JP 2015518816-A/23674: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCCTAG
>HZ303743.1 JP 2015518704-A/29645: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAGTAG
>HZ321593.1 JP 2015518704-A/47495: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATATAG
>HZ302920.1 JP 2015518704-A/28822: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>HZ302919.1 JP 2015518704-A/28821: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>HZ320473.1 JP 2015518704-A/46375: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGATAG
>HZ320371.1 JP 2015518704-A/46273: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCGTAG
>HZ319719.1 JP 2015518704-A/45621: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAGTAG
>HZ216317.1 JP 2015519040-A/26368: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
ATGGCCTAG
>HZ318896.1 JP 2015518704-A/44798: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>HZ318895.1 JP 2015518704-A/44797: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTCTAG
>HZ258882.1 JP 2015518816-A/19186: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCCTAG
>HZ237287.1 JP 2015519881-A/20002: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>HZ297629.1 JP 2015518704-A/23531: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATCTAG
>HZ296509.1 JP 2015518704-A/22411: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGGTAG
>HZ296407.1 JP 2015518704-A/22309: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCGTAG
>HZ211801.1 JP 2015519040-A/21852: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
ATGGCCTAG
>HZ351941.1 JP 2015519373-A/54: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>HZ351938.1 JP 2015519373-A/51: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>HZ351937.1 JP 2015519373-A/50: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>HZ351935.1 JP 2015519373-A/48: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
TGATCCTGT
>HZ351934.1 JP 2015519373-A/47: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>HZ351931.1 JP 2015519373-A/44: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
TGATCCTGT
>HZ351927.1 JP 2015519373-A/40: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>HZ351924.1 JP 2015519373-A/37: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>HZ351921.1 JP 2015519373-A/34: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>HZ351918.1 JP 2015519373-A/31: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>HZ351890.1 JP 2015519373-A/3: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
TGATCCTGT
>HZ351888.1 JP 2015519373-A/1: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST
CAGGCTACG
>HZ351437.1 JP 2015519899-A/27: Ribosomal Polynucleotides and Related Expression Systems
ATCGACCTT
>HZ295755.1 JP 2015518704-A/21657: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAATAG
>HZ185569.1 JP 2015144604-A/27: Materials and Methods for Respiratory Disease Control in Canines
GATGTACCC
>HZ185567.1 JP 2015144604-A/25: Materials and Methods for Respiratory Disease Control in Canines
ACAATGAGT
>HZ185562.1 JP 2015144604-A/20: Materials and Methods for Respiratory Disease Control in Canines
AGAACTGGG
>HZ185561.1 JP 2015144604-A/19: Materials and Methods for Respiratory Disease Control in Canines
CAAACCAGA
>HZ185560.1 JP 2015144604-A/18: Materials and Methods for Respiratory Disease Control in Canines
CCGTTGGTC
>HZ185559.1 JP 2015144604-A/17: Materials and Methods for Respiratory Disease Control in Canines
GAGAGTTGG
>HZ289641.1 JP 2015518704-A/15543: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATCTAG
>HZ226181.1 JP 2015519881-A/8896: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAATAG
>HZ202769.1 JP 2015519040-A/12820: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
ATGGCTTAG
>HZ288521.1 JP 2015518704-A/14423: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGCTAG
>HZ288419.1 JP 2015518704-A/14321: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCCTAG
>HZ287767.1 JP 2015518704-A/13669: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAGTAG
>HZ286944.1 JP 2015518704-A/12846: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>HZ286943.1 JP 2015518704-A/12845: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>HZ245418.1 JP 2015518816-A/5722: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCCTAG
>HZ198253.1 JP 2015519040-A/8304: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
ATGGCCTAG
>HZ222479.1 JP 2015519881-A/5194: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>HZ163754.1 JP 2015133970-A/30: COMPOSITIONS AND METHODS OF USE FOR MGD-CSF IN DISEASE TREATMENT
GCCGCCACC
>HZ159089.1 JP 2015130862-A/1913: Micromirs
GCAGCTGGG
>HZ159088.1 JP 2015130862-A/1912: Micromirs
GTATACCCA
>HZ159087.1 JP 2015130862-A/1911: Micromirs
GTCGCGCCT
>HZ159086.1 JP 2015130862-A/1910: Micromirs
CATGGGATC
>HZ159085.1 JP 2015130862-A/1909: Micromirs
GTGCTGCTG
>HZ159084.1 JP 2015130862-A/1908: Micromirs
AAAACCATC
>HZ159083.1 JP 2015130862-A/1907: Micromirs
AGGCATCCT
>HZ159082.1 JP 2015130862-A/1906: Micromirs
CGGTTTAGC
>HZ159081.1 JP 2015130862-A/1905: Micromirs
CAGTATTCT
>HZ159080.1 JP 2015130862-A/1904: Micromirs
GTGACCGCG
>HZ159079.1 JP 2015130862-A/1903: Micromirs
CAGAATGTG
>HZ159078.1 JP 2015130862-A/1902: Micromirs
GACTACAGT
>HZ159077.1 JP 2015130862-A/1901: Micromirs
GTGGCCTGG
>HZ159076.1 JP 2015130862-A/1900: Micromirs
TAAGCATTA
>HZ159075.1 JP 2015130862-A/1899: Micromirs
GACAACACC
>HZ159074.1 JP 2015130862-A/1898: Micromirs
GACAACACT
>HZ159073.1 JP 2015130862-A/1897: Micromirs
TTCCTGTAA
>HZ159072.1 JP 2015130862-A/1896: Micromirs
ACGGGAAGT
>HZ159071.1 JP 2015130862-A/1895: Micromirs
GATCTCTGA
>HZ159070.1 JP 2015130862-A/1894: Micromirs
AAACTCTAC
>HZ159069.1 JP 2015130862-A/1893: Micromirs
GACAGGCAA
>HZ159068.1 JP 2015130862-A/1892: Micromirs
ACAGTCCCA
>HZ159067.1 JP 2015130862-A/1891: Micromirs
GCGCGTGCG
>HZ159066.1 JP 2015130862-A/1890: Micromirs
CTGGCTCAG
>HZ159065.1 JP 2015130862-A/1889: Micromirs
CGTCCTTCC
>HZ159064.1 JP 2015130862-A/1888: Micromirs
CACGAGCTT
>HZ159063.1 JP 2015130862-A/1887: Micromirs
TCTACGGGT
>HZ159062.1 JP 2015130862-A/1886: Micromirs
AGCGAGCTT
>HZ159061.1 JP 2015130862-A/1885: Micromirs
TCTACGGGT
>HZ159060.1 JP 2015130862-A/1884: Micromirs
TACTACCTC
>HZ159059.1 JP 2015130862-A/1883: Micromirs
GCACATGAT
>HZ159058.1 JP 2015130862-A/1882: Micromirs
TAGTGCCAA
>HZ159057.1 JP 2015130862-A/1881: Micromirs
ACCCGTTGA
>HZ159056.1 JP 2015130862-A/1880: Micromirs
ACAATAATT
>HZ159055.1 JP 2015130862-A/1879: Micromirs
CAACAGTCA
>HZ159054.1 JP 2015130862-A/1878: Micromirs
ACAGAGAAG
>HZ159053.1 JP 2015130862-A/1877: Micromirs
CAGCCGGGT
>HZ159052.1 JP 2015130862-A/1876: Micromirs
GCCCTGCCT
>HZ159051.1 JP 2015130862-A/1875: Micromirs
CAGCTCCCC
>HZ159050.1 JP 2015130862-A/1874: Micromirs
TTTAAGGGC
>HZ159049.1 JP 2015130862-A/1873: Micromirs
GAGCGCGGA
>HZ159048.1 JP 2015130862-A/1872: Micromirs
CCTCTACTG
>HZ159047.1 JP 2015130862-A/1871: Micromirs
CGGTAACTG
>HZ159046.1 JP 2015130862-A/1870: Micromirs
GTAGTAGAC
>HZ159045.1 JP 2015130862-A/1869: Micromirs
CCTGCGCAC
>HZ159044.1 JP 2015130862-A/1868: Micromirs
GCTCAGCAG
>HZ159043.1 JP 2015130862-A/1867: Micromirs
CAGCACTTT
>HZ159042.1 JP 2015130862-A/1866: Micromirs
TCCCGTCCC
>HZ159041.1 JP 2015130862-A/1865: Micromirs
GAGTGCAAT
>HZ159040.1 JP 2015130862-A/1864: Micromirs
ATCCCCACC
>HZ159039.1 JP 2015130862-A/1863: Micromirs
ATCCCAACC
>HZ159038.1 JP 2015130862-A/1862: Micromirs
AAGTGCAAT
>HZ159037.1 JP 2015130862-A/1861: Micromirs
ACAAGACTC
>HZ159036.1 JP 2015130862-A/1860: Micromirs
CTCCGCTGA
>HZ159035.1 JP 2015130862-A/1859: Micromirs
TCTCTGCTG
>HZ159034.1 JP 2015130862-A/1858: Micromirs
CCCTCACTA
>HZ159033.1 JP 2015130862-A/1857: Micromirs
ACAGCTCCC
>HZ159032.1 JP 2015130862-A/1856: Micromirs
CTAGCTTTA
>HZ159031.1 JP 2015130862-A/1855: Micromirs
TAACCAAAG
>HZ159030.1 JP 2015130862-A/1854: Micromirs
GGAGCCAGT
>HZ159029.1 JP 2015130862-A/1853: Micromirs
GGACACAGT
>HZ159028.1 JP 2015130862-A/1852: Micromirs
GTAAGTTGC
>HZ159027.1 JP 2015130862-A/1851: Micromirs
GTTCGTTGC
>HZ159026.1 JP 2015130862-A/1850: Micromirs
TTTCCAAGT
>HZ159025.1 JP 2015130862-A/1849: Micromirs
CCGATATTA
>HZ159024.1 JP 2015130862-A/1848: Micromirs
GGTGTCAGT
>HZ159023.1 JP 2015130862-A/1847: Micromirs
TTTTTGAGT
>HZ159022.1 JP 2015130862-A/1846: Micromirs
GCCCGTTCA
>HZ159021.1 JP 2015130862-A/1845: Micromirs
CTCCGACCC
>HZ159020.1 JP 2015130862-A/1844: Micromirs
AGCACCCGC
>HZ159019.1 JP 2015130862-A/1843: Micromirs
GTGTAATGG
>HZ159018.1 JP 2015130862-A/1842: Micromirs
CCCGCTGCC
>HZ159017.1 JP 2015130862-A/1841: Micromirs
GAGAAGAGG
>HZ159016.1 JP 2015130862-A/1840: Micromirs
TCTCCTCTA
>HZ159015.1 JP 2015130862-A/1839: Micromirs
AAGAAATCC
>HZ159014.1 JP 2015130862-A/1838: Micromirs
TAAACCACC
>HZ159013.1 JP 2015130862-A/1837: Micromirs
CTGAGGTAT
>HZ159012.1 JP 2015130862-A/1836: Micromirs
TGTTTCCAG
>HZ159011.1 JP 2015130862-A/1835: Micromirs
GCCAGGGCA
>HZ159010.1 JP 2015130862-A/1834: Micromirs
AAGTTCCTG
>HZ159009.1 JP 2015130862-A/1833: Micromirs
TTTGTTACT
>HZ159008.1 JP 2015130862-A/1832: Micromirs
TGGTACTGG
>HZ159007.1 JP 2015130862-A/1831: Micromirs
AGAGGTCTC
>HZ159006.1 JP 2015130862-A/1830: Micromirs
GAGATCCCA
>HZ159005.1 JP 2015130862-A/1829: Micromirs
CCATGGTGC
>HZ159004.1 JP 2015130862-A/1828: Micromirs
TATGAGCAG
>HZ159003.1 JP 2015130862-A/1827: Micromirs
GGGCTGGAG
>HZ159002.1 JP 2015130862-A/1826: Micromirs
TTCTCCTCC
>HZ159001.1 JP 2015130862-A/1825: Micromirs
CCCAGAGCC
>HZ159000.1 JP 2015130862-A/1824: Micromirs
AGGTCACAA
>HZ158999.1 JP 2015130862-A/1823: Micromirs
GTGGCAACA
>HZ158998.1 JP 2015130862-A/1822: Micromirs
TAGCCCCGC
>HZ158997.1 JP 2015130862-A/1821: Micromirs
CCCAGCGAG
>HZ158996.1 JP 2015130862-A/1820: Micromirs
AGTCTAGTT
>HZ158995.1 JP 2015130862-A/1819: Micromirs
TAAGCTCCT
>HZ158994.1 JP 2015130862-A/1818: Micromirs
GGATTTGTT
>HZ158993.1 JP 2015130862-A/1817: Micromirs
TGATTTGTT
>HZ158992.1 JP 2015130862-A/1816: Micromirs
TAGTCTTCC
>HZ158991.1 JP 2015130862-A/1815: Micromirs
GGGCATACA
>HZ158990.1 JP 2015130862-A/1814: Micromirs
CTCCGCACC
>HZ158989.1 JP 2015130862-A/1813: Micromirs
AGGGCTTCC
>HZ158988.1 JP 2015130862-A/1812: Micromirs
GAGAACCGG
>HZ158987.1 JP 2015130862-A/1811: Micromirs
CCGAGTGAC
>HZ158986.1 JP 2015130862-A/1810: Micromirs
GCCTCCTGG
>HZ158985.1 JP 2015130862-A/1809: Micromirs
CCTAGCCAG
>HZ158984.1 JP 2015130862-A/1808: Micromirs
TAAATGAAT
>HZ158983.1 JP 2015130862-A/1807: Micromirs
CCGGGCCAC
>HZ158982.1 JP 2015130862-A/1806: Micromirs
CGCCCCGCC
>HZ158981.1 JP 2015130862-A/1805: Micromirs
CAACGTGGG
>HZ158980.1 JP 2015130862-A/1804: Micromirs
GACCCAGGC
>HZ158979.1 JP 2015130862-A/1803: Micromirs
GCAATGGGT
>HZ158978.1 JP 2015130862-A/1802: Micromirs
CTGAACCAA
>HZ158977.1 JP 2015130862-A/1801: Micromirs
TCCCTCCGC
>HZ158976.1 JP 2015130862-A/1800: Micromirs
AGAACCTGC
>HZ158975.1 JP 2015130862-A/1799: Micromirs
GTATAATAT
>HZ158974.1 JP 2015130862-A/1798: Micromirs
CATGTATTA
>HZ158973.1 JP 2015130862-A/1797: Micromirs
CGGCCCACC
>HZ158972.1 JP 2015130862-A/1796: Micromirs
AGCAGACAT
>HZ158971.1 JP 2015130862-A/1795: Micromirs
GTTTCAACA
>HZ158970.1 JP 2015130862-A/1794: Micromirs
TGGCGCCAT
>HZ158969.1 JP 2015130862-A/1793: Micromirs
TTATCCTAA
>HZ158968.1 JP 2015130862-A/1792: Micromirs
GCTGCCTCC
>HZ158967.1 JP 2015130862-A/1791: Micromirs
ACACAGGTT
>HZ158966.1 JP 2015130862-A/1790: Micromirs
CTGCACACT
>HZ158965.1 JP 2015130862-A/1789: Micromirs
GTGCAGCCA
>HZ158964.1 JP 2015130862-A/1788: Micromirs
GCAGCTGCT
>HZ158963.1 JP 2015130862-A/1787: Micromirs
CCAGCCTAG
>HZ158962.1 JP 2015130862-A/1786: Micromirs
AAGCCACAC
>HZ158961.1 JP 2015130862-A/1785: Micromirs
GCATACAAG
>HZ158960.1 JP 2015130862-A/1784: Micromirs
GGAGAGGGA
>HZ158959.1 JP 2015130862-A/1783: Micromirs
CTATGTCTT
>HZ158958.1 JP 2015130862-A/1782: Micromirs
CCTGGATCA
>HZ158957.1 JP 2015130862-A/1781: Micromirs
CCGCAGCGA
>HZ158956.1 JP 2015130862-A/1780: Micromirs
CGCGATCCC
>HZ158955.1 JP 2015130862-A/1779: Micromirs
AGCCCCCAG
>HZ158954.1 JP 2015130862-A/1778: Micromirs
AGCAAGCAC
>HZ158953.1 JP 2015130862-A/1777: Micromirs
GTGCCCAAG
>HZ158952.1 JP 2015130862-A/1776: Micromirs
GGTGCTGGT
>HZ158951.1 JP 2015130862-A/1775: Micromirs
ATACTATTA
>HZ158950.1 JP 2015130862-A/1774: Micromirs
AAGCAGACA
>HZ158759.1 JP 2015130862-A/1583: Micromirs
ACCAGGGTC
>HZ158750.1 JP 2015130862-A/1574: Micromirs
CTGTGATGT
>HZ158729.1 JP 2015130862-A/1553: Micromirs
GCCAGCCTC
>HZ158728.1 JP 2015130862-A/1552: Micromirs
CGTGTATGA
>HZ158727.1 JP 2015130862-A/1551: Micromirs
CTGAGCCTG
>HZ158726.1 JP 2015130862-A/1550: Micromirs
CTCCCGTCT
>HZ158725.1 JP 2015130862-A/1549: Micromirs
AGAGGAGTG
>HZ158724.1 JP 2015130862-A/1548: Micromirs
AAGGCACAT
>HZ158723.1 JP 2015130862-A/1547: Micromirs
CATGGACTG
>HZ158722.1 JP 2015130862-A/1546: Micromirs
TTGATAGGG
>HZ158721.1 JP 2015130862-A/1545: Micromirs
TATTGCACT
>HZ158720.1 JP 2015130862-A/1544: Micromirs
CGGACAACC
>HZ158719.1 JP 2015130862-A/1543: Micromirs
TGCAGATGA
>HZ158718.1 JP 2015130862-A/1542: Micromirs
GCAAACAGT
>HZ158717.1 JP 2015130862-A/1541: Micromirs
GTAACGGTT
>HZ158716.1 JP 2015130862-A/1540: Micromirs
TATTGCAAA
>HZ158715.1 JP 2015130862-A/1539: Micromirs
ATGATCCCA
>HZ158714.1 JP 2015130862-A/1538: Micromirs
CATCGCAAA
>HZ158713.1 JP 2015130862-A/1537: Micromirs
TACACTGCC
>HZ158712.1 JP 2015130862-A/1536: Micromirs
TACACTGCC
>HZ158711.1 JP 2015130862-A/1535: Micromirs
ACATATGCA
>HZ158710.1 JP 2015130862-A/1534: Micromirs
CCATCATGA
>HZ158709.1 JP 2015130862-A/1533: Micromirs
AGCCATCCA
>HZ158708.1 JP 2015130862-A/1532: Micromirs
TACTCCAAG
>HZ158707.1 JP 2015130862-A/1531: Micromirs
AGACGACCT
>HZ158706.1 JP 2015130862-A/1530: Micromirs
CTGCAAGAC
>HZ158705.1 JP 2015130862-A/1529: Micromirs
GACAGTATT
>HZ158704.1 JP 2015130862-A/1528: Micromirs
CATTCCCGA
>HZ158703.1 JP 2015130862-A/1527: Micromirs
TCGTGTCAT
>HZ158702.1 JP 2015130862-A/1526: Micromirs
TCACGTTTT
>HZ158701.1 JP 2015130862-A/1525: Micromirs
ATTGCTGCT
>HZ158700.1 JP 2015130862-A/1524: Micromirs
CTGCCCCTC
>HZ158699.1 JP 2015130862-A/1523: Micromirs
AGACCGAGC
>HZ158698.1 JP 2015130862-A/1522: Micromirs
TAAGTCCAG
>HZ158697.1 JP 2015130862-A/1521: Micromirs
GTCTGTTGA
>HZ158696.1 JP 2015130862-A/1520: Micromirs
CAGGTGAAG
>HZ158695.1 JP 2015130862-A/1519: Micromirs
GTGTTACAT
>HZ158694.1 JP 2015130862-A/1518: Micromirs
CGGTCTACT
>HZ158693.1 JP 2015130862-A/1517: Micromirs
GTGTTATAT
>HZ158692.1 JP 2015130862-A/1516: Micromirs
CGGGTAACC
>HZ158691.1 JP 2015130862-A/1515: Micromirs
AGCAACATT
>HZ158690.1 JP 2015130862-A/1514: Micromirs
TTCTAGGAA
>HZ158689.1 JP 2015130862-A/1513: Micromirs
CTTCTGATC
>HZ158688.1 JP 2015130862-A/1512: Micromirs
GAACAACTT
>HZ158687.1 JP 2015130862-A/1511: Micromirs
CCCTTGTAT
>HZ158686.1 JP 2015130862-A/1510: Micromirs
TGGTCAACC
>HZ158685.1 JP 2015130862-A/1509: Micromirs
ATATTACAT
>HZ158684.1 JP 2015130862-A/1508: Micromirs
ATGTTACAT
>HZ158683.1 JP 2015130862-A/1507: Micromirs
TAGTCTACC
>HZ158682.1 JP 2015130862-A/1506: Micromirs
GAGTCAGGA
>HZ158681.1 JP 2015130862-A/1505: Micromirs
CAAGTCCAG
>HZ158680.1 JP 2015130862-A/1504: Micromirs
GGCAACCTC
>HZ158679.1 JP 2015130862-A/1503: Micromirs
TTTGTGTGA
>HZ158678.1 JP 2015130862-A/1502: Micromirs
CCTCTATGT
>HZ158677.1 JP 2015130862-A/1501: Micromirs
CCTCTATGA
>HZ158676.1 JP 2015130862-A/1500: Micromirs
GAGAATCTA
>HZ158675.1 JP 2015130862-A/1499: Micromirs
CCTCTATGA
>HZ158674.1 JP 2015130862-A/1498: Micromirs
AACGAACAA
>HZ158673.1 JP 2015130862-A/1497: Micromirs
ACCTGCTAA
>HZ158672.1 JP 2015130862-A/1496: Micromirs
TGTATTATA
>HZ158671.1 JP 2015130862-A/1495: Micromirs
ATCTGATAA
>HZ158670.1 JP 2015130862-A/1494: Micromirs
TGTATTATA
>HZ158669.1 JP 2015130862-A/1493: Micromirs
CATTTTGAG
>HZ158668.1 JP 2015130862-A/1492: Micromirs
GAAGCACTT
>HZ158667.1 JP 2015130862-A/1491: Micromirs
GCAGCACTT
>HZ158666.1 JP 2015130862-A/1490: Micromirs
CAGTTTGAG
>HZ158665.1 JP 2015130862-A/1489: Micromirs
GGCGGCACT
>HZ158664.1 JP 2015130862-A/1488: Micromirs
CCCAGCAGG
>HZ158663.1 JP 2015130862-A/1487: Micromirs
CGGTCGATC
>HZ158662.1 JP 2015130862-A/1486: Micromirs
ATGTATTAT
>HZ158661.1 JP 2015130862-A/1485: Micromirs
TAGCAACAG
>HZ158660.1 JP 2015130862-A/1484: Micromirs
AAGTGCAAT
>HZ158659.1 JP 2015130862-A/1483: Micromirs
AGGGGCATT
>HZ158658.1 JP 2015130862-A/1482: Micromirs
GATCCACCC
>HZ158657.1 JP 2015130862-A/1481: Micromirs
CCGTGCAAT
>HZ158656.1 JP 2015130862-A/1480: Micromirs
TCCAAGGAT
>HZ158655.1 JP 2015130862-A/1479: Micromirs
TAGGTGTGT
>HZ158654.1 JP 2015130862-A/1478: Micromirs
ATTCTGATA
>HZ158653.1 JP 2015130862-A/1477: Micromirs
ACCTGGGGG
>HZ158652.1 JP 2015130862-A/1476: Micromirs
TACACTGCC
>HZ158651.1 JP 2015130862-A/1475: Micromirs
GTTAGTGAT
>HZ158650.1 JP 2015130862-A/1474: Micromirs
ACACTGCCT
>HZ158649.1 JP 2015130862-A/1473: Micromirs
TTAGTGATT
>HZ158648.1 JP 2015130862-A/1472: Micromirs
TTGCTGATT
>HZ158647.1 JP 2015130862-A/1471: Micromirs
GACACTGCC
>HZ158646.1 JP 2015130862-A/1470: Micromirs
CGGGCAGAC
>HZ158645.1 JP 2015130862-A/1469: Micromirs
AGGAGTCAG
>HZ158644.1 JP 2015130862-A/1468: Micromirs
TAGCACCCC
>HZ158643.1 JP 2015130862-A/1467: Micromirs
CTGTGTGAG
>HZ158642.1 JP 2015130862-A/1466: Micromirs
CTGAGACGG
>HZ158641.1 JP 2015130862-A/1465: Micromirs
TGCTTTATA
>HZ158640.1 JP 2015130862-A/1464: Micromirs
CGAGGCACT
>HZ158639.1 JP 2015130862-A/1463: Micromirs
AGCAATGCA
>HZ158638.1 JP 2015130862-A/1462: Micromirs
GGAAACATT
>HZ158637.1 JP 2015130862-A/1461: Micromirs
TACAATGCA
>HZ158636.1 JP 2015130862-A/1460: Micromirs
AGGACAGGG
>HZ158635.1 JP 2015130862-A/1459: Micromirs
GAGGCGCTC
>HZ158634.1 JP 2015130862-A/1458: Micromirs
GGATATTGT
>HZ158633.1 JP 2015130862-A/1457: Micromirs
TGATGCTGG
>HZ158632.1 JP 2015130862-A/1456: Micromirs
GAAGCCGTT
>HZ158631.1 JP 2015130862-A/1455: Micromirs
CATATAGGA
>HZ158630.1 JP 2015130862-A/1454: Micromirs
TAATGAAAA
>HZ158629.1 JP 2015130862-A/1453: Micromirs
TTGCTCTTG
>HZ158628.1 JP 2015130862-A/1452: Micromirs
CCATACCTA
>HZ158627.1 JP 2015130862-A/1451: Micromirs
GCCCAGGGG
>HZ158626.1 JP 2015130862-A/1450: Micromirs
GGCCCAGAG
>HZ158625.1 JP 2015130862-A/1449: Micromirs
TGTGCTTTG
>HZ158624.1 JP 2015130862-A/1448: Micromirs
CAGGTGTGT
>HZ158623.1 JP 2015130862-A/1447: Micromirs
AGAGGGCCA
>HZ158622.1 JP 2015130862-A/1446: Micromirs
GGCCCAGAG
>HZ158621.1 JP 2015130862-A/1445: Micromirs
ACCTACTAG
>HZ158620.1 JP 2015130862-A/1444: Micromirs
AGGGGATGC
>HZ158619.1 JP 2015130862-A/1443: Micromirs
CTGGGGCAG
>HZ158618.1 JP 2015130862-A/1442: Micromirs
CGGACCACC
>HZ158617.1 JP 2015130862-A/1441: Micromirs
GTGTAATGT
>HZ158616.1 JP 2015130862-A/1440: Micromirs
CCCAGCTTT
>HZ158615.1 JP 2015130862-A/1439: Micromirs
CCCAGCTTT
>HZ158614.1 JP 2015130862-A/1438: Micromirs
CCCAGCTTT
>HZ158613.1 JP 2015130862-A/1437: Micromirs
CCCAGCTTT
>HZ158612.1 JP 2015130862-A/1436: Micromirs
CACTAAATT
>HZ158611.1 JP 2015130862-A/1435: Micromirs
ATGTGCAAT
>HZ158610.1 JP 2015130862-A/1434: Micromirs
TGGCATAGC
>HZ158609.1 JP 2015130862-A/1433: Micromirs
CATCTTGCC
>HZ158608.1 JP 2015130862-A/1432: Micromirs
CGACTGAAA
>HZ158607.1 JP 2015130862-A/1431: Micromirs
GATGTTTAC
>HZ158606.1 JP 2015130862-A/1430: Micromirs
TGACTGAAA
>HZ158605.1 JP 2015130862-A/1429: Micromirs
GATGTTTAC
>HZ158604.1 JP 2015130862-A/1428: Micromirs
CTTCTCCCA
>HZ158603.1 JP 2015130862-A/1427: Micromirs
CCTCTCCCA
>HZ158602.1 JP 2015130862-A/1426: Micromirs
GATGTTTAC
>HZ158601.1 JP 2015130862-A/1425: Micromirs
CACCTCCCA
>HZ158600.1 JP 2015130862-A/1424: Micromirs
GATGTTTAC
>HZ158599.1 JP 2015130862-A/1423: Micromirs
CGACTGAAA
>HZ158598.1 JP 2015130862-A/1422: Micromirs
GATGTTTAC
>HZ158597.1 JP 2015130862-A/1421: Micromirs
GAAGCAATT
>HZ158596.1 JP 2015130862-A/1420: Micromirs
GAAGCACTT
>HZ158595.1 JP 2015130862-A/1419: Micromirs
ATGTTAAAG
>HZ158594.1 JP 2015130862-A/1418: Micromirs
GAAGCACTT
>HZ158593.1 JP 2015130862-A/1417: Micromirs
CCATGTTAA
>HZ158592.1 JP 2015130862-A/1416: Micromirs
GAAGCACTT
>HZ158591.1 JP 2015130862-A/1415: Micromirs
ATGTTAAAG
>HZ158590.1 JP 2015130862-A/1414: Micromirs
GAAGCACTT
>HZ158589.1 JP 2015130862-A/1413: Micromirs
ACGTTTAAG
>HZ158588.1 JP 2015130862-A/1412: Micromirs
GAAGCACTT
>HZ158587.1 JP 2015130862-A/1411: Micromirs
CATTGCACT
>HZ158586.1 JP 2015130862-A/1410: Micromirs
TATTGCACT
>HZ158585.1 JP 2015130862-A/1409: Micromirs
CCCTTGTAT
>HZ158584.1 JP 2015130862-A/1408: Micromirs
AAATCGGTC
>HZ158583.1 JP 2015130862-A/1407: Micromirs
AATGGTGCT
>HZ158582.1 JP 2015130862-A/1406: Micromirs
GTGAAACCA
>HZ158581.1 JP 2015130862-A/1405: Micromirs
TGAAACCAG
>HZ158580.1 JP 2015130862-A/1404: Micromirs
AATGGTGCT
>HZ158579.1 JP 2015130862-A/1403: Micromirs
AGAAATCAG
>HZ158578.1 JP 2015130862-A/1402: Micromirs
GATGGTGCT
>HZ158577.1 JP 2015130862-A/1401: Micromirs
CGGTAAACC
>HZ158576.1 JP 2015130862-A/1400: Micromirs
ATCCCACAT
>HZ158575.1 JP 2015130862-A/1399: Micromirs
TGCTTCTGC
>HZ158574.1 JP 2015130862-A/1398: Micromirs
ACACATACA
>HZ158573.1 JP 2015130862-A/1397: Micromirs
GGGGGGCCC
>HZ158572.1 JP 2015130862-A/1396: Micromirs
CCCAACCCT
>HZ158571.1 JP 2015130862-A/1395: Micromirs
TGAGCTCCT
>HZ158570.1 JP 2015130862-A/1394: Micromirs
CAATCTAGT
>HZ158569.1 JP 2015130862-A/1393: Micromirs
GCTAAGCTC
>HZ158568.1 JP 2015130862-A/1392: Micromirs
CCACTGTGA
>HZ158567.1 JP 2015130862-A/1391: Micromirs
GCTAAGCCC
>HZ158566.1 JP 2015130862-A/1390: Micromirs
CCACTGTGA
>HZ158565.1 JP 2015130862-A/1389: Micromirs
GGAGAACAG
>HZ158564.1 JP 2015130862-A/1388: Micromirs
ATTACTTGA
>HZ158563.1 JP 2015130862-A/1387: Micromirs
CAAGAATAG
>HZ158562.1 JP 2015130862-A/1386: Micromirs
CAAGAATAG
>HZ158561.1 JP 2015130862-A/1385: Micromirs
ATTACTTGA
>HZ158560.1 JP 2015130862-A/1384: Micromirs
GTCTCCGCC
>HZ158559.1 JP 2015130862-A/1383: Micromirs
AAGTGCAAT
>HZ158558.1 JP 2015130862-A/1382: Micromirs
TCAGTAGGC
>HZ158557.1 JP 2015130862-A/1381: Micromirs
TCAGTAGGC
>HZ158556.1 JP 2015130862-A/1380: Micromirs
AACTGAGCC
>HZ158555.1 JP 2015130862-A/1379: Micromirs
CAGGAACCC
>HZ158554.1 JP 2015130862-A/1378: Micromirs
GCAATGTGA
>HZ158553.1 JP 2015130862-A/1377: Micromirs
CAGGAACCC
>HZ158552.1 JP 2015130862-A/1376: Micromirs
GCAATGTGA
>HZ158551.1 JP 2015130862-A/1375: Micromirs
TAGTGACTT
>HZ158550.1 JP 2015130862-A/1374: Micromirs
CAAATACAC
>HZ158549.1 JP 2015130862-A/1373: Micromirs
CAAACTGAC
>HZ158548.1 JP 2015130862-A/1372: Micromirs
GGCTACTGA
>HZ158547.1 JP 2015130862-A/1371: Micromirs
AGATGTAGC
>HZ158546.1 JP 2015130862-A/1370: Micromirs
TATGCCAGG
>HZ158545.1 JP 2015130862-A/1369: Micromirs
CAATGTAGC
>HZ158544.1 JP 2015130862-A/1368: Micromirs
AGCCCTGTG
>HZ158543.1 JP 2015130862-A/1367: Micromirs
ACGGTGGTG
>HZ158542.1 JP 2015130862-A/1366: Micromirs
TACGGTGTG
>HZ158541.1 JP 2015130862-A/1365: Micromirs
CTGAAGAAC
>HZ158540.1 JP 2015130862-A/1364: Micromirs
CTGGCAGCT
>HZ158539.1 JP 2015130862-A/1363: Micromirs
TGGACAATC
>HZ158538.1 JP 2015130862-A/1362: Micromirs
CCACAATTC
>HZ158537.1 JP 2015130862-A/1361: Micromirs
ACTCAACTC
>HZ158536.1 JP 2015130862-A/1360: Micromirs
CAGAACCAT
>HZ158535.1 JP 2015130862-A/1359: Micromirs
ACGGAACCA
>HZ158534.1 JP 2015130862-A/1358: Micromirs
TCAAGCACA
>HZ158533.1 JP 2015130862-A/1357: Micromirs
TGATGCAGT
>HZ158532.1 JP 2015130862-A/1356: Micromirs
GCAGAGATT
>HZ158531.1 JP 2015130862-A/1355: Micromirs
GCTGAGATT
>HZ158530.1 JP 2015130862-A/1354: Micromirs
CATAGGTCA
>HZ158529.1 JP 2015130862-A/1353: Micromirs
TAGACAGGC
>HZ158528.1 JP 2015130862-A/1352: Micromirs
TGCCTGCTG
>HZ158527.1 JP 2015130862-A/1351: Micromirs
GAGACTGTT
>HZ158526.1 JP 2015130862-A/1350: Micromirs
ACAAAGGGA
>HZ158525.1 JP 2015130862-A/1349: Micromirs
ACACGCACA
>HZ158524.1 JP 2015130862-A/1348: Micromirs
ACTGGTGTT
>HZ158523.1 JP 2015130862-A/1347: Micromirs
TGATAAGCT
>HZ158522.1 JP 2015130862-A/1346: Micromirs
ATACTACAG
>HZ158521.1 JP 2015130862-A/1345: Micromirs
GAGCACTTT
>HZ158520.1 JP 2015130862-A/1344: Micromirs
ATAATGCAG
>HZ158519.1 JP 2015130862-A/1343: Micromirs
AAGCACTTT
>HZ158518.1 JP 2015130862-A/1342: Micromirs
TTCGTCTTA
>HZ158517.1 JP 2015130862-A/1341: Micromirs
CTCGTCTTA
>HZ158516.1 JP 2015130862-A/1340: Micromirs
TTACATTCC
>HZ158515.1 JP 2015130862-A/1339: Micromirs
GAATGAAGG
>HZ158514.1 JP 2015130862-A/1338: Micromirs
ACAAAGGGA
>HZ158513.1 JP 2015130862-A/1337: Micromirs
AACATTTCA
>HZ158512.1 JP 2015130862-A/1336: Micromirs
TGCATAGGA
>HZ158511.1 JP 2015130862-A/1335: Micromirs
CTATACCTC
>HZ158510.1 JP 2015130862-A/1334: Micromirs
GGGTAAGAC
>HZ158509.1 JP 2015130862-A/1333: Micromirs
GGCAGTATT
>HZ158508.1 JP 2015130862-A/1332: Micromirs
CAGTAAGAT
>HZ158507.1 JP 2015130862-A/1331: Micromirs
GGCAGTATT
>HZ158506.1 JP 2015130862-A/1330: Micromirs
CGGTAAGAT
>HZ158505.1 JP 2015130862-A/1329: Micromirs
GACAGTGTT
>HZ158504.1 JP 2015130862-A/1328: Micromirs
CTGCAAAAC
>HZ158503.1 JP 2015130862-A/1327: Micromirs
CTGCAAAAC
>HZ158502.1 JP 2015130862-A/1326: Micromirs
GATTTGCAC
>HZ158501.1 JP 2015130862-A/1325: Micromirs
ATGCAAAAC
>HZ158500.1 JP 2015130862-A/1324: Micromirs
GATTTGCAC
>HZ158499.1 JP 2015130862-A/1323: Micromirs
AAACACTGG
>HZ158498.1 JP 2015130862-A/1322: Micromirs
AGACTACTG
>HZ158497.1 JP 2015130862-A/1321: Micromirs
GAACACTGG
>HZ158496.1 JP 2015130862-A/1320: Micromirs
CCTCTGGAC
>HZ158495.1 JP 2015130862-A/1319: Micromirs
AGGTGGTGA
>HZ158494.1 JP 2015130862-A/1318: Micromirs
AAACTACCT
>HZ158493.1 JP 2015130862-A/1317: Micromirs
CTTGTTGCC
>HZ158492.1 JP 2015130862-A/1316: Micromirs
AAACTACCT
>HZ158491.1 JP 2015130862-A/1315: Micromirs
CCAATATTG
>HZ158490.1 JP 2015130862-A/1314: Micromirs
TGTGCTGCT
>HZ158489.1 JP 2015130862-A/1313: Micromirs
GCCCCACTG
>HZ158488.1 JP 2015130862-A/1312: Micromirs
TGCTGTTAC
>HZ158487.1 JP 2015130862-A/1311: Micromirs
CAAAACCCC
>HZ158486.1 JP 2015130862-A/1310: Micromirs
AGGGCCAGT
>HZ158485.1 JP 2015130862-A/1309: Micromirs
CAAAGACCC
>HZ158484.1 JP 2015130862-A/1308: Micromirs
TAGGCCAGT
>HZ158483.1 JP 2015130862-A/1307: Micromirs
GAATTGGCA
>HZ158482.1 JP 2015130862-A/1306: Micromirs
CATAGGTCA
>HZ158481.1 JP 2015130862-A/1305: Micromirs
AAGGCAAGG
>HZ158480.1 JP 2015130862-A/1304: Micromirs
CGCCCTGGG
>HZ158479.1 JP 2015130862-A/1303: Micromirs
GGACCCCTC
>HZ158478.1 JP 2015130862-A/1302: Micromirs
GGGCACAGG
>HZ158477.1 JP 2015130862-A/1301: Micromirs
AGGGGGCAG
>HZ158476.1 JP 2015130862-A/1300: Micromirs
GCTCTGGGT
>HZ158475.1 JP 2015130862-A/1299: Micromirs
ATGCCTGGT
>HZ158474.1 JP 2015130862-A/1298: Micromirs
GCGGTACTC
>HZ158473.1 JP 2015130862-A/1297: Micromirs
ACAGGACTG
>HZ158472.1 JP 2015130862-A/1296: Micromirs
CAAGCGCAG
>HZ158471.1 JP 2015130862-A/1295: Micromirs
GATTCCGTT
>HZ158470.1 JP 2015130862-A/1294: Micromirs
AAACATATC
>HZ158469.1 JP 2015130862-A/1293: Micromirs
CCGGCACTC
>HZ158468.1 JP 2015130862-A/1292: Micromirs
GGCCCCTGC
>HZ158467.1 JP 2015130862-A/1291: Micromirs
GTCCCCGCC
>HZ158466.1 JP 2015130862-A/1290: Micromirs
AAACATATC
>HZ158465.1 JP 2015130862-A/1289: Micromirs
ATTTAGGGC
>HZ158464.1 JP 2015130862-A/1288: Micromirs
ATGCACCTT
>HZ158463.1 JP 2015130862-A/1287: Micromirs
TTAGGGCAG
>HZ158462.1 JP 2015130862-A/1286: Micromirs
ATGCACCTT
>HZ158461.1 JP 2015130862-A/1285: Micromirs
GCAAGGGAT
>HZ158460.1 JP 2015130862-A/1284: Micromirs
CATGTGGGA
>HZ158459.1 JP 2015130862-A/1283: Micromirs
TGTTGTAGC
>HZ158458.1 JP 2015130862-A/1282: Micromirs
CAAGACACG
>HZ158457.1 JP 2015130862-A/1281: Micromirs
ACCTTTGGG
>HZ158456.1 JP 2015130862-A/1280: Micromirs
GAATTCTTT
>HZ158455.1 JP 2015130862-A/1279: Micromirs
GCCAGCCCC
>HZ158454.1 JP 2015130862-A/1278: Micromirs
TTTCTCTCC
>HZ158453.1 JP 2015130862-A/1277: Micromirs
TCTCCGTCC
>HZ158452.1 JP 2015130862-A/1276: Micromirs
GGTAATTCA
>HZ158451.1 JP 2015130862-A/1275: Micromirs
CAGTGCCAT
>HZ158450.1 JP 2015130862-A/1274: Micromirs
TACTGCCTC
>HZ158449.1 JP 2015130862-A/1273: Micromirs
GATGATCAA
>HZ158448.1 JP 2015130862-A/1272: Micromirs
GGGCACTGG
>HZ158447.1 JP 2015130862-A/1271: Micromirs
TCTAGAACC
>HZ158446.1 JP 2015130862-A/1270: Micromirs
CATTGCCAA
>HZ158445.1 JP 2015130862-A/1269: Micromirs
AATGAATGT
>HZ158444.1 JP 2015130862-A/1268: Micromirs
GTCGATGGT
>HZ158443.1 JP 2015130862-A/1267: Micromirs
GTTGAATGT
>HZ158442.1 JP 2015130862-A/1266: Micromirs
AATGAATGT
>HZ158441.1 JP 2015130862-A/1265: Micromirs
GGTCAGTGG
>HZ158440.1 JP 2015130862-A/1264: Micromirs
GGTCGATGG
>HZ158439.1 JP 2015130862-A/1263: Micromirs
GTTGAATGT
>HZ158438.1 JP 2015130862-A/1262: Micromirs
TCACTGCAG
>HZ158437.1 JP 2015130862-A/1261: Micromirs
AAGCACTTT
>HZ158436.1 JP 2015130862-A/1260: Micromirs
GTAATATTG
>HZ158435.1 JP 2015130862-A/1259: Micromirs
TTAATACTG
>HZ158434.1 JP 2015130862-A/1258: Micromirs
CGTGCTGCT
>HZ158433.1 JP 2015130862-A/1257: Micromirs
TAATGATTC
>HZ158432.1 JP 2015130862-A/1256: Micromirs
TGTGCTGCT
>HZ158431.1 JP 2015130862-A/1255: Micromirs
ATATGGCCT
>HZ158430.1 JP 2015130862-A/1254: Micromirs
TGTGCTGCT
>HZ158429.1 JP 2015130862-A/1253: Micromirs
TATGTAGGA
>HZ158428.1 JP 2015130862-A/1252: Micromirs
TTAGCATTA
>HZ158427.1 JP 2015130862-A/1251: Micromirs
GTGTATGAT
>HZ158426.1 JP 2015130862-A/1250: Micromirs
GGATAACCT
>HZ158425.1 JP 2015130862-A/1249: Micromirs
ACGCGCAGG
>HZ158424.1 JP 2015130862-A/1248: Micromirs
GCCCGGGCC
>HZ158423.1 JP 2015130862-A/1247: Micromirs
AGACGGTTT
>HZ158422.1 JP 2015130862-A/1246: Micromirs
GACTATGCA
>HZ158421.1 JP 2015130862-A/1245: Micromirs
CATGCACTG
>HZ158420.1 JP 2015130862-A/1244: Micromirs
AGCTCCTCG
>HZ158419.1 JP 2015130862-A/1243: Micromirs
TTCAGTCTA
>HZ158418.1 JP 2015130862-A/1242: Micromirs
CCTGTACCA
>HZ158417.1 JP 2015130862-A/1241: Micromirs
GGTTGGGAG
